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Synaptic communication involves action potentials (AP) being generated and travelling along the 
axon such that they depolarise the presynaptic nerve terminal to induce synaptic vesicles (SVs) to 
exocytose and release their neurotransmitter. Changes in the properties of the synapse is the basis 
of synaptic plasticity and memory and defects in this process can lead to neuronal dysfunction. 
However, a full molecular description of synaptic transmission is lacking and this means that our 
understanding of many neuronal diseases is incomplete. 
The research reported in this thesis concerns the properties of three distinct pools of SVs that are 
present within nerve terminals. Normally, both the readily releasable pool (RRP) and the reserve 
pool (RP) can contribute to release during strong stimulation. However, the third pool, silent pool 
(SP), of vesicles does not normally get released and so this has not been very well characterised. 
Herein, we have successfully managed to evoke the release of the SP of glutamate (GLU) 
containing SVs. This was achieved using Roscovitine, a Cdk5 inhibitor. We have established that 
this drug truly can allow the evoked release of the SP as such release is not due to the RRP and RP 
recycling and re-releasing. Some properties of the SP were: (i) it has very specific Ca2+ requirements 
and it is inhibited if one reduces Ca2+ entry through any of three VDCCs: P/Q, N or L type; (ii) it is 
perturbed by activation of PKCs or inhibition of protein phosphatase 2; (iii) it can still be released 
if the actin cytoskeleton is stabilised by treating nerve terminals with Jasplakinolide (JASP) or non-
muscle myosin 2 (NM-II) activity is blocked by Blebbistatin. Synapsin 1 (Syn 1) is a phospho-
protein which has been suggested to regulate the SP. Using western blotting of synaptosomes that 
had been stimulated under various conditions, preliminary experiments were performed to ascertain 
whether changes in specific phosphorylation sites on Syn 1 correlated with SP release: the Cdk5 
phosphorylated site at Ser-553 seemed to have reduced phosphorylation whilst the CaMKII 
phosphorylated site Ser-603 seemed to have an increase in phosphorylation.  
Very intriguingly, an antidepressant drug, Fluoxetine, can also allow the evoked release of the SP 
of GLU containing SVs and this drug works on the same pool as Roscovitine and there is no 
additivity in SP release if both drugs are employed.   
III 
 
Previously, it was found that using High Potassium (HK5C) or Ionomycin (ION5C) the RRP is 
released by a Kiss-and-Run exocytotic mechanism (KR) whilst the RP is released by a full fusion 
(FF) mechanism. Furthermore, it was discovered that ION5C acts on a dynamin (Dyn) dependent 
KR pathway whilst HK5C works through a NM-II dependent KR pathway. Herein, some further 
properties of these 2 distinct pathways have been deduced. Some properties of the Dyn dependent 
KR pathway dissected, herein, were: (i) utilises Dyn already located on a membrane compartment 
for the closure of the fusion pore. This was ascertained by the fact that MITMAB – a drug that 
prevents Dyn binding to membranes – failed to perturb this KR process whereas this is switched to 
FF by the drug Dynasore that inhibits the GTPase activity of Dyn; (ii) requires the activity of 
endogenous PKA because this mode is switched to FF when PKAs are blocked by the drug KT 
5720; (iii) regulated specifically by P/Q VDCCs because blockade of these channels, but not others, 
switched this KR mode to FF;  (iv)  requires intact actin microfilaments for the closure of the fusion 
pore because disassembly of these cytoskeletal components by Latrunculin (LAT) switches this 
mode to FF and this drug action is not perturbed by blockade of PKCs with Go 6983;  (v) 
stabilisation of actin microfilaments with JASP does not perturb this KR. Additionaly, the NM-II 
dependent KR shows some distinct properties from the Dyn dependent KR: (i) it is not switched to 
FF following inhibition of PKAs; (ii) L-type VDCCs blockers switched this mode to FF but 
blockers of other VDCCs did not; (iii) LAT treatment seems to switch this KR mode but further 
investigation suggests that this treatment may perturb the action of the stimulus itself (HK5C) rather 
than the mode and it would appear that LAT may activate PKCs that induce the apparent effect 
since this is blocked by Go 6983. 
The RP of GLU containing SVs evoked by both ION5C or HK5C is also dependent on the actin 
microfilaments because LAT induced disassembly blocks its release although JASP does not. As 
the RP is blocked by LAT, the effect of actin microfilament disassembly on the release of the SP 
could not be studied. 
In conclusion, some properties of the SP of GLU containing SVs have been characterized whilst 
there were further differences determined between the Dyn dependent and the NM-II dependent 
KR modes. These latter findings suggest that rather than one common KR mechanism that can be 
regulated by either Dyn or NM-II, there is probably two distinct KR mechanisms that get activated 
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1.1. Synaptic Transmission 
Synaptic transmission is the basis of neuronal communication and disturbance of this 
process is linked to the pathophysiology of numerous neuronal and psychiatric disorders 
(e.g. Parkinson disease, Alzheimer’s disease, and others). Therefore, it is imperative to 
elucidate the molecular mechanism of synaptic vesicle (SV) exocytosis. In synaptic 
transmission, action potentials (AP) travelling along axons induce the depolarisation of 
presynaptic nerve terminals, this leads to the opening of voltage gated Ca2+ channels 
(VGCC), with a consequent increase in Ca2+ entry and an increase in intracellular Ca2+ 
([Ca2+ ]i). This [Ca2+]i increase promotes fusion between SV membranes and the 
presynaptic plasma membrane (PM), with the initial production of a fusion pore (FP). 
Following the creation of FPs, SVs undergo exocytosis and release their neurotransmitter 
(NT) content. Such released NTs then diffuse across the synaptic cleft, and bind to 
postsynaptic receptors leading to either excitation or inhibition of the postsynaptic neuron. 
The exocytosed SV proteins and lipids are then recovered from the PM via endocytosis. 
After the endocytosis and the reformation of the SVs, these are re-acidified and re-filled 
with NT so that they are prepared for subsequent rounds of release. This whole process is 
referred to as SV recycling. The limited number of SVs contained in the neurons means 
that a highly efficient and fast recycling process is required to allow maintenance of 
neurotransmission in response to various stimulation intensities (Sudhof, 2004; Becherer 
and Rettig, 2006; Di Maio, 2008; Alabi and Tsien, 2012).  
1.2 SV pools 
The development of the electron microscope (EM) in the early 1950s enabled the 
discovery of synaptic vesicles (SVs). During this period, Bernard Katz, with Jose del 
Castillo and Paul Fatt, had proposed the quantal theory of transmitter release in which NT 
molecules were released in discrete packages. This theory, alongside the first EM images 
of the synapse, led to the development of the vesicular hypothesis of neurotransmission. 
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In this hypothesis, transmitter is stored in SVs and its release from the vesicle interior 
following vesicular exocytosis forms the structural basis of quantal neurotransmission. 
Clearly, SVs are important structural features of presynaptic terminals and the disruption 
of their normal function is related to various neurological or psychiatric diseases (Alabi 
and Tsien, 2012).  
Many studies have highlighted that neurons contain three distinct pools of SVs: the 
Readily Releasable Pool (RRP), the Reserve Pool (RP; also known as Recycling pool), 
and the Silent Pool (SP; also known as Resting pool and Reserve pool) (Denker and Rizzoli, 
2010; Alabi and Tsien, 2012; Crawford and Kavalali, 2015; Fowler and Staras, 2015). 
High frequency repetitive stimulation of nerve terminals induces dramatic drops in NT 
release and this eventually leads to lower steady-state level of neurotransmission. This 
phenomenon of synaptic depression represents the depletion of SVs from the RRPs. RRPs 
are replenished by their recycling or by recruitment of the SVs from the RP. These two 
pools, which participate in exo- and endocytosis under prolonged stimulation, are jointly 
referred to as the total recycling pool. In cultured hippocampal cells, it was estimated that 
the total recycling pool contained ~21-25 vesicles per terminal, with ~4-8 vesicles in the 
RRP and ~17-20 vesicles in the RP (Fig 1.1). Considering the total amount of SVs in the 
terminal are >200, these values are strikingly low, suggesting that there is a large group of 




Figure 1.1. Vesicle pools and size (From Sudhof, 2000). 
Rizzoli and Betz (2005) have proposed a three-pool model consisting of the RRP, RP, and 
SP organised in the order of their release. The model suggests that when stimulation arrives 
in the nerve terminal, the RRP, which are already docked at the active zone (AZ), release 
first, and the RP replenishes the RRP in the case of repetitive stimulation and any release, 
but that the SP is only released under extremely intense non-physiological stimulations 




Figure 1.2. Three-pool model of SV pools (From Denker and Rizzoli, 2010). 
This three-pool model fits in quite well with data produced utilising pHluorin experiments. 
Fernandez-Alfonso and Ryan (2008) showed that for three main SVs components (vGlut-
1, VAMP-2, and Synaptotagmin 1 all linked to pHluorin molecules), around half of the 
tagged proteins appeared in the recycling pool that respond readily to prolonged 
stimulation by mobilising and fusing with the PM so these underwent exocytosis and 
endocytosis as detected by the pH sensitive pHluourin linked to these vesicular proteins. 
However, half of the labelled vesicles were targeted to a non-recycling, acidic 
compartment. The fraction of recycling and SPs varies across boutons within an individual 
axons, from 100% silent to 100% recycling. However, morphological studies on 
localisation of these pools shows strong evidence of intermixing between the SP and the 
recycling pools. Whilst RRPs, that are understood to release first following the stimulation, 
may be docked at the AZ release sites, all other vesicles are positioned throughout the 
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synapse. Indeed, not all SVs docked at the AZ are necessarily releasing first. Moreover, in 
a study at frog neuromuscular junctions (NMJs), it was found that AZs were largely 
occupied by vesicles that do not normally release during physiological stimulation (Rizzoli 
and Betz, 2004; Denker and Rizzoli, 2010). 
The properties of the RRP and RP have been well characterised. Currently one major 
debate is what mode of vesicle exocytosis occurs under particular stimulation conditions 
(Richards, 2009, 2010; Zhang et al, 2009; Alabi and Tsien, 2013). Ashton’s group has 
shown that under strong stimulation-conditions, the RRP and the RP SVs are found to 
undergo different modes of fusion to release their NT contents. The RP SVs undergo a full 
fusion mode (FF), where during vesicular membrane fusion with the PM the FP opens, 
transmitter is released, but concurrently the FP continues to expand and the vesicle 
membrane collapses and fully integrates into the PM. Subsequently, the SV membrane is 
recovered via a clathrin- and dynamin (Dyn)-dependent process or via a Dyn-dependent 
process alone. Intriguingly, under strong stimulation conditions Asthon’s group (Bhuva, 
2015; Singh, 2017) have shown that the RRP SV undergoes a Kiss-and-run (KR) mode in 
which the FP opens, but rather than fully expanding and causing vesicle membrane 
collapse into the PM, it recloses via a process independent of clathrin. Research by Ashton 
and colleagues has discovered that these modes of exocytosis can switch and this depends 
upon changes in intracellular calcium levels and in protein 
phosphorylation/dephosphorylation (Ashton and Ushkaryov, 2005; Ashton et al, 2009, 
2011, 2013).  
1.3 The Silent Pool (SP) 
There are many challenges in order for one to study the third pool, the SP. Studies on 
synapses have shown that this pool can contain up to 80% of all terminal SVs, but that 
under normal physiological conditions these SVs are not released. Why such a large 
number of SVs do not normally release remains an enigma. Some studies have suggested 
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that the SP may act as a buffer for proteins involved in SV recycling (Denker et al, 2011). 
The SP has been investigated at the neuromuscular junction (NMJ) of Drosophila 
melanogaster through various manipulations to this model. Particularly, it was determined 
that in flies carrying the temperature sensitive mutation of ShibireTS, which is a homologue 
to the mammalian Dyn protein, extra release due to the SP SVs undergoing exocytosis was 
found under non-permissive raised temperatures. This is because at such increased 
temperature Dyn was inactive so that the RRP and the RP cannot recycle and this, therefore, 
allowed the SP to participate in the release. Subsequent reduction of the temperature back 
to a permissive temperature, Dyn became active again and allowed the recovery of all 
pools of SVs, and such results indicate that the SP is localised at a specific position within 
the SV aggregates (Kuromi and Kidokoro, 1998). This model further revealed that the SP 
vesicles share distinct biochemical properties with vesicles from the other two pools and 
they were released under normal physiological condition, and they could be involved in 
exocytosis under high frequency stimulation in this model (Kuromi and Kidokoro, 2005). 
Equivalent studies have not been made in mammalian nerve terminals because whilst there 
are Dyn knockout animals (Ferguson et al, 2007; Raimondi et al, 2011), there are no 
temperature sensitive Dyn mutations that might allow the SP to come on line and release 
following the release of the RRP and the RP.  
Afuwape et al (2017) investigated the stability of recycling SVs via performing an 
extended incubation of FM 1-43 labelled terminals prior to a stimulation. They 
subsequently triggered the dye release from the hippocampal culture cells after incubation 
of FM labelled terminals at physiological temperature for 6 hours. It was found that 
vesicles in the SP are highly reluctant to intermix with the labelled recycling pool because 
the kinetics of FM dye release were the same after this extended incubation as after only 
a 10 min resting period following initial loading (Afuwape et al, 2017). 
Molecular mechanisms underpinning the SP are mainly unknown. In contrast to the RRP 
that is known to dock at the AZ membrane, the RP and SP are identified to be highly 
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intermixed at the presynaptic terminal (Denker and Rizzoli, 2010). Despite this intermix, 
the fact that SVs are still capable of releasing in organised sequence means it is highly 
likely that there are unknown molecular tags that partition the SVs. It is possible that the 
SP has distinctive morphological features, such as size or shape of the vesicle that could 
distinguish this group of pool from others, but, ultrastructural studies have failed to 
discover significant morphological parameters that one could refer to when classifying 
each pool (Rizzoli & Betz, 2005). As over 400 different proteins are found on SVs 
(Takamori et al, 2006), it could be that variation in these proteins could provide the 
diversity in these vesicle pools. Thus, a combination of certain proteins on vesicle surface 
could explain how vesicles within the same presynaptic terminal have varying functional 
characteristics (Chamberland and Toth, 2015).  
One of the possibilities is that there are molecular tags that associate with SV membrane 
that specify their identity and direct them to one pool or the other (Guarnieri, 2017). 
Synapsin I (Syn I) is a SV associated protein, and it is also a molecular marker of the RP, 
restricting SVs from this pool participating in neurotransmission (Denker et al, 2011). 
Thus, it could also contribute to restrict the mobilisation of the SP, justifying Syn I as one 
of the likely candidates to regulate the SP organisation. Another study has also suggested 
that the presence of vesicular zinc could be a possible hallmark of the SP. This study 
showed that zinc predominantly exists in a subpopulation of SVs and that such zinc-
containing SVs only preferentially release during high frequency stimulation, an indication 
that these SVs may be derived from the SP (Lavoie et al, 2011). 
1.4 Roscovitine 
Recently Kim & Ryan (2010) used a small molecule inhibitor of Cdk5 [a proline-directed 
Ser/Thr kinase that is characterised to be implicated in cytoskeleton assembly and its 
organisation during axonal growth (Maccioni et al, 2001) and in many other processes 
such as SV recycling (Evans and Cousins, 2007)], called Roscovitine, and successfully 
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released SVs that were previously in a silent state from mammalian hippocampal cell 
cultures, i.e. part of the SP. The study reported that following Roscovitine treatment, 
stimulation with 100 action potentials (APs) was able to evoke 80%-90% of the entire 
vesicle pool in the terminal. The fact that a small stimulation like 100 AP, can drive 
exocytosis of virtually all of the SVs in the terminal suggests that Cdk5 inhibition has 
increased the size of the available SV pool. Kim and Ryan (2010) concluded that an 
inhibition of Cdk5 via Roscovitine leads to an elevation of the recycling vesicle pool size 
by converting the SP vesicles into functional recycling vesicles.  
Kim and Ryan (2013) have further claimed that the balance of Cdk5 with Calcineurin 
operates a release probability of SV pools, and it is mediated through Cav 2.2 voltage-
gated calcium channels (N-type Ca2+ channel). Such studies and others outlined below 
suggest that Cdk5 has an important role in regulation of the SP and other vesicle pools, 
and also outline which proteins Cdk5 could potentially work on in this regulation (Kim 
and Ryan, 2013).  
1.5 Cdk5 Phosphorylation targets 
1.5.1 Dynamin I 
Cdk5 is known to phosphorylate Dyn I at Ser 778 (Evans and Cousin, 2007) and in the 
absence of this, Ser-774 cannot be phosphorylated by GSK3 (Clayton et al, 2010) and both 
of these sites are targets of calcineurin (CN)-induced dephosphorylation. These sites have 
been found to be involved in clathrin-dependent endocytosis (Armbruster et al, 2013) and 
it was also suggested that they may be involved in the control of phospho-dependent bulk 
endocytosis of SVs (Clayton and Cousin, 2009). As Dyn I requires Cdk5 phosphorylation 
for its continued recycling activity, it is likely to be involved in SP recycling and re-
releasing following release of this pool. Intriguingly, Dyn can also be involved in the 




1.5.2 Myosin 2 
The role of non-muscle myosin 2 (NM-II) in exocytosis has been highlighted in various 
studies on non-neuronal cells (Neco et al, 2008; Bhat and Thorn, 2009; Doreian et al, 2009) 
and Ashton’s group has shown that it has a role in regulating the FP of SVs in nerve 
terminals (Bhuva, 2015; Singh, 2017). It is also possible that NM-II may regulate the SP 
independent of its fusion mode. In studies focused exclusively on the RRP and RP, the 
myosin light chain kinase (MLCK) inhibitors were shown to perturb (Ryan, 1999) or 
augment (Srinivasan et al, 2008) the release while other works have shown that the role of 
MLCK is independent of actin cytoskeleton (Tokuoka and Goda, 2006). Actin 
microfilaments may be involved in the regulation of the SP. A study on Drosophila NMJ 
has found that the SP SVs require actin microfilament for their recruitment (Kuromi and 
Kidokoro, 2005). It is therefore, possible that one might be able to link the properties of 
NM-II as a motor protein for the SP and its requirement for actin microfilaments (e.g. 
Neco et al, 2004; Dorein et al, 2008; Haviv et al, 2008). Hence, it will be worth studying 
the phosphorylated state of non-muscle myosin under the condition investigating the 
regulation of the SP (Ludowyke et al, 2006; Beach et al, 2011; Sanborn et al, 2011). 
1.5.3 Synapsin I 
Syns are SV associated phosphoproteins that are proposed to have a key role in the 
regulation of neurotransmitter release and synapse formation. They are substrates of 
multiple kinases that phosphorylate the proteins at several distinct sites (Cesca et al, 2010). 
Syn was first discovered by Paul Greengard’s group. The neuronal specific Protein I (later 
named Syn I) was found to be one of the main endogenous substrates for cAMP-dependent 
protein kinase (PKA) in synaptic fractions. Early evidences has demonstrated that Syn 
phosphorylation was induced following electric stimulation in rabbit cervical ganglia 
(Nestler and Greengard, 1982) and in the rat neurohypophysis (Tsou and Greengard, 1982). 
Later, Syn phosphorylation by CaMKII was studied intensively as such phosphorylation 
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induced a major conformational change in Syn (Benfenati et al, 1990) and this reduced its 
association with SVs (Schiebler et al, 1986) and with the actin cytoskeleton (Valtorta et 
al, 1992). The relevance of this to synaptic transmission was shown by the fact that 
microinjections of Syn phosphorylated at the CaMK II sites failed to stop the SV release, 
whilst dephospho-Syn inhibited release (Llinas et al, 1985, 1991). However, it is now clear 
that Syn function in vivo is regulated through multiple activity dependent phosphorylation 
pathways, and PKA, Cdk5, and CaMK II all have important roles in Syn regulation (Cesca 
et al, 2010; Shupliakov et al, 2011; Bykhovskala, 2011). 
The Syn family consists of ten homologous proteins, Syn Ia-b, IIa-b, and IIIa-f, and an 
analysis of the amino acid sequence of Syn I and Syn II allowed the domain structure of 
the Syn family to be elucidated. Syn are composed of a highly homologous N-terminal 
region, and a more variable C-terminus. The N-terminal region can be split into three 
domains, called domain A, B, C, which except from domain B, are highly conserved across 
isoforms and species. In contrast, the C-terminal region of Syn is more divergent, and is 
composed of various spliced domains (domain D-I). Domain A is a short N-terminal region, 
that exist in all Syn isoforms. It contains the phosphorylation site (site 1) for PKA, CaMK 
I and IV. Domain B, shows relatively weak similarity between Syn isoforms, and it is 
suggested to be a linker region connecting domain A to domain C. In Syn I, domain B 
contains phosphophrylation sites 4 and 5 for MAP kinase/Erk. Domain C is a large region 
of about 300 amino acid which consists of both hydrophobic and highly charged sequences 
with the potential to assume -helix and -sheet conformations. It is considered to be 
important region for Syn interaction with the actin cytoskeleton and SV phospholipids, as 
well as contributing to Syn homo or heterodimerisation. The amino acid sequence diverges 
after domain C. However, all isoforms contain a proline-rich domain (domain D in Syn Ia 
and Ib; domain G in Syn IIa, domain G and H in Syn IIb, and domain J in Syn IIIa). 
Domain D in Syn Ia and Ib contains phosphorylation site 2 for CaMKII, site 3 for CaMKII 
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Figure 1.3. Phosphorylation sites in synapsins. (A) Phosphorylation sites in synapsins Ia-IIIa; 
(B) Summary of kinases and the phosphorylation sites in synapsin Ia, the diagram describes 
changes in phosphorylation levels in response to Ca2+ entry and the effect that site specific 
phosphorylation has upon synapsin function (Taken from Cesca et al, 2010). 
The exact functions of Syn are not yet fully elucidated. The classical view suggests that 
vesicles are tethered to the cytoskeleton by Syn and cages these vesicles. Phosphorylation 
of Syn leads to these vesicles becoming uncaged and makes these vesicles available for 
release (Bykhovskala, 2011). An early study in squid giant synapses from Llinas and 
colleagues (1985) demonstrated that the presynaptic injection of dephosphorylated Syn I 
reduced the amplitude and rate of rise of postsynaptic potential (i.e. neurotransmitter 
release was decreased) whilst injection of either phosphorylated or heat inactivated 
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dephosphorylated Syn I had no effect. Injection of CaMKII was found to increase the post 
synaptic potentials by increasing release (Llinas et al, 1985, 1991). Later, the introduction 
of dephosphorylated Syn I, phosphorylated Syn I or activated CaMKII into rat brain 
synaptosomes produced a similar result in vitro (Nichols et al, 1992), outlining that Syn 
dephosphorylation acts as an organiser of the SV pool, keeping SVs together and 
connecting them to actin filaments, whereas phosphorylated Syn allows SV to becomes 
untethered so that they can fuse with the PM. In addition, presynaptic injection of a highly 
conserved peptide fragment of domain E in to the squid giant synapse revealed a drastically 
reduced number of SVs located distal from the AZ and this increased the synaptic 
depression following relevant stimulation. Similar results were also observed when a 
peptide corresponding to domain C was injected. Importantly, both peptides were found 
to inhibit the Syn-actin interaction, indicating the importance of Syn I in maintaining the 
SV pools distal to the AZ through an interaction with actin (Hilficker et al, 1998, 2005).  
Other characteristics of Syn have been highlighted in relatively recent research. Kim et al 
(2017) have observed alterations in SVs at presynaptic terminal on mice exposed to 835 
MHz RF-EMF (Radiofrequency electromagnetic fields), and in such mice there is a 
marked decrease of expression of Syn I and II genes and their protein product (Kim et al, 
2017). Furthermore, the phosphorylation of Syn I was found to be reduced upon Lead (Pb) 
exposure. Lead is a toxin that impairs the nervous system and it was found that it reduces 
presynaptic neurotransmission through the disarrangement of the distribution, and a 
decrease in the density, of presynaptic vesicles. These authors were able to reverse the 
effect of the Pb exposure using Roscovitine, suggesting that Pb disrupted the distribution 
of SVs and impaired the neurotransmitter release by changing the Cdk5 dependent 
phosphorylation levels of Syn I through Cdk5 (Ding et al, 2018). 
Much research has linked Syn activity to regulation and maintenance of SVs located distal 
to AZ (Li et al, 1995b; Samigullin et al, 2004; Siksou et al, 2007; Akbergenova and 
Bykhovaskaia, 2007; Fornasiero et al, 2012; Orenbuch et al, 2012). This suggests that Syn 
14 
 
is one of the major proteins that contribute to the SP regulation. Electron microscopy (EM) 
investigation of boutons from Syn deficient mice has demonstrated that Syn maintains 
vesicle clustering at the periphery of the bouton. Syn deficiency did not affect the mixing 
of the RP and SP but it did selectively reduced the size of the SP. Intriguingly, under 
intense stimulation, a significant amount of vesicles were found to be distributed at the 
central core of the bouton in the presence of Syn, but in the absence of Syn, the area 
occupied by vesicles appeared unchanged. Further, whilst strong stimulation led to an 
elevated basal release in Syn deficient terminals, this was not the case in Syn containing 
terminals indicating that Syn may direct vesicles to the SP (Akbergenova and Bykhovskaia, 
2010). Verstegen et al (2014) demonstrated that Cdk5 phosphorylation of Syn I at Ser 549 
(site 6) and Ser 551 (site 7) isolates recycling SVs to the SP via a mechanism involving 
the actin cytoskeleton. They claimed that the phosphorylation of Syn I with Cdk5 at Ser551 
site enhances its interaction with F-actin. F-actin can dynamically regulate SV 
transmission and may be responsible for scaffolding and the cycling, turnover, and 
mobility of SVs (Cingolani and Goda, 2008). This cytoskeletal component does not 
regulate the RP size, although, an absence of F-actin was reported to perturb the spatial 
segregation of recycling SVs (Marra et al, 2012; Ratnayaka et al, 2012). Such information 
led Verstegen et al (2014) to conclude that increased phosphorylation of Syn I with Cdk5 
leads to an elevation of SV interaction with F-actin, leading to the relocation of the 
recycling SVs to the SP, such that SV in the recycling pool are reduced (i.e. the RRP and 
the RP) (Verstegen et al, 2014).  
Recent evidence has reported that Cdk5 phosphorylates Tomosyn I, a SNARE binding 
protein, and this can also regulate the SP. This protein appear to exert its function through 
an interaction with Syn I via Rab3A-GTP and this tomosyn function is independent of its 
SNARE binding properties (Cazares et al, 2016). Clearly such studies demonstrate that 
phosphorylation of Syn I plays an important role in organising the SV pools located distal 
from the AZ, and leads to the idea that changes in the phosphorylated state of Syn I (at 
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various phosphorylation sites) may potentially contribute to the regulation of the 
exocytosis of the SP. 
1.5.4 -Synuclein 
The synuclein protein family consists of -, -, and -synuclein. Amongst all the synuclein 
proteins, interest in the - form of the protein is high due to the fact that it has previously 
been found to contribute to Parkinson disease (PD) (Polymeropoulos et al, 1997; Clayton 
and George, 1999; Spinelli et al, 2014). An exact role of -synuclein in the synapse has 
yet to be discovered. Previous studies investigating the protein’s structure and localisation 
suggest that it does feature in various synaptic transmission processes including SV 
endocytosis, regulation of SV pool size, SV mobilisation and the trafficking between 
synapses (Gedalya et al, 2009; Cabin et al, 2002, Nemani et al, 2010; Scott and Roy, 2012; 
Vargas et al, 2014). The study by Vargas and colleagues (2014) used optical imaging, 
electron microscopy and slice electrophysiology to determine that synucleins are required 
for rapid and efficient clathrin dependent SV endocytosis, and by comparing the WT 
synapses to those from Dyn DKO synapses led to the suggestion that synuclein acts at an 
early step of SV endocytosis. Others have suggested that -synuclein is organised into 
multimers and these cluster SVs and restrict their motility (Wang et al, 2014). Another 
study demonstrated that the -synuclein decreases the trafficking of recycling pool 
vesicles between presynaptic boutons – such SVs constitute a pool known as the superpool 
– and that -synuclein also has a role in maintaining the overall size of the recycling pool. 
Overexpression of -synuclein led to a smaller recycling pool size and blocked the 
trafficking between the synaptic boutons. Whereas, removal of this protein resulted in 
larger recycling pools and enhanced trafficking between boutons (Scott and Roy, 2012). 
Nemani and colleagues (2010) had previously suggested that overexpression of -
synuclein reduced the size of the SV recycling pool and this significantly inhibited NT 
release. These authors demonstrated a decreased SV density at the AZ and defects in the 
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reclustering of SV after endocytosis by using ultrastructural analysis. Clearly, -synuclein 
does participate in synaptic transmission and as it is involved in regulation of the size of 
the recycling pool it may also be potentially involved in the regulation of the SP. Although 
this thesis does not address the role of -synuclein, it is felt that data detained in this thesis 
may lead on to some studies to investigate the role of this enigmatic protein. That is why 
it is mentioned here. 
1.6 Fluoxetine 
Recently, it has been found that the antidepressant drug, Fluoxetine can induce extra 
release from synapses (Jung et al, 2014). Fluoxetine is a selective serotonin reuptake 
inhibitor (SSRI) and it is one of the most widely prescribed treatment for depression. 
SSRIs are understood to operate through an inhibition of the uptake of exocytosed 
serotonin into the presynaptic terminal, and this leads to an increase of serotonin levels in 
the synaptic clefts of drug treated patients suffering from depression. Jung et al (2014) 
reported that a clinically relevant dosage of Fluoxetine, 1 M, had an effect on SV 
recycling and plasticity, and that the drug mobilises the SP of SVs so that they can be 
released. Higher drug concentrations attenuated evoked exocytosis. They showed that the 
observed increase of SVs exocytosis was due to an increase in the number of active 
vesicles after Fluoxetine incubation (Jung et al, 2014). This study is significant as it could 
reflect that the antidepressant effect of SSRIs might involve an expansion of the releasable 
SVs from nerve terminals.  
Research in this thesis utilises synaptosomes prepared from rat cerebral cortex. Such 
preparation contain 80% glutamatergic terminals but only a very small % of serotonergic 
terminals. Therefore, it would be interesting to investigate whether Fluoxetine could 
produce equivalent effect to the one from Jung and colleagues’ study utilising these 
cortical synaptosomes. This is some evidence from earlier study that Fluoxetine could 
affect the release of nerve terminals that do not involve serotonin. Bymaster et al (2003) 
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showed that Fluoxetine increases that extracellular levels of dopamine and norepinephrine 
in the hypothalamus, cortex and prefrontal cortex (Bymaster et al, 2003). Although, 
studies highlighted claimed that Fluoxetine has several additional effects besides 
inhibiting neuronal serotonin reuptake and this includes effects on glutamate release from 
nerve terminals and it was found that Fluoxetine inhibited 4-aminopyridine (4AP) evoked 
glutamate release from cerebral cortical synaptosomes primarily by suppression of P/Q 
type calcium channels (Wang et al, 2003).  
1.7 SV cycling 
SV cycling has two major stages; exocytosis and endocytosis. In nerve terminals, NTs are 
stored in SVs, and such NTs are release through exocytosis. Subsequently, empty SVs can 
be rapidly recycled by undergoing endocytosis to enable them to become ready for reuse 
(For detailed review, see Rizzoli, 2014). Much progress has been made in our knowledge 
about exocytosis, but details on certain specific mechanisms and endocytosis regulation 
are less well understood.  
A study from Heuser and Reese in the early 1970s, contributed to the establishment of a 
concept of SV recycling using EM on frog NMJs. The study proposed that SV membranes 
are recycled by clathrin mediated endocytosis (CME) via cisternal structures located at 
AZs (Heuser and Reece, 1973). Intriguingly in the preparation using a distinct stimulation 
paradigm, Ceccarelli and colleagues suggested an alternative clathrin-independent fast 
mode of SV recycling called Kiss and Run (KR) that involves a transient FP opening 
(Ceccarelli et al, 1973). Later on it was shown that a sustained strong stimulation of nerve 
terminals could trigger activity dependent bulk endocytosis (ADBE) of extensive 
membrane patches containing membrane. This pathway may serve during very high 
frequency stimulation, as an emergency response, as it might not selectively recover SV 
proteins alone. For definite, this produces a large endosome and SVs have to bud off from 
this before entering the cytosol and being able to load up NT. Recently, data using high-
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pressure freezing EM paired with optogenetic stimulation proposed that at invertebrate 
and mammalian synapses there was another distinctive mode of SV recycling, called 
ultrafast endocytosis (UE) existed (Fig 1.4) (Kononenko and Haucke, 2015; Soykan et al, 
2016; Watanabe et al, 2017). 
 
Figure 1.4. Overview of KR, CME, UE, ADBE. (A) Kiss and Run mode. Characterised with 
a transient opening of a fusion pore to discharge SV content followed by closure and 
detachment of the SV from the plasma membrane and directly reused through a fast 
mechanism. (B) CME. Classical model of endocytosis with open of a fusion pore followed by 
complete flattening of SV to the plasma membrane. Subsequently, SV components are 
retrieved directly from the cell surface via formation of a clathrin coated vesicle. (C) UE. Fast 
invagination of a larger area of the PM (2 to 4 times larger than the area that one SV would 
produce which then becomes an endosome and SVs pinch off of this via a clathrin dependent 
process. (D). Strong stimulation results in appearance of large bulk endocytic structures, 
which later resolved into SVs through clathrin dependent or clathrin independent 




Each pathway of recycling operates through distinctive mechanism to retrieve SVs from 
the PM and each possesses its own advantages and disadvantages (He et al, 2006; Granseth 
et al, 2007; Watanabe et al, 2013, 2014). Which endocytic pathway is the most prevalently 
used is still a matter of fierce debate, although it is clear that this can be dependent on 
many factors such as stimulation intensity and duration. For instance, CME maybe the 
dominant SV endocytosis mode during low levels of stimulation, and at even milder 
neuronal activity, UE is proposed to be the most prevalently used pathway. This is because 
this has routinely only been measured after the equivalent of one AP and even then for one 
SV fusion, there appear to be 2-4 SV recycled. This clearly could not be maintained over 
a strong stimulation period otherwise the terminal would shrink. At elevated stimulation, 
these two mechanisms saturate and ADBE is found to get triggered and therefore, ADBE 
may be the predominant pathway during elevated neuronal activity (Granseth et al, 2006; 
Harata et al, 2006; Wu and Wu, 2007; Mellander et al, 2012; Nicholson-fish et al, 2015; 
Morton et al, 2005; Kokotos et al, 2018).  
For these three distinctive pathways of endocytosis, CME, ADBE, and UE SV undergo 
classical exocytosis such that vesicles fully collapse into the PM prior to their endocytotic 
retrieval. In this exocytotic mode, vesicles are found to be completely flattened into the 
PM via FF (Rizzoli and Jahn, 2007). Following these types of exocytosis, endocytosis 
involves invagination of membrane containing vesicular component that may require Dyn-
dependent vesicle fission. Whilst CME utilises clathrin at the PM invagination step, in UE, 
the Dyn-dependent fission produces an endosome and clathrin acts at the endosomal stage 
– at physiological temperature – to produce pinched off SVs (Watanabe et al, 2014). 
Whilst Dyn has been suggested to pinch off a large invagination to produce an endosome 
during ADBE, this is controversial since bulk endocytosis still occurs in Dyn deficient 
nerve terminals. Subsequent uncoating, trafficking, re-acidification and recharging with 





The other mode of release known as KR is characterised with a transient FP without 
complete loss of vesicle identity. Since the KR mechanism does not involve collapse of 
the vesicular membrane it possesses some advantage over FF in terms of speed of recycling. 
Studies estimate that in KR mode of fusion process, the vesicle recycles within 1s, which 
is faster compared to FF that takes ~20s, although, others have claimed that CDE can occur 
in <10s, but this is still slower than KR. Also, KR allows one to utilise less energy than 
full vesicles collapse and subsequent vesicle reformation. There is also rapid clearance of 
the vesicle membrane and proteins from the AZ release site if KR recycling occurs, which 
can facilitate vesicle replenishment of the release sites. Although, UE can allow some SV 
membrane to endocytosed in 30 ms, faster than KR, the actual recycled endosomal 
compartment needs SVs to pinch off from this and then take up NT and this process 
actually takes about 5s and so UE is still slower than KR in producing a SV that is ready 
to re-release (Zhang et al, 2007; Park et al, 2012; Alabi and Tsien, 2013; Watanabe et al, 
2014).  
SVs are proposed to use different modes of exocytosis depending on various factors such 
as intensity of stimulation. Evidence supporting this hypothesis was proposed from 
Elhamdani et al (2001) studying chromaffin granule exocytosis. The group used 
amperometric recording to monitor single exocytotic events in chromaffin cells and found 
that the intensity of stimulation determines the amount of catecholamine release through 
an individual FP. These authors reported that at low frequency stimulation, 0.25 Hz, the 
quantal size was more than two-fold smaller compared to under high frequency, 10 Hz 
(Elhamdani et al, 2001). Research from Fulop et al (2005) has obtained a similar result. 
This group revealed that the quantal size of amperometric spikes triggered by 0.5 Hz 
stimulation was more than two-fold smaller than the one induced by 15 Hz stimulation. 
Additionally, the size of amperometric spikes at 0.5 Hz was very similar to the value of 
the one from pre-spike current recorded at 15 Hz. This part of spike is often referred to as 
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‘foot’, and these currents represent the slow release of catecholamine through the FP. At 
this stage, FP can either close or expand into a larger pore. In the case of the FP closing, 
one may get an incomplete release of the vesicle as it may close before all the 
catecholamine has been released. Thus, at a lower frequency, the catecholamine is partially 
released through a relatively narrow FP that closes back after short period of time, whilst 
under higher frequency stimulation, the FP totally expands into the PM and so there is 
complete release of the vesicular contents (Fulop et al, 2005). In these chromaffin cells, 
the rapid closure of a non-expanded FP represents KR whilst the full release of an 
expanded FP is FF (Cardenas and Marengo, 2016).   
Ceccarelli and colleagues (1973) showed morphological vesicle depletion and the elevated 
plasma membrane area under 10 Hz stimulation (i.e. FF), as reported by others (Heuser 
and Reese, 1973), but they did not get an equivalent result under a lower frequency of 
stimulation, 2 Hz where there was neither a substantial reduction in the amount of SVs nor 
evidence of any coated vesicles. Moreover, a 10 Hz stimulation for 20 minutes led to an 
increased number of dimples (representing exo-endocytosis events) near the AZ but the 
number and location of SVs were unchanged during the first minute of recovery when 
endocytosis would predominate. Additionally, under quick-freeze procedure, the image of 
dimples remained the same during 2, 5, and 10 ms after initial stimulation, and they were 
also found inside the AZ. Vesicles were often observed to form narrow pores while in 
contact with PM under conditions in which neurotransmission occurred. Based on these 
observations, Ceccarelli and colleagues proposed the mechanism of KR in which there 
was vesicular retrieval on the spot without the vesicle collapsing into the PM and losing 
its identity (Harata et al, 2006). 
There is strong evidence for KR using preparations with fluorescently labelled SVs. SVs 
can be filled with FM dyes during recycling, and subsequent rounds of stimulation evokes 
these fluorescent dyes to exocytose. Direct measurement of this dyes to determine 
properties of exocytosis has been used for a substantial time period (FM dyes first used in 
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the 1990s). Work carried out by Richard Tsien and colleagues (Aravanis et al, 2003; 
Harata et al, 2006) and earlier by Stevens and colleagues (Stevens and Williams, 2000) 
suggested that whilst some SVs underwent exocytosis with release of FM dye, other SVs 
underwent exocytosis without the release of the dye. This was due to the fact that FM dye 
takes time to departition from the vesicle membrane after it is exposed to the extracellular 
buffer following exocytosis and if the initial FP formed closes quickly (<0.5s) the dye will 
not be released, although glutamate will be, and this represents KR. For FF all dye will be 
released. The use of bromophenol blue (BPB) also revealed that there was a significant 
proportion of FM dye that was retained in a BPB sensitive pool. BPB will quench FM dye 
fluorescence but it is membrane impermeable. However, BPB is a small molecule and so 
it can penetrate into the vesicles through fusion pores formed during exocytosis even 
though these pores maybe too short lived for FM dyes to departition and escape. However, 
under such circumstances the FM dye fluorescence will be quenched by the BPB. However, 
vesicles undergoing FF will lose all the dye in FM fluorescence and so this reduction in 
FM fluoresce during exocytosis will not be altered by BPB. The fact that significant 
proportion of FM dye could remain in a BPB sensitive pool allowed one to interpret that 
this pool of SVs must be undergoing KR (Rizzoli and Jahn, 2007). 
The KR mode of exocytosis is regulated through various mechanisms, including the Ca2+ 
level and the presence or absence of various proteins (Dyn, myosin, or actin cytoskeleton). 
As previously mentioned, KR is the prevalent exocytosis mechanism used under low 
frequency stimulation whilst FF is the dominate mechanism for high frequency. This result 
would appear to suggest that a lower increase in [Ca2+]i may induce KR whilst a higher 
level may induce FF. However, Ashton and colleagues (Bhuva, 2015; Singh, 2017) have 
found that it is the RRP that undergoes KR and this is released under mild stimulation 
whilst the RP undergoes FF and this would only be released under high frequency 
stimulation. Furthermore, the RRP SVs docked at the AZ release sites will be nearest to 
the Ca2+ channels involved in release and so these SVs will see the highest local [Ca2+]i 
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whereas the RP SVs that come on line are exposed to a lower [Ca2+]i as they get activated 
and move and fuse at the AZ after the RRP SVs. Importantly, it was shown that an increase 
of extracellular calcium concentrations shifted the preferred mode of exocytosis to the KR 
mechanism in calcium dependent manner (Ales et al, 1999). The level of Ca2+ has been 
linked to the regulation of KR via synaptotagmins. Synaptotagmin (Syt) are a family of 
membrane proteins that are well characterised as a Ca2+ sensors that initiate SNARE-
dependent vesicle fusion during synaptic transmission (Xie et al, 2017). Amongst this 
large family of Syt, Ca2+ interaction with Syt 7 C2A domain could regulate the triggering 
of the fusion pore opening. Such pore opening through this process is unstable, so that the 
pore closure leads to KR fusion events (Segovia et al, 2010, Neuland et al, 2014).  
Modification of Ca2+ level has also been implicated in the regulation of dynamin and actin 
meshwork (Cardenas and Marengo, 2016) which may play a role in regulating the fusion 
mode. Dyn is a large GTPase that has been established to control fission of invaginated 
pits that are produced during some forms of endocytosis. Dyn forms rings or collars around 
the necks of budding endocytic vesicles inducing GTP hydrolysis which result in 
membrane remodelling and eventual fission of the invaginated pit. However, the role of 
Dyn GTPase activity has also been linked to the regulation of FP expansion (Decamilli et 
al, 1995; Warnock and Schmid, 1996; Ramachandran, 2011; Anantharam et al, 2011). 
Samasilp et al (2012) showed that under elevated stimulation, Dyn I is dephosphorylated 
at Ser-774 site by CN and this leads to an association between Dyn I-syndapin binding, 
but that disruption of this interaction may limits FP (Samasilp et al, 2012). Recently, Wu 
et al (2019) reported that most Ca2+ induced exocytosis occurs through the KR mode; 
author referred to this as subquantal mode because in chromaffin granules not all 
catecholamine is release by KR mode. The study proposed that this releasing mode is 
promoted by Dyn I because in the absence of it, substantial increase of FF was identified 
(Wu et al, 2019).  
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Actin microfilaments, in conjunction with NM-II, have also been suggested to regulate KR. 
Doreian et al (2008) demonstrated that at low frequency stimulation, actin microfilaments 
were found to play an important role in stabilising the KR fusion event. Under increased 
stimulation, actin was disrupted and FF fusion became abundant. These authors tried to 
correlate the activity of NM-II with this cytoskeleton-dependent control of the fusion event 
since inhibition of NM-II or blockade of MLCK led to perturbation of FP dilation during 
increased stimulation frequencies which maintains the granule in KR mode of exocytosis 
(Doreian et al, 2008). These results were in chromaffin cells, which are distinct from nerve 
terminals. Ashton and colleagues (Bhuva, 2015; Singh, 2017) have actually found that 
NM-II can regulate the KR mode of the RRP of SVs in nerve terminals because this mode 
is switched to FF if the motor protein activity is blocked by Blebbistatin. The activator of 
NM-II does appear to involve protein kinase C (PKC) induced phosphorylation (Bhuva, 
2015; Singh, 2017).  Others have found that inhibition of NM-II with Blebbistatin led to a 
decreased mobility of the granule near to the AZ. A reduction in FP expansion speed and 
longer FP life times were identified when actin microfilaments were disassembled with 
cytochalasin D. This study in chromaffin cells demonstrated an increase spike half widths 
in amperometric recordings without change in quantal size after either NM-II or actin 
activities were silenced. These authors proposed that actin and NM-II facilitate release 
from individual chromaffin granules by accelerating dissociation of catecholamines from 
the intragranular matric potentially via generation of mechanical forces which is distinct 
from regulating the exocytotic mode and such regulation would not occur in glutamatergic 
SVs in which glutamate is not bound to a matrix (Berberian et al, 2009). 
Thus, there has been much research suggests that regulation of the KR mode of exocytosis 
involves the contribution of numerous proteins, including Dyn, NM-II, and actin, and these 
may be regulated by Ca2+ levels. Further, investigation into the precise properties of such 
proteins would be helpful in furthering the understanding of the mechanism mediating the 




The research in this thesis involves studying both the different pools of SVs and also 
investigating further the properties of the distinct modes of exocytosis. This work will all 
be carried out using rat cerbrocortical synaptosomes from adult animals. Some of the 
research represents a total new area for research for the Ashton laboratory whereas others 
represents a continuation of research that has been going on in the lab for over 10 years. 
 The areas to be investigated in this thesis are as follows: 
(i) Release of the silent pool (SP) of SVs. This pool is not normally released but previous 
work on hippocampal cultured cells utilising electrophysiological measurements 
suggested that roscovitine is able to induce the release of the SP of SVs. Thus, we will 
employ Roscovitine and determine whether we can indeed induce extra glutamate release 
from treated nerve terminals. Provided that we can study the SP we will perform further 
experiments to determine: (a) the calcium requirements for SP release; (b) the voltage 
dependent Calcium channel requirements for SP release;  (c) the regulation of the SP 
release by Protein Kinase C; (d) the release of the SP following the stabilisation of actin 
microfilaments; (e) a correlation between roscovitine induce release of the SP with 
changes in the phosphorylation of Syn 1 at various Ser residues that are regulated by 
distinct protein kinases and phosphatases. 
(ii) the use of Fluoxetine to study the silent pool of SVs. Recently, Jung et al (2014) 
suggested that this anti-depressant actually can induce the release of the SP of 
glutamatergic SVs. Thus, we will seek conditions to induce the SP of GLU containing SVs 
in synaptosomes following treatment with Fluoexetine. We will establish that any extra 
release is truly coming from the SP. 
(iii) The role that actin cytoskeleton has on the release of distinct pools of SVs. The effect 
that actin disassembly (using Latrunculin) or actin microfilament stabilisation (using 
Jasplakinolide) has on the release of the RRP and the RP and also what effect this might 
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have on the modes of exocytosis can be determined. This will be studied by measuring 
GLU release evoked by either high potassium (HK5C) or Ionomycin (ION5C). 
Subsequently, SV exocytosis can be studied using FM2-10 dye release and any differences 
in the requirements for these 2 stimuli may reveal differences in the Dyn dependent KR 
mode (induced by ION5C) and the NM-II dependent KR mode (induced by HK5C). This 
work is required before one could investigate any role of this cytoskeleton on the release 
of the SP. 
(iv) Determining whether Dyn is already present on a membrane compartment during 
synaptic vesicle exocytosis involving the Dyn dependent KR mode. This can be done using 
a drug MITMAB that prevents dynamin binding to membranes. 
(v) Determining whether the Dyn dependent KR mode requires the activity of endogenous 
PKA whilst the NM-II dependent KR mode does not. This will be investigated by 
inhibiting PKAs with KT 5720. 
(vi) Determining whether the Dyn dependent KR mode and the NM-II dependent KR 
mode can be regulated by distinct voltage dependent Calcium channels. This will be 
investigated by blocking P/Q, N and L-type channels with distinct toxins/drugs and 



















2.1.1 Buffering Reagents 
- Physiological buffer (L0): 125 mM NaCl, 5 mM KCl, 1 mM MgCl2, 20 mM Hepes 
and 10 mM glucose; pH 7.4. Note, where required, 5 mM Ca2+ was added to this 
(final concentration). 
- Homogenisation sucrose buffer: 320 mM sucrose and 10 mM Hepes; pH 7.4 
- Stock high potassium (HK0) buffer: 130 mM KCl, 20 mM Hepes, 1 mM MgCl2 
and 10 mM glucose; pH 7.4. Note, where required, 25 mM Ca2+ is added to this 
such that when diluted the final concentration of KCl is 30 mM and that of CaCl2 
is 5 mM. 
- Bioenergetics buffer: 120 mM NaCl, 14 mM D-glucose, 3 mM KCl, 2 mM MgSO4, 
12 mM NaSO4, 1.3 mM CaCl2, 0.4 mM KH2PO4, 10 mM pyruvate, 60 M bovine 
serum albumin (BSA), pH 7.4, This was employed as previous synaptosomal 
bioenergetics studies in the Seahorse flux analyser has utilised this buffer 
(Seahorse Bioscience, N.D). 
2.1.2 Stimulation Solutions 
The current study employed three 5 mM Ca2+ based stimuli, High potassium (30 mM K+; 
HK5C), Ionomycin (5 M ionomycin; ION5C) and 4-aminopyridine (1 mM 4-
aminopyridine; 4AP5C) to induce SV release. It has been established from previous 
studies by Ashton and colleagues that 5 mM Ca2+ with HK or ION containing buffers give 
maximal release of glutamate (GLU) from both the RRP and the RP, and equivalent 
amount of 4AP only gives maximal release of GLU exclusively from the RRP (see 
appendix 1). This latter stimulus, therefore allows investigation of RRP separately from 
the RP using the assays listed below (Bhuva, 2015; Singh, 2017; Rostron, 2019). Ca2+ free 
solutions; HK0 and 4AP0, were employed for HK5C and 4AP5C as a basal condition for 
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GLU assays (such Ca2+ free stimuli may induce some non-vesicular glutamate release), 
while L0 was used for the FM 2-10 dye assay as this only measure vesicular exocytosis 
which is totally Ca2+ dependent. The natural characteristic of ION where it can insert into 
terminal membranes and also internal membranes to cause Ca2+ release from intracellular 
stores disallowed the possibility of creating Ca2+ free solution contacting ION alone, 
therefore L0 was used instead. A. Ashton has established through comparison studies that 
L0 produces indistinguishable results from HK0 and 4AP0 for FM 2-10 dye, and therefore 
L0 was used as the control condition for these experiments, as the latter two have no impact 
upon vesicular release (as mentioned above). 
2.1.3 Drugs employed and their final concentrations (all Dissolved 
in DMSO unless specified otherwise)  
All optimum concentration of the following drugs have been established previously in 
A.Ashton’s laboratory. 
- Roscovitine (10 M, 33 M, 100 M, 200 M) 
- Dynasore (80-160 M) 
- Blebbistatin (50 M) 
- Pitstop 2TM (15 M) 
- Phorbol 12-myristate 13-acetate (PMA) (40 nM, or 1 M) 
- Go6983 (1 M) 
- KT5720 (2M) 
- Latrunculin (LAT) (15 M) 
- -Conotoxin GVIA (CONO) (1 M) 
- -Agatoxin TK (AGA) (50 nM) 
- Nifedipine (NIF) (1 M) 
- Jasplakinolide (JASP) (2.5 M) 
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- Cyclosporine A (Cys A) (1 M) 
- Okadaic acid (OA) (0.8 M) 
- Fluoxetine (1 M, 200 nM, 100 nM, 60 nM, 40 nM, 20 nM, 5 nM) 
- KN-93 (10 M) 
Drug utilised in bioenergetics measurements (stock and final) 
- Oligomycin (32 M, 4 M Final) 
- FCCP (18 M, 2 M Final) 
- Rotenone ( 50 M, and 5 M, or 5 M and 0.5 M Final) 
- Antimycin A (50 M, 5 M or 5 M and 0.5 M Final) 
2.1.4 Other drugs employed 
- 1 x sample buffer with DTT for NuPAGE gel system (Life Technologies) 
- 1 x NuPAGE MES SDS Running buffer 
- 3-5 l Unstained MagicMarkTM XP Western Protein Standard 
- 3 ml SuperSignalTM West Dura Extended Duration Substrate 
- 15 ml RestoreTM PLUS Western Blot Stripping Buffer 
- 35 milli-Units (mUnits) of glutamate dehydrogenase type-II (GDH) 
- 1 mM NADPH 
- 100 M FM 2-10 dye 
- 5 M Fura-2 AM 
2.1.5 Measuring Instruments 
- Tecan Genious Pro Infinite 200 multimode microplate reader. 
- Seahorse Bioscience – Xfp extracellular flux analyser 




- Beckman-Coulter Avanti®  J-25 series centrifuge, utilising the JA-17 rotor.  
- PowerEase 500 power packs. 
- Thermo Fisher – iBlot and iBlot 2. 
- NuPAGE gel electrophoresis tanks and pre-cast gel system 
- Bio-Rad ChemiDoc XRS+ imaging system with Image Lab software version 3.0.1. 
2.1.6 Antibodies used for Western blotting 
For western blot analysis, specific commercially available antibodies shown in figure 2.1 
were employed to investigate the phosphorylation profile of Syn-I. All antibodies were 






Pan synapsin I 1:2000 Anti-rabbit 1:2000 
Phospho-Ser-9 
Synapsin I 
1:2000 Anti-rabbit 1:2000 
Phospho-Ser-553 
Synapsin I 
1:4000 Anti-rabbit 1:2000 
Phospho-Ser-603 
Synapsin I 
1:1000 Anti-rabbit 1:2000 
Figure 2.1: Antibodies employed for Western Blotting 
2.2 Preparation of Synaptosomes 
A Wister rat was killed by cervical dislocation and the cerebral cortex was removed. The 
dissected brain tissue was then homogenised in chilled homogenising buffer (320 mM 
sucrose, 10 mM Hepes, pH 7.4). The suspension was centrifuged at 1941 x g for 10 min 
at 4oC with Beckman 25 centrifuge. The pellet was discarded, and the supernatant 
centrifuged at 21,075 x g for 20 min at 4oC. The supernatant was discarded, and the pellet 
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was resuspended and homogenised in 40 ml chilled, gassed basal physiological buffer. 
Supernatant was then re-centrifuged at 21,075 x g for 20 min at 4oC. The supernatant was 
discarded, and pellet resuspended and homogenised in gassed L0 (varying volumes that 
depended upon the assay being employed). The resulting synaptosomes (P2) were kept on 
ice and gassed with oxygen until use. Note that synaptosomes were resuspended in 
physiological buffer that has been saturated with oxygen.  
2.3 Glutamate Release Assay 
This glutamate (GLU) release assay was developed by Nicholls et al (1987) and adapted 
by Sim et al (2006) for use on a fluorescence plate reader. A volume of 2 ml synaptosomes 
(from an 8 ml initial suspension) were centrifuged with L0 and resuspended in 1 ml of L0. 
The resulting suspension was then stimulated for 90 sec with HK5C (induce all the 
releasable vesicles to exocytose). Synaptosomes were then centrifuged, resuspended in L0, 
centrifuged and resuspended in L0, this ensured complete removal of the stimulus. The 
synaptosomes were then incubated at room temperature (RT) for 10 min to allow all the 
originally stimulated exocytosed SVs to recycle. Subsequently, the appropriate drug or 
equivalent amount of drug solvent (DMSO only in control tests) was added to the 
synaptosomes and these were incubated at 37oC for 5, 10, or 20 min depending on the 
particular drug being used. The samples were then washed, and resuspended in 1.6 ml of 
L0 containing the relevant concentration of drug being tested (control simply had the 
equivalent amount of DMSO added) in order to prevent the reversibility of the drug action. 
A volume of 121 l aliquots of the resulting sample was then added to each of 12 wells of 
a row of a Grenier 96 well microtitrate plate (black with transparent bottom); 20 l of L0 
was also added to these wells. Subsequently, 10 l NADP+ (20 mM stock NADP+, 1 mM 
final conc.) and 9 l (36 mUnits final conc.) of glutamate dehydrogenase type-II (GDH) 
were then added to each well and synaptosomes were incubated at RT for 10 min. At this 
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stage, non-evoked extracellular glutamate is converted to -ketoglutarate by GDH in the 
presence of NADP+ which is itself converted to NADPH (see the equation below).  
GLDH2 + H2O + NADP+ = -ketoglutarate + NH3 + NADPH + H+ 
The NADPH is measured by its fluorescence; this enables all the non-evoked GLU to be 
reacted and a background fluorescence to be established. After the incubation, an 
appropriate stimulus without Ca2+ (e.g. HK0) was added to wells 6-12 and the 
corresponding Ca2+ containing stimulus (e.g. HK5C) was added to well 1-5. For ION, L0 
was added to the basal sample (6-12) whilst L0 + 5 mM Ca2+ plus 5 M ION was added 
to wells 1-5. For 4AP5C, 4AP0 was added to wells 6-12 whilst 1 mM 4AP plus 5mM Ca2+ 
was added to wells 1-5. 
The plate was inserted into Tecan GENIOS pro infinite 200 plate reader (at excitation 
wavelength: 340 nm; emission wavelength: 465 nm; gain: 100; read mode: bottom) and 
measurements were made for 21 cycles for wells 1-9 (this represented just over 5 minutes 
at which times all the release GLU had reacted with GDH). After these measurements, 10 
l of L0 was added to wells 7-9 and to wells 10-12, 10 l of 1 mM GLU (freshly prepared 
from 679 mM stock glutamate) was added. The plate was reinserted into the plate reader, 
and the effect of the addition of this stock GLU (10 nmol) was measured for 15 cycles 
using the same settings as above but just measuring wells 7-12. Subtracting the average 
background values (6-9) from the average stimulation values (1-5) provided a measure of 
the Ca2+ dependent GLU release. This was in arbitrary fluorescent units (AFU). The AFU 
measured following the inclusion of 10 nmol GLU enables one to convert the data from 
AFU to nmol of evoked GLU release. Also, since 10 nmol GLU was added after the 
measurement of each row of the microtitre plate, this value of fluorescence could be 
utilised to correct for the sensitivity of the assay in each row which allows a direct 
comparisons between rows containing different conditions within the same experiment 
and this can also be used between different trial of experiments to ensure all samples 
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measure are normalised to similar sensitivity. The corrected values for all relevant 
stimulated samples from all experiments were averaged and the SD determined as were 
the corresping basal release mean determined plus its SD. The basal mean was subtracted 
from the release in the presence of the stimulus to produce the Calcium dependent release. 
The SD for the release induced by the stimulus was squared and was added to the square 
of the SD for the basal condition. The square root of this sum represented the SD of the 
Calcium dependent evoked release. The two conditions were compared using two-tailed 
Student’s t-test, with a significance threshold of 0.05. This was following the averaging of 
at least 3 independent repeates of the experiment (see further comments below). 
2.4 FM 2-10 Styryl Dye Release Assay 
A volume of 1 ml synaptosomes was taken from an initial 8 ml final resuspension stored 
in ice, prepared as outlined above and pelleted, and re-suspended in 1 ml L0 at room 
temperature. 100 M of FM 2-10 dye (final) was added to this and incubated for 60s 
followed by stimulation with HK5C for 90 sec. 
After the incubation, the stimulus was removed via centrifugation and the synaptosomes 
were resuspended in 1 ml L0 containing FM 2-10, and spun down again (to ensure stimulus 
removed), it was then resuspended in buffer containing 100 M FM2-10 dye and incubated 
for 10 min; this allowed all SVs labelled with FM dye to recycle. Subsequently, 
synaptosomes were treated with the desired amount of drug or equivalent amount of 
DMSO (control samples) and incubated at 37oC for 5-20 min. A 4 l of 250 mM advasep-
7 (1 mM final) was then added to the mixture (at RT), this removes the FM 2-10 dye from 
the synaptosomal plasma membrane and reduces the background fluorescence. The 
samples were then washed twice and re-suspended in 1.5 ml of L0 along with the 
corresponding concentration of the drug or DMSO. 
A volume of 160 l of aliquots were then added to the 8 wells of Greiner 96 well microtitre 
plate (black with opaque bottom). A Tecan GENIOS Pro infinite 200 plate reader was used 
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to determine fluorescence measurement with the following settings; excitation wavelength: 
465 nm; emission wavelength: 555 nm; gain: 40; read mode: top; number of cycles: 461. 
Each well was measured individually (just over 2 min per well) 
Just before measuring the fluorescence, the synaptosomes in the well were stimulated 
using the relevant stimulus (HK5C, ION5C, or 4AP5C) or were subjected to the equivalent 
amount of L0. For each row, 4 wells were stimulated and 4 just had basal buffer added 
(L0). These steps repeated for the eight rows of the plate for different treatment conditions. 
The precise treatment conditions were repeated again during the same experiment, but this 
time, the order of wells that had stimulus or basal buffer added was changed to ensure that 
there were at the end of the experiment 8 readings for basal and 8 for stimulus and that the 
time before the measurement of each well were on average equivalent. After the 
experiment, the basal data were subtracted from the average stimuli data (for the relevant 
treatment). Prior to this, all individual wells were corrected such that they had the 
equivalent starting value of FM 2-10 dye fluorescence. This normalisation allowed the one 
to directly compare each individual experiments. This value represented the true Ca2+- 
dependent FM dye released, expressed in terms of decrease in fluorescence. 
The actual starting fluorescence allowed one to see whether the drug treatment perturbed 
the total dye labelled SV content prior to stimulation (see appendix 3). 
Significance values were calculated using a two-way student’s t-test with a significance 
threshold of 0.05. This was following a minimum of 3 independent repeats of the 
experiment. 
2.5 Fura-2 Assay 
2.5.1 Background 
The current study has used Fura-2-acetoxymethyl ester (Fura-2-AM) assay to measure the 
evoked change in the level of intracellular Ca2+ level ([Ca2+]i). Fura-2-AM is a Ca2+ 
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insensitive, cell permeable ester which when it is taken up by a cell, its AM is cleaved off 
by esterases. Following this procedure, the drug (free Fura-2) is unable to cross the plasma 
membrane but it is now Ca2+ sensitive, which binds to the Ca2+ within the cell. When it 
combines with Ca2+ Fura-2 produces an increase in fluorescence when excited at a 
wavelength of 340 nm and fluorescence measured at 535 nM. When it is in a Ca2+ free 
environment, Fura-2 produces a maximum fluorescence when excited at a wavelength of 
380; the emission wavelength of Fura-2 is always 535. Hence the ratio between the 
collected 340:380 fluorescence values is proportional to the concentration of [Ca2+]i (nM). 
This can be calculated via the Grynkiewicz equation (Grynkiewicz et al., 1985):  
[𝐶𝑎2+]𝑖(nM) = kd X B X 
(R − Rmin)
(R max − 𝑅)
 
Kd represent the constant of Ca2+ binding: 224 nM; B is the ratio of average fluorescence 
at 380 nm under Ca2+ free and Ca2+ bound condition; R stand of the ratio of 340/380; Rmin 
is 340/380 ratio in Ca2+ free environment; Rmax is 340/380 ratio in a Ca2+ saturated 
environment. 
2.5.2 Procedure 
Cerebrocortical synaptosomes were prepared by the above method and resuspended in 10 
ml L0. Then 50 g Fura-2-AM in 50 l DMSO (1 mM stock; 5 M final) was added and 
the synaptosomes were incubated for 30 min at 37oC. Subsequently, 3 ml L0 were added 
to this suspension and 12 x 1 ml fractions were taken, then spun down in an Eppendorf 
centrifuge, each fraction was then washed with 1 ml L0 at room temperature before being 
centrifuged again. These samples were resuspended 12 x 0.7 ml L0 (cold buffer) pooled 
and kept on ice and oxygenated. When required, a 1 ml aliquot of stimulus was added to 
0.25 ml (130 mM K+, 25 mM Ca2+) i.e. HK5C, and incubated for 90 sec. The samples were 
then spun down and resuspended in 1 ml L0 following another centrifugation (to reproduce 
the pre-stimulation used for GLU and FM dye release assays) and then resuspended in 
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0.88 ml L0 (final volume 1 ml as pellet has some volume) before being incubated for 10 
minutes at room temperature. Then, either control solvent or drug was added and the 
resulting synaptosomes were incubated for 5-20 min at 37oC before being centrifuged. 
Subsequently, the sample was washed with 1 ml L0 buffer and recentrifuged before being 
resuspended in 1.6 ml L0 containing relevant drug or solvent. 12 x 0.12 ml aliquots were 
added to wells 1-12 of a black flat bottom plate and 40 l L0 was also added to these wells. 
The plate was then inserted into the plate reader. 
The plate reader was programmed with the following settings; measurement mode: top; 
excitation wavelength: 340 or 390 nm; emission wavelength: 535 nm; gain 30; well 
kinetics 40 (no injection) or 160 (injection); injection volume: 40 l. Pump A contained: 
130 mM K+ containing buffer, 25 mM Ca2+ or L0 plus 25 mM Ca2+, or 5 mM 4AP in L0 
plus 25 mM Ca2+. Pump B contained L0. Fluorescence was measured from each well 
individually. The first well was read for 40 cycles at the excitation wavelength of 340 nm 
and emission wavelength 535 nm, which is equivalent to approximated 10s, providing an 
average, baseline-fluorescence value. Subsequently, 40 l of either a particular stimuli or 
L0 was injected into the well and the well was measured for 160 cycles, which took ~40 
sec, at the same excitation and emission wavelength. For the next well, a similar procedure 
is used, but this time the excitation is at 390 nm (this was the nearest filter available to 380 
nm, but it had a bandwidth which includes 380 nm). 
The benefit of using two excitation wavelengths is that it allows calculation of the 340/390 
ratio metric value for these wells. For each row, six wells were injected with 40 l of a 
stimuli (for ION, it could not be injected and thus it was added to the relevant well just 
prior to the injection of L0 containing 25 mM Ca2+ (final concentration of it was 5 M)), 
and other six wells were injected with 40 l of L0. The 340/390 ratio calculated for L0 
treated wells were subtracted from the ratio from stimulated wells in order to determine 
the change in [Ca2+]i evoked by the stimulation alone. Hence each row produces three 
340/390 ratio sets for stimulation and control conditions of the drug treatment. 
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Following the measurements of all 12 wells in a row, aliquots of 2.25 mM Ca2+ and 0.3% 
Triton X-100 (final concentrations) were added to the six wells that had been injected with 
a stimuli (final volume: 240 l). For the other six wells with L0, aliquots of 15 mM EGTA 
and 0.3% Triton X-100 (final concentration) were added. Subsequently, all 12 wells were 
measured for 40 cycles, first at the excitation wavelength 340 nm then at excitation 
wavelength 390 nm. Data collected through this procedure allowed one to calculate Rmax 
and Rmin from samples treated with 2.25 mM Ca2+ and 15 mM EGTA respectively. A 
spreadsheet was designed which used the Grynkiewicz equation (see equation above) to 
calculate the concentration of [Ca2+]i. Significance values were calculated using two-tailed 
student’s t-test, with a significance threshold of 0.05, after the experiment had been 
performed at least 3 independent times.  
2.6 Data analysis 
The data shown herein are the average of several independent experiments (n). All basal 
values and stimulated values from all experiments were averaged. The average basal value 
was subtracted from average stimulated value with the statistical analysis performed using 
Microsoft Excel. The values were statistically analysed by comparing control and tested 
values using two-tailed student’s t-test with P<0.05 being considered as significant. The 
results were shown in graph as a percentage of maximum control. For a convenience in 
presentation, selective data points at an interval of 10 sec were shown, wherein the error 
bar indicates the standard error of mean (S.E.M). In chapter 3-6, ‘n’ value shown in the 
figures represents is the total number of independent replicates performed whilst in the 
legends of figure this same n values is shown together with the total number of independent 
experiments. Previously, A. Ashton had ascertained that the data exhibited a normal 
distribution with these types of experiments and that two-way ANOVA produced exactly 
the same P values as the student’s t-test. Thus, we used the student’s t-test in the 
experiments herein.  
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2.7 Western Blotting 
2.7.1 Sample Preparation 
Synaptosomes were prepared by above method, pre-stimulated with HK5C, incubated for 
10 mins at RT and then treated with the relevant drugs or DMSO (control) for 5 min at 
37oC. Following this treatment and the relevant washes, the appropriate stimulus (HK5C, 
ION5C, 4AP5C or L0) was applied for various time points (2, 15, 30, 120 sec) before the 
reaction was terminated by the applying LDS (lithium dodecyl sulfate) sample buffer 
containing reducing agent DTT (dithiothreitol). Samples were then heated for 10 min at 
70oC. Subsequently, samples were stored at -20oC until required.  
2.7.2 Bradford Assay 
Protein concentration in each sample was determined using Bradford assay. Final 
concentration of the protein was adjusted to 1.5 mg/ml. Bradford assay measurements were 
read on a Tecan GENIOS Pro infinite 200 plate reader (absorbance wavelength: 595 nm). 
Note an equivalent sample to that used on stimulation for western blotting was used for 
the protein assay, but no LDS was added. Samples were solubilised in 1 M NaOH and then 
diluted to 0.25 M NaOH. All standards also dissolve in 0.25 M NaOH. 
2.7.3 Electrophoresis and Transfer 
The frozen stored samples were re-heated for 10 min at 70oC before carrying out 
electrophoresis on 4-12% NuPAGETM gels in the NuPAGETM gel system from Life 
Technologies using NuPAGETM MES running buffer. Western blotting was then 
performed using iBlotTM or iBlot2 from Thermo Fisher, transferring the proteins to PVDF 
membrane. The membrane was subsequently blocked for 60 min with either 30 ml of 
blocking buffer (3% dried milk powder, 1% Tween-20 in tris buffered saline (TBS); pH 
7.4) or 15 ml of StartingblockTM T20 blocking buffer. The blocking buffer was discarded 
and the blots were washed for 10s with 1% Tween-20 in TBS.  
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2.7.4 Probing and Chemiluminescence 
After the transferring of the PVDF membrane, it was then probed for the study of specific 
phosphorylation sites on proteins by adding 10-15 ml buffer (dried milk powder, 1% 
Tween-20 in TBS; pH 7.4) containing specific primary antibody for 60-90 min at room 
temperature (see table above for dilution of antibody employed). Antibody solution was 
removed from the membrane and membrane was washed for 6 x 5 min with 25 ml wash 
buffer (0.5% Tween-20 in TBS; pH 7.4). Wash buffer was then discarded and a HRP 
conjugated secondary antibody, relevant to the primary antibody, was then added. This 
was added to 10-15 ml antibody buffer and incubated for another 60-90 min at room 
temperature. 
After the incubation, antibody buffer was removed and washed using same procedure. 
Then, PVDF membrane were incubated with 3 ml SuperSignalTM West Dura Extended 
Duration Substrate chemiluminescence agent for 5 min and then its bands were visualised 
using BioRad ChemiDoc XRS+ with Image lab software. For re-probing of blots, they 
were stripped using 15 ml Restore TM PLUS Western Blot Stripping Buffer and blocked 
ready for antibody probing (Bhuva, 2015). 
2.7.5 Quantification of bands 
The combination of ChemiDoc XRS+ system with Image Lab software reads the 
chemiluminescence of protein bands on the membrane, where signal intensity is directly 
associated with the amount of protein or phospho-protein in the band of interest. However, 
the signal intensity is also closely related to duration of exposure, whereby a longer 
exposure time means higher chance of error to occur in band quantification because of 
over-exposure. Thus each blot was developed for many exposure times to ensure the 
linearity of the chemi-luminescence signal (see appendix 2). 
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Such semi-quantification analysis also employed internal controls whereby bands are 
quantified relative to each other and the relevant internal control. Bands of interest were 
quantified via the volume calculation tool from the Image Lab software where the user 
could draw a box around the bands of interest and the software calculates average signal 
intensity within the box (higher the intensity of the box means higher reading in arbitrary 
units). In addition, the software could also reduce the localised errors as it accounts for 
changes in background signal intensity between bands, reducing artefacts potentially been 
detected by uneven background signal. Once all the bands from the blot are quantified 
through this method, they were expressed as a percentage of the unstimulated control 
sample (in order to get the relative quantities of protein present in the given set of bands). 
Note usually the phospho-band was detected and quantified. Then the same blot was 
stripped and re-probed for the total content of that protein (pan antibody). Then the 
phospho-bands could be normalised to the total pan-content of the band.  
2.8 Bioenergetic measurement with Seahorse XF machine 
2.8.1 Background 
The XF Cell Mito stress test measured the mitochondrial respiratory activity of 
synaptosomes under various conditions. Mitochondrial are acknowledged as an essential 
energy supplier for the cell and it is responsible of producing the majority of energy in the 
form of ATP through numerous pathways (Johri and Beal, 2012). Hence such 
measurement could indicate whether any of the drugs employed in this study might perturb 
the bioenergetics of the terminals. This could indicate a non-specific action of such drugs. 
The protocol measured key parameters of mitochondria function via the direct 
measurement of oxygen consumption rate (OCR) from the synaptosomes. The machine 
used modulators of respiration which focused on the components of the electron transport 
chain (ETC) of the mitochondria; thus, revealing the key parameter of metabolic function 
(see diagram 2 and 3). The compounds (oligomycin, FCCP, and rotenone/anitimycin A) 
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were serially injected into the well and these revealed levels of ATP production, maximal 
respiration, and non-mitochondrial respiration. Proton leak (represents a remaining basal 
respiration not coupled to ATP production, hence showed the mitochondrial damage) and 
spare respiratory capacity (measure of the cell’s ability to respond to increased energy 
demand) could then be calculated using these parameters then compared to basal 






Figure 2.2. Diagram showing the key parameters of mitochondrial respiration measured by 
the instrument; Oxygen consumption rate (OCR) is a parameter to study mitochondrial 
function (Taken from Seahorse Bioscience, N.D). 
Figure 2.3. Diagram showing the complexes in electron transport chain (ETC) that each 





Oligomycin (C45H74O11) disturbs ATP synthase and the injection of this drug leads to the 
decrease in OCR which represents the basal mitochondrial respiration associated with 
cellular ATP production. Carbonyl cynanide-4 (trifluoromethoxy) phenylhydrazone 
(FCCP) (C10H5F3N4O) is an uncoupling agent that collapses the proton gradient and 
disrupts the mitochondrial membrane potential. Consequently, electrons flow into the 
electron transport chain (ETC) and this leads to maximum oxygen consumption by the cell, 
such measurement could then be calculated to reveal spare respiratory capacity. The third 
injection included a combination of rotenone (C23H22O6) (complex I inhibitor) and 
antimycin A (C28H40N2O9) (a complex III inhibitor). These stopped the mitochondrial 
respiration and allowed the determination of the non-mitochondrial respiration driven by 
processes outside the mitochondria (see Fig 2.3) (Seahorse Bioscience, N.D).  
2.8.2 Method 
A volume of 0.04 ml of the final synaptosomes suspension (from 8 ml total) was 
centrifuged and resuspended in 1.2 ml of the bioenergetics solution containing 4 mg/ml 
bovine serum albumin (60 M) (see sections 2.1.1 for buffer composition: note this was 
carefully titrated to pH 7.4 just prior to its use after 10 mM pyruvate had been added). 
0.175 ml of this synaptosomal suspension was aliquoted into wells B-G of XF Miniplate 
which has been pre-treated with 1:1500 dilution of a 50% solution of polyethylenemine 
(plate coated overnight, and then solution removed and plate allowed to dry). The 
synaptosomes were then spun in an Eppendorf A-2 MTP swing out rotor for 20 min at 4oC 
at 2000 x g for synaptosomes adherence onto the well floors. The supernatant in the wells 
were removed from the immobilised synaptosomes and these were then treated with 37oC 
bioenergetics buffer containing the required concentration of selected drug dissolved in 
DMSO into wells A-D or buffer and DMSO only into wells E-H for control. This was 
incubated for 5-20 min at 37oC prior to two washes at RT, with the bioenergetics buffer. 
Note that wells A and H are a background control hence it just has buffer and DMSO 
added without synaptosomes. 
44 
 
A sensor cartridge was hydrated overnight at 37oC in calibration buffer (supplied by 
company but represents phosphate buffered saline). The relevant drugs for the 
mitochondrial stress test assay were dissolved in DMSO, apart from antimycin A which 
was in ethanol, and were added into the injector ports (32 M oligomycin in port A, 18 
M FCCP in port B, 50 M or 5 M rotenone/antimycin A in port C) prior to the 
experiment. The sensor cartridge was added to XP extracellular flux analyser to calibrate 
and the loaded miniplate was added. The synaptosomes had to be fresh so only one 
experiment was run per synaptosomes preparation. The measurement were performed at 
either 37oC or RT (22-27oC) and the Seahorse XFp flux analyser was kept at 37oC with 
the inbuilt heater or the heater was not employed and with the aid of a cooling mobile air 
conditioning unit the temperatures was kept at RT. This was dependent on the actual RT 
which varied such that the actual measurement temperature varied between 22 oC to 27oC.  
The machine then measured 3 x 3 min measurement of basal oxygen consumption rate 
(OCR). Then oligomycin was automatically injected into each well and a further 3 x 3 min 
measurement performed. Subsequently, FCCP were injected and 3 x 3 min measurements 
taken. Lastly, rotenone/antimycin A was injected and another 3 x 3 min measurement 
made. The result enabled one to obtain average oxygen consumption rate (OCR) traces of 
the wells following the drug treatment (wells B-D) and control (wells E-F), minus the 
baseline (wells A and H). The data was saved in an Excel spreadsheet and the raw data for 
each well could then be analysed and such data was then combined with the repeated 
experiments and produced average values which then could be statistically analysed with 















3.1 SP SVs are released by HK5C or ION5C following pre-
treatment with Roscovitine 
The SP of SVs has been largely an enigma because it is not released under normal 
physiological conditions, and therefore it is difficult to explore its properties. Kim and 
Ryan (2010) in their research have used Roscovitine, a Cdk5 inhibitor, to induce extra 
release from hippocampal cultured cells, which they suggested is from the SP. The results 
from the following research has indicated that it is possible to investigate the properties of 
the SP by pre-treating synaptosomes with Roscovitine and then evoking release with 
various stimuli. 
3.1.1 100 M Roscovitine induced maximum HK5C evoked GLU 
release 
It was essential to establish whether a suitable concentration of Roscovitine could induce 
more GLU release than just that due to exocytosis of the RRP and RP (see appendix 1 Fig 
A1). A dose-response curve for Roscovitine action on HK5C evoked GLU release was 
established. Synaptosomes were pre-treated with 10 M, 33 M, 100 M, and 200 M 
Roscovitine and the GLU release was evoked using HK5C. The results demonstrate that 
Roscovitine increased the amount of HK5C evoked GLU release in a dose dependent 
manner with 100 M inducing the maximum release (Fig 3.1). As HK5C maximally 
released the RRP and the RP (see appendix 1 Fig A1), it can be deduced that the extra 
release must be from the SP. Increasing the concentration of Roscovitine from 100 M to 
200 M failed to produce any further release relative to that induced by HK5C in the 





Figure 3.1. Increasing Roscovitine concentration induced greater HK5C evoked GLU release 
relative to non-drug treated control. Data are mean ± SEM, N=3 independent experiments; 
P <0.05 for 100 M i.e. 100 M Roscovitine can evoke a significant increase in release of GLU 
compared to control. 
 
Figure 3.2. 200 M Roscovitine does not evoke significantly higher GLU release compared to 
100 M Roscovitine. HK5C evoked GLU release following treatment with 100 M and 200 
M Roscovitine. Data are mean ± SEM, N=3 independent experiments; P <0.05 for both 100 





3.1.2 ION5C also releases the SP following 100 M Roscovitine 
treatment 
Ionomycin (ION) has a different mechanism than HK action but it can induce the maximal 
release of the RRP and RP in the presence of 5 mM Ca2+ (see appendix 1 Fig A1). This 
ionophore bypasses the requirement for activated Ca2+ channels, as it transports Ca2+ 
across the PM, thereby increase the [Ca2+]i level throughout the cell. It was important to 
establish that the SP could be released using ION5C and Roscovitine. Indeed, there was a 
significant increase in the ION5C evoked GLU release when terminals were treated with 
100 M Roscovitine (Fig 3.3).  
Figure 3.3. 100 M Roscovitine is able to produce significantly higher ION5C evoked GLU 
release compared to non-drug treated control. ION5C evoked GLU release following 100 M 





3.1.3 Inhibition of Cdk5 with Roscovitine does not perturb the 
HK5C and ION5C-induced changes in [Ca2+]i in synaptosomes 
As Ca2+ levels play a pivotal role in regulating the release of the neurotransmitter, it was 
important to establish whether the SP release induced by HK5C and ION5C in Roscovitine 
treated terminals was due to any changes in evoked [Ca2+]i. The change in [Ca2+]i induced 
by HK5C was measured using the Fura-2 assay for both 100 M Roscovitine and in non-
drug treated terminals. However, Roscovitine did not affect the HK5C-evoked change in 
[Ca2+]i (Fig 3.4).  
 
Figure 3.4. 100 M Roscovitine treatment did not change HK5C evoked [Ca2+]i compared 
to control. [Ca2+]i induced by HK5C in control and 100 M Roscovitine treated terminals. 
Data are mean ± SEM, N=3 independent experiments; P>0.05 for test compared to control 
(i.e. no significant differences). 
Similarly, there were no significant differences in  [Ca2+]i identified between control and 






Figure 3.5. ION5C evoked [Ca2+]i was unaffected by Roscovitine treatment compared to 
control.  [Ca2+]i induced by ION5C in control and 100 M Roscovitine treated terminals. 
Data are mean ± SEM, N=7 independent experiments; P>0.05 for test compared to control 
(i.e. no significant differences). 
 
3.2 Roscovitine did not induce recycling and re-release of the RRP 
and the RP 
Research from Ashton’s group has shown that neither HK5C nor ION5C can induce more 
than one round of release of the RRP and the RP, such that there is no recycling, reloading 
and re-release of these vesicle pools in the presence of these stimuli (see Appendix 1 Fig 
A3). However, there was still a potential that Roscovitine – by blocking Cdk5 activity – 
could actually enable the recycling, reloading, and re-release which mean the release 
observed could possibly be from recycling of the vesicle from the RRP and the RP rather 
than release from the SP. As such, this study checked this by blocking all forms of Dyn 
dependent endocytosis including bulk endocytosis and clathrin mediated endocytosis by 
inhibiting the GTPase of Dyn with 160 M Dynasore (i.e. Macia et al, 2006). Comparing 
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HK5C evoked release in control and 100 M Roscovitine treated terminals (Fig 3.6a) vs 
HK5C evoked release in control and 160 M Dynasore plus 100 M Roscovitine 
synaptosomes (Fig 3.6b) clearly demonstrated that SVs recycling via a Dyn dependent 
process did not contribute to the extra GLU release. Similarly, inhibition of clathrin-
dependent endocytosis with 15 M Pitstop2TM (Dutta et al, 2012) failed to perturb the 
extra release evoked by HK5C in Roscovitine treated terminal (Fig 3.6c). The 
concentration of 80-160 M dynasore has been shown by others to inhibit dynamin 
dependent endocytosis (e.g. Macia et al, 2006). Likewise, 15 M Pitstop 2TM has been 
shown to inhibit clathrin dependent endocytosis. Further, A.Ashton (unpublished results) 
has shown that pre-treatment of synaptosomes wither either of these drugs – at these 
concentrations – prior to HK5C pre-stiumation, inhibits the recycling of those SVs that 
recycle by a clathrin and or dynamin dependent pathway; these represent those SVs that 
undergo FF during the pre-stimulation phase. These earlier results clearly indicate that the 
concentration of the drugs employed and the incubation condition used do allow such 


































































































































































































































































































































3.3 Roscovitine induces the HK5C evoked release of the SP of SVs 
independently of NM-II activity 
A previous study has shown that non-muscle myosin II (NM-II) activity can regulate the 
kiss-and-run (KR) mode of the RRP SVs evoked by HK5C (Bhuva, 2015; appendix 1 Fig 
A8, A9) and others have suggested a role for this motor protein regulating the release of 
various SV pools including the SP. Therefore, this study used the inhibitor Blebbistatin 
(50 M) (Kovacs et al, 2004; Shu et al, 2005) to block the enzyme activity of NM-II and 
looked to see whether this had any impact on Roscovitine’s action on the SP released by 
HK5C. Note that this concentration was shown to inhibit NM-II previously (e.g. Kovacs 
et al, 2004) and it was shown to exhibit an effect on the mode of RRP SV exocytosis 
evoked by HK5C (Bhuva, 2015; Singh 2017). The result show that Blebbistatin did not 
prevent the SP from being released from Roscovitine treated terminals (Fig 3.7) 
Figure 3.7. Extra release of GLU in Roscovitine treated terminals are independent of NM-II 
activity. HK5C evoked GLU release with 50 M Blebbistatin plus 100 M Roscovitine. Data 




3.4. Calcium dependency of Roscovitine induced SP release 
Entry of external calcium ions into the cytosol of the nerve terminal via Ca2+ channels has 
been acknowledged as a major step in neurotransmitter release. An arrival of action 
potential to a nerve terminal leads to opening of Ca2+ channels, which promote highly 
localised, transient rise in intracellular Ca2+ level at the active zone. Subsequently, Ca2+ 
stimulates synaptic vesicle exocytosis, release of the neurotransmitters contained within 
such vesicles and this initiates synaptic transmission. This mechanism was elucidated in 
the classical study on neuromuscular junction (NMJ) by Katz and Miledi (1967) (Sudhof, 
2012). Katz and Miledi (1968) later tested whether a residue of the active calcium entering 
the cell during the nerve impulse could be responsible for short term facilitation. This was 
tested through varying the external calcium level so that in the first of two nerve impulse 
[Ca2+]e is much lower than that for the subsequent impulse. They found that facilitation 
was more substantial in the latter condition; this was in accordance with the calcium 
hypothesis (Katz and Miledi, 1968). Calcium was also proposed to have two distinct role 
in vesicle recruitment; its role in accelerating SV docking and the buildup of a release 
machinery, and the other enhancing the coupling between releasable vesicles and the Ca2+ 
channels (Neher and Sakaba, 2008). In addition, Luo et al (2015) has also reported that 
SV exocytosis in NMJ is mainly triggered by calcium ion entering through the nearest 
calcium channel to the SV that is open, highlighting not only calcium entry as an essential 
feature of initiating the neurotransmission, but also an importance of the role calcium 
channels have in the course of exocytosis.  
The presynaptic active zone contains various types of voltage dependent calcium channels 
(VDCC), including N-type, P/Q-type and L-type. The role and specificity of such calcium 
channels on various processes occurring in active zones has been an issue of debate for a 
long time (Catterall et al, 2013). Previously for the release of the SP, evidence has been 
provided for some Ca2+ channel specificity. For instance, an electrophysiological study - 
using specific calcium channel blockers for each subtype - has demonstrated that Cdk5 
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inhibition with Roscovitine led to enhanced Ca2+ influx through the P/Q-type VDCCs 
(Tomizawa et al, 2002). Intriguingly, research showed that the intracellular loop 
connecting domains II and III (LII-III) between amino acid residues 724 and 981 of the rat 
brain 1A subunit of P/Q-type Ca2+ channels was phosphorylated by Cdk5, but that such 
phosphorylation perturbed the interaction of LII-III with SNAP-25 and synaptotagmin I. 
However, this information led to the suggestion that Cdk5 prevents neurotransmitter 
release through the phosphorylation of P/Q-type VDCC and downregulation of the channel 
activity (Tomizawa et al, 2002). Clearly this does not fit in with our results, but Kim and 
Ryan (2013) reported that the SP exocytosis triggered with Roscovitine (i.e. increased 
release) is predominately operated through N-type calcium channel. They showed this by 
pharmacologically blocking each channel types with specific toxins and then stimulating 
the SP release with Roscovitine in hippocampal neurons. This study indicated that in the 
condition when P/Q type was blocked with AGA, further release was identified when 
Roscovitine was treated together with AGA, whilst when N-type channel was blocked 
using CONO, no further release was observed, which suggest that it is N-type calcium 
channel that operates the SP release (Kim and Ryan, 2013). Herein, we re-examined the 
Ca2+ and Ca2+ channel requirement for release of the SP. 
3.4.1 Higher [Ca2+]e did not support the SP release 
Whether higher [Ca2+]e combined with HK and 100 M Roscovitine pre-treatment may 
give a further increase in the release of the SP was investigated. As previously shown (e.g. 
appendix 1 Fig A), relative to HK5C, HK10C (Fig. 3.8a) or HK20C (Fig. 3.8b) failed to 
produce any further release in control terminals. Furthermore, in 100 M Roscovitine pre-
treated terminals HK10C (Fig 3.9a) or HK20C (Fig 3.9b) did not produce any release from 
the SP, therefore, it would appear that the higher [Ca2+]e did not support exocytosis of the 
SP in rat cerebrocortical synaptosomes.  
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For further understanding of the result, the intracellular Ca2+ level was measured with 
Fura-2 assay. Employing HK10C (Fig 3.10) or HK20C (Fig 3.11), the [Ca2+]i level was 
reduced in Roscovitine treated terminal compared to that for non-drug treated and this 
implies that the higher [Ca2+]e level may perturb the SP release by actually reducing the 






































































































































































































































































































































































































Figure 3.10. HK10C evoked [Ca2+]i in Roscovitine treated terminals were significantly lower 
than non-drug treated terminals. Change in [Ca2+]i induce by HK10C in control and 100 M 
Roscovitine treated synaptosomes. Data are mean ± SEM, N=3 independent experiments; 
P<0.05.  
 
Figure 3.11. HK20C evoked [Ca2+]i in Roscovitine treated terminals were significantly lower 
than non-drug treated terminals Change in [Ca2+]i induced by HK20C in control and 100 




3.4.2 Regulation of PKC activity can inhibit the SP release evoked 
in Roscovitine-treated synaptosomes 
The previous result from 3.4.1 has revealed that the higher extracellular calcium levels (i.e. 
HK10C or HK20C) do not support the SP exocytosis in the Roscovitine treated 
synaptosomes and in fact such conditions reduced the intracellular calcium level, This 
suggests a critical role for the precise [Ca2+]i level for SP exocytosis. This may involve 
Ca2+ dependent regulation of certain enzymes. Therefore, we looked to see if changes in 
PKC activation could regulate the SP. 1 M Phorbol 12-myristate 13-acetate (PMA) 
(Virmani et al, 2005) was employed to activate most PKCs within the terminal and the 
effect this had on the SP in Roscovitine-treated terminals was investigated. PMA pre-
treatment failed to perturb normal amount of the SP in HK5C stimulated Roscovitine 
treated terminals (Fig 3.12). Thus, activation of PKCs does not interfere with the action of 
Roscovitine in inducing the SP release evoked by HK5C. However, HK5C alone activates 
some specific PKC, which complicates the conclusion derived from using PMA. ION5C, 
unlike HK5C, appears not to activate certain PKCs at the active zone (Ashton, unpublished 
observation) so we also tested this stimulus. PMA pre-treatment failed to induce any 
further increase in the release evoked by ION5C (Fig 3.13a). However, such pre-treatment 
prevented the ION5C evoked release of the SP in terminals that were also treated with 
Roscovitine (Fig 3.13b). Therefore, under certain circumstances the activation of PKCs 
can inhibit the release of the SP induced when Cdk5 is inhibited. 
Fura-2 measurements were performed under the same conditions outlined above and the 
results demonstrated that HK5C evoked [Ca2+]i was similar in Roscovitine or 
Roscovitine plus PMA treated terminals (Fig 3.14) whilst higher [Ca2+]i was observed in 
Roscovitine plus PMA relative to Roscovitine alone when ION5C was employed (Fig 
3.15). As it was found that PMA treatment blocked ION5C evoked SP in Roscovitine 
treated terminals, it would appear that this failure to induce the SP is due to an increase of 
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the intracellular Ca2+ level elicited by stimulation with ION5C. It should be noted that in 
these experiments ION5C induced a larger [Ca2+]i than HK5C which may explain the 
results. Furthermore, the difference between HK5C and ION5C may reflect the difference 
in activation of certain PKCs. 
 
Figure 3.12. Supramaximal activation of PKC with 1 M PMA pre-treatment failed to 
perturb normal amount of the SP in HK5C stimulated Roscovitine treated terminals. HK5C 
evoked GLU release in non-drug treated control and 1 M PMA plus 100 M Roscovitine 
treated synaptosomes. Data are mean ± SEM, N=3 independent experiments; P <0.05 

































































































































































































































































































Figure 3.14. HK5C evoked [Ca2+]i was similar in Roscovitine treated terminals and 
Roscovitine plus PMA treated terminals. HK5C evoked [Ca2+]i comparing Roscovitine alone 
and 1 M PMA plus 100 M Roscovitine. This results are an average from 3 independent 
experiments and there is no significant difference (P>0.05) between these conditions. 
 
Figure 3.15. Roscovitine plus PMA shown higher [Ca2+]i relative to Roscovitine alone when 
ION5C was employed. ION5C evoked [Ca2+]i in Roscovitine plus 1 M PMA and 100 M 
Roscovitine treated terminals. These traces are an average from 3 independent experiments 
and there is a significant difference between the 2 conditions (P<0.05). 
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Intriguingly as HK5C is able to activate certain PKCs at the AZ, there was actually the 
possibility that the release of the SP in Roscovitine treated terminals was not maximal with 
HK5C because some of this pool was being blocked by the activated PKCs. To test this, 
we pre-treated the terminals with 1 M of the PKC inhibitor Go6983 (this is known to 
inhibit conventional, novel and atypical PKCs (Gschwendet et al, 1996) and A.Ashton 
(unpublished) has shown that this blocks PMA evoked effects in both release asays and 
phosphorylation assays in synaptosomes) with or without 100 M Roscovitine and then 
stimulated the terminals with HK5C. Terminals in which PKCs are inhibited with Go6983 
had a similar amount of release evoked by HK5C as control (Fig 3.16a). Moreover, 
inhibition of PKCs with Go6983 did not perturb the HK5C evoked release of the SP in 
Roscovitine treated terminal (Fig 3.16b). Thus, the activation of certain active zone PKCs 
with HK5C did not perturb the release of the SP in Roscovitine treated terminals. A 
possible explanation for the earlier finding that very high [Ca2+]e plus HK (HK10C or 
HK20C) actually blocks the SP is that this level of [Ca2+]e was able to stimulate PKCs 













































































































































































































































































3.4.3 Inhibition of Ca2+ entry through N-, P/Q-, L-type Ca2+ 
channels does not perturb the HK5C evoked release of the RRP 
and the RP but it does inhibit the release of the SP in Roscovitine 
treated terminals. 
Previously, Ashton’s group has shown that N-type Ca2+ channel blockade with 1 M -
conotoxin GVIA (CONO) fails to inhibit the release of the RRP and the RP SVs evoked 
by HK5C and this study repeated the findings (Fig 3.17a): this is despite the fact that this 
toxin does reduce the HK5C evoked change in [Ca2+]i (Fig 3.18). However, addition of 
CONO did inhibit the HK5C evoked release of the SP in Roscovitine treated terminals 
(Fig 3.17b). The toxin’s action in reducing HK5C evoked changes in [Ca2+]i was still 
apparent in the Roscovitine treated terminals (Fig 3.19). This result suggests that the SP 
does require a certain level of change in [Ca2+]i for it to be induced and this does not occur 










































































































































































































































































Figure 3.18. Inhibiting N-type Ca2+ channel reduce HK5C evoked [Ca2+]i. HK5C evoked 
[Ca2+]i in control and 1 M CONO treated synaptosomes. The number of independent 











Figure 3.19. CONO plus Roscovitine treatment reduced the HK5C evoked [Ca2+]i compared 
to control. HK5C evoked [Ca2+]i in control and 1 M CONO plus 100 M Roscovitine 
treated terminals. This trace is an average from 3 independent experiments There was a 
significant decrease in [Ca2+]e with 1 M CONO plus 100 M Roscovitine compared to control 
(P>0.05). 
nMAgatoxin TK (AGA) was used to block P/Q-type Ca2+ channels in synaptosomes. 
HK5C evoked GLU release in AGA plus Roscovitine treated terminals was not 
significantly different compared to release from control non-drug treated terminals (Fig 
3.20 a) and also it was significantly lower compared to Roscovitine alone (Fig 3.20 b) 
indicating that this toxin does prevent the SP from being released. Furthermore, it was 
apparent in the Fura-2 assay that AGA plus Roscovitine treatment has significantly 
reduced HK5C induce [Ca2+]i in comparison with either control (Fig 3.21 a) or 
Roscovitine treated terminals (Fig 3.21 b) (Note this latter experiment was performed 














































































































































































































































































































































































































































































































































L-type Calcium channel blockade with Nifidepine (NIF) produced results that were similar 
to the other Ca2+ channel blockers. Its presence substantially attenuated the HK5C evoked 
release compared to Roscovitine alone (Fig 3.22 b) and its presence produce a similar 
amount of HK5C evoked release in Roscovitine treated terminals as found in the non-drug 
treated controls (Fig 3.22 a). Clearly, SP release is perturbed by the treatment with NIF. 
Fura-2 assay has demonstrated that NIF treatment of Roscovitine treated terminals leads 
to significant decrease in the HK5C evoked [Ca2+]i compared to Roscovitine treated 
terminals (Fig 3.23 b) and to non-drug treated control synaptosomes (Fig 3.23 a). Note 
that the choice of concentrations of calcium channel blockers to use was taken from the 
literature including papers that studied synaptosomes (Thomas et al, 1994; Meder et al, 
1997). It is clear that these blockers do exert an action as they were shown to reduce the 
HK5C evoked change in [Ca2+]i and Asthon and colleagues (unpublished) have shown that 
the combitnation of all three drugs can greatly perturb the HK5C evoked change and each 




























































































































































































































































































































































































































































































































































































3.5 The role of actin microfilament in the SP exocytosis 
Several lines of evidence have suggested that Actin dynamics play a major role in 
presynaptic functions and is implicated in various stages of the synaptic vesicle cycle, 
including vesicle clustering, neurotransmitter exocytosis, and endocytosis (Pollard, 2014). 
Morales et al (2000) have used Latrunculin (LAT), a toxin promoting actin 
depolymerisation by sequestering actin monomers, to monitor the role of actin on fusion 
of a single SV, represented with spontaneous mEPSCs. They have treated the preparation 
with LAT and found it rapidly increased the frequency of mEPSC by 5-fold. They have 
also treated the sample with Jasplamide, which promotes the stabilisation of actin 
filaments, and found this blocks the LAT induced increase in mEPSC frequency, 
indicating that the LAT triggered increase was derived from regulation of actin dynamics 
instead of a non-specific effect of the drug. This research suggested that LAT did not 
induce this effect by increasing the actual size of the RRP (Morales et al, 2000). Cole et 
al (2000) suggested that actin filaments facilitate a transmitter release rather than delaying 
it. They have tested this by treating nerve-muscle preparations from garter snake with LAT 
and measured the FM 1-43 release and found that LAT treatment reduced the evoked 
destaining (due to FM dye release) which suggests that transmitter release is partially 
blocked by the drug treatment (Cole et al, 2000).  
Actin microfilaments are known to interact with several other proteins, such as Syn I and 
-synuclein, to play pivotal role in presynaptic functions (Lee et al, 2018). Bloom et al 
(2003) used immunogold electron microscopy to investigate the subcellular localisation of 
actin and Syn and found that in synapses at rest, Syn was localised near to the vesicle 
cluster that was located distal from the AZ, but that during synaptic activity, Syn migrated 
to the pool of vesicles near to the AZ. Furthermore, actin and Syn were seen to colocalise 
in a dynamic filametous cytomatrix at the endocytic zone. These results highlight that actin 
and Syn co-operate during their participation in synaptic activity (Bloom et al, 2003). In 
the study from Bellani et al (2010), it was indicated that actin is a possible target for -
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synuclein (-syn) function. The precise role of -syn in synaptic function is not yet fully 
understood but few studies have suggested that it is important in regulation of SV mobility. 
In this study, -syn binds to actin and, through regulation of actin dynamic, -syn 
participates in the tuning of the vesicle release process, and consequently modulate 
synaptic function and plasticity (Bellani et al, 2010). Cleary, from such research it is 
evident that actin contributes to neurotransmission, and therefore, an investigation to 
ascertain whether the actin microfilaments are also involved in the release or regulation of 
the SP is warranted. 
3.5.1 The SP cannot be studied following disassembly of actin 
microfilaments as the RP is perturbed 
An investigation into how actin microfilaments could affect the properties of the SP 
appears an important point to study and we aimed to explore this by employing LAT to 
disassemble the actin microfilaments. However, before studying the release of the SP, it 
was necessary to first ascertain the effect that disassembly of actin microfilaments may 
have on the release of the RRP and RP (Chapter 6 outlines these results). Whilst for 4AP5C 
evoked release of GLU from the RRP of synaptosomes (Fig 6.1c) there were no difference 
between non-drug treated control and terminals treated with 15 M LAT (10 min at 37oC), 
for HK5C or ION5C stimulation - where both RRP and the RP are exocytosed - the release 
appears to be reduced by LAT compared to control (Fig 6.1a and b). This indicated that 
whilst the RRP is not blocked, the RP release has been blocked by disassembly of actin. 
This means that our results would be complicated if we determined the effect of 
Roscovitine after the disassembly of actin by LAT. The SP may not release at all because 
the RP is not released because SP release only occurs after all of the RP is released. Thus 




3.5.2 RRP, RP, and SP SVs release normally when actin 
microfilament is stabilised 
As disassembly of actin microfilaments by LAT was shown to perturb the RP exocytosis 
(concluded as RRP induced by 4AP5C is not perturbed), we investigated whether actin 
stabilisation would affect the release of either the RRP or the RP. 2.5 M Jasplakinolide 
(JASP) (a drug that promotes the stabilisation of the actin) was applied to the synaptosome 
and GLU release was subsequently measured. These experiments revealed that JASP 
treatment failed to effect HK5C evoked GLU release as this was the same as in drug-free 
control (Fig 6.11). This indicates that, in contrast to disassembly of the actin, the RRP and 
the RP are released normally when actin is stabilised. 
From our results on the RRP and RP, the properties of SP was investigated when actin is 
stabilised (see chapter 6). Synaptosomes were pre-treated with Roscovitine and JASP, and 
GLU release was subsequently evoked by HK5C. A significant increase in HK5C evoked 
GLU release was found in JASP plus Roscovitine treated terminals compared to control 
(Fig 3.24) and this release was similar to that with Roscovitine is treated alone (Fig 3.25). 
This indicates that the stabilisation of actin microfilaments does not have significant 
detrimental effect upon the evoked release of the SP SVs in Roscovitine treated terminals. 
Note that it is known that 2.5 M JASP is exherting its effect on actin microfilament 
because pretreatment of synaptosomes with this drug prevents 15 M LAT from 






Figure 3.24. HK5C evoked SP release in Roscovitine treated terminals are unaffected by Actin 
stabilisation. HK5C evoked GLU release from terminals treated with or without 100 M 
Roscovitine plus 2.5 M JASP. Data are mean ± SEM, N=13-14 from 4 independent 
experiments; There is a significant difference between control and Roscovitine plus JASP 
treated samples (P<0.05). 
 
Figure 3.25. Actin stabilisation had no effect on HK5C evoked SP release in Roscovitine 
treated terminals. HK5C evoked GLU release from 100 M Roscovitine or 100 M 
Roscovitine plus 2.5 M JASP treated synaptosomes. Data are mean ± SEM, N=13-14 from 




3.6 Antagonism between Cdk5 and PP2B 
It was highlighted by Kim and Ryan (2013) that the balance between Cdk5 and Calcineurin 
(CN, PP2B) can regulate neurotransmission. The study reported that a removal of CN 
activity significantly reduces AP-driven calcium influx and exocytosis, whereas inhibition 
of Cdk5 activity leads to a large potentiation of calcium influx and exocytosis (Kim and 
Ryan, 2013). We investigated these interaction between Cdk5 and CN in synapstosomes 
using Roscovitine to inhibit Cdk5 and cyclosporine A (Cys A) to inhibit CN. 
3.6.1 Inhibition of CN and Cdk5 with Cys A and Roscovitine did 
not affect the RRP and the RP release but inhibited the SP 
exocytosis. 
Synaptosomes were treated with 1 M Cys A and Roscovitine together and results were 
compared with non-drug treated control and Roscovitine treated terminals. Previous work 
has shown that 1 M Cys A does not inhibit the release of the RRP or RP evoked by HK5C 
(appendix 1 Fig 10a). Cys A plus Roscovitine treated synaptosomes released the same 
amount of HK5C evoked GLU as the non-drug treated control (Fig 3.26b), indicating that 
the RRP and RP SVs undergoing exocytosis following this dual treatment but intriguingly 
the SP SVs were prevented from undergoing exocytosis. When release was compared to 
that in Roscovitine treated terminals, clearly the SP release has been suppressed following 
the treatment with Cys A (Fig 3.26a). These results suggest that there is clear antagonism 
existing between CN and Cdk5 and that such enzymes may contribute towards the SP 


























































































































































































































































































































































3.6.2 The SP exocytosis is disturbed following Cys A plus 
Roscovitine treatment because of reduction in the HK5C evoked 
[Ca2+]i. 
Previous observation from A.Ashton has discovered that Cys A treatment elevates the 
HK5C evoked [Ca2+]i levels compared to the control (see Fig 3.27b). Intriguingly, 
treatment with Roscovitine plus Cys A has led to substantial reduction in [Ca2+]i level  
evoked by HK5C compared to that achieved by HK5C stimulated in Roscovitine treated 
synaptosomes (Fig 3.27a). Thus, inhibition of Cdk5 antagonises the normal effect of 
blocking CN so that rather than getting an increased [Ca2+]i following HK5C stimulus 
compared to the control, there is a reduction. Such results again demonstrate that evoked 
































































































































































































































































































































3.7 Measurement of the bioenergetics of synaptosomes following 
various drug treatments  
It was important to determine that the effect of the drugs employed, herein, were 
specifically acting on the pathway/substrate that were being tested and that they were not 
affecting the SV exocytosis non-specifically by perturbing the bioenergetics of the 
synaptosomes. Fortunately, it was possible to measure certain bioenergetics parameters by 
utilising the Seahorse XFp flux analyser and the mitochondria stress test assay. It should 
be noted that whilst the terminals were treated with the drugs for the same time as for the 
release assays, the synaptosomes were then actually incubated for an extended period (100 
min) in order to carry out the stress test assay. Thus, this could mean that over this greater 
period (much longer than used for the other tests) some detrimental effects of the drugs 
could possibly be determined. Furthermore, whilst the initial incubation with the drugs 
were done at 37 oC, all the release assays employed herein were then performed at room 
temperature. However, some of the initial bioenergetics measurement (highlighted in 
figure legends and text) were performed at 37 oC because this was the lowest temperature 
that originally could be employed with the Seahorse XFp flux analyser. Thus, not only 
were the synaptosomes incubated for an extended period but they were incubated at a 
higher temperature. Fortunately, the Seahorse Company recently made a manifold that 
allowed the machine to incubate at lower temperatures and following the purchase of this, 
it was then possible to do the assays at room temperature. It was discovered that one 
difference in carrying out these assays at the two temperatures is that at 37oC, 0.5 M 
rotenone and 0.5 M antimycin A was able to fully work and enable the values for proton 
leakage and non-mitochondrial respiration to be determined, but at RT these drugs (in the 
time scale) did not fully work. However, this study herein determined that by using 10 
times more of each of these drugs (5 M of each) then these were able to block all 
mitochondrial respiration. For some of the drugs tested in the Seahorse XFp analyser at 
room temperature – PMA, Dynasore – these higher rotenone/antimycin A concentrations 
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were not employed and so one was unable to determine the proton leakage and the non-
mitochondrial respiration. 
The data are shown as Oxygen consumption vs time for the different conditions. These 
data could then be used to determine the following parameters: basal respiration; ATP 
production; spare capacity; maximal respiration; proton leakage; non-mitochondrial 
respiration. These values were determined by using the three individual time points for the 
different conditions (in some cases one time point might have been erroneous and this was 
removed) for each experiment, and combining these for the repeated experiments so that 














3.7.1 100 M Roscovitine 
The treatment with 100 M Roscovitine failed to perturb the bioenergetics of 
synaptosomes even using the extended 37oC conditions (Fig 3.28). This is made more 
obvious when the different parameters are plotted in Fig 3.29 A-F. 
Figure 3.28. Synaptosomal bioenergetics were unaffected by 100 M Roscovitine treatment 
using the extended 37oC conditions. The experiment was repeated 3 times and the data 
represents the average of 8 individual synaptosome samples. Data points represent the mean 
and the error bars represent the SD; P>0.05 which means that there is no significant 





Figure. 3.29. 100 M Roscovitine treatment did not perturb any bioenergetics parameter 
measured as it looks similar to those for the controls. Bar charts showing the effect of 100 M 
Roscovitine compared to non-drug treated control on (A) basal respiration, (B) ATP 
production, (C) spare capacity, (D) maximal respiration, (E) proton leakage and (F) non-
mitochondrial respiration. The data was calculated from the average of the three time points 
for each condition in the assay and these were averaged for the 3 repeat independent 
experiments shown in Fig 3.27. The histobars represent the mean and the error bar shows the 
SEM; P>0.05. 
It should be noted that 200 M Roscovitine, that had also been employed in release assays 
was also tested. However this concentration also did not perturb the bioenergetics integrity 
of the synaptosomes. Thus, Roscovitine action is not due to some non-specific perturbation 




As Roscovitine did not perturb the synaptosomes, the effect of some of the individual 
drugs that was employed in conjunction with Roscovitine were also tested to ensure that 
these did not perturb the bioenergetics integrity of the nerve terminals.  
An amount of 160 M Dynasore pre-treatment of synaptosomes had negligible effect on 
the bionenergetics of the terminals employing assay at 27oC (Fig 3.30). Although, there 
appears to be a slight difference in these curves the only parameter that showed any 
significant difference was in the basal respiration and this was minimal (Fig 3.31 A-D). 
Note that this study only used 0.5 M rotenone/ 0.5 M antimycin A and it was not 
possible to measure proton leakage and non-mitochondrial respiration. 
 
Figure 3.30. Synaptosomal bioenergetics were unaffected by 160 M Dynasore treatment. 
Data are mean ± SD, n=6 from 3 independent experiments. Note that there was no significant 









Figure 3.31. 160 M Dynasore treatment did not perturb majority of the bioenergetics 
parameter measured as it looks similar to those for the controls. Bar charts showing effect 
of 160 M Dynasore on (A) basal respiration, (B) ATP production, (C) spare capacity, and 
(D) maximal respiration. The data was calculated from the average of the three time points 
for each condition and included data from 3 independent experiments shown in Fig 3.30 
(n=18). The histobars represent the mean and the error bar shows the SEM. Note that there 
was no significant difference (P > 0.05) in the data comparing control with test apart from 
basal respiration and this was a minimal difference. 
The use of 80 M Dynasore produced no effect on any parameter. However, if the assay 
was done with the extended time course at 37oC, it was evident that Dynasore did seem to 
perturb certain parameters (data not shown). This result might actually be important for 
the use of Dynasore to study Dyn action. This study only used Dynasore acutely and it is 
tested only after about 20 mins post-initial incubation at RT. At this time, the Dynasore 
does not appear to have much detrimental effect on the bioenergetics. However, clearly 
89 
 
after the prolonged 37oC incubation Dynasore starts affecting the bioenergetic integrity of 
the terminals. This interesting finding could explain some recent findings (Park et al, 2013) 
which claimed that Dynasore had an off target effect that meant that it could not be used 
to study Dyn. However, they treated fibroblasts for many hours (24 hours or more) with 
Dynasore and this may very well disturb the cells bioenergetics which would then produce 
some extra effects. In fact, this may still reflect a specific action of Dynasore on a Dyn but 
rather than Dyn I, this could be that the drug can also block the mitochondrial specific Drp 
I (Dyn-related protein 1). Such a perturbation could very well disturb mitochondrial 
function. However, in the present studies by only using an acute treatment with Dynasore 
and not a chronic treatment it would appear that the experiment is specifically targeting on 
Dyn 1. Although, Dynasore also works on Dyn 2, the Asthon group (unpublished 
observation) has shown that inhibiting Dyn 2 specifically (using a low dose of a drug called 













Acute treatment with 50 M Blebbistatin failed to perturb the bioenergetics of 
synaptosomes (Fig 3.32, Fig 3.33 A-F) even with the extended 37oC assay 
employed with the Seahorse XFp flux analyser.  
 
 
Figure 3.32. Synaptosomal bioenergetics were unaffected by 50 M Blebbistatin treatment. 
The experiment was done three times and the mean values represent an average of 6 
independent measurements and error bars represent the SD. Note that there was no 





Figure 3.33. 50 M Blebbistatin treatment did not perturb any bioenergetics parameter 
measured as it looks similar to those for the controls. The effect of 50 M Blebbistatin on 
(A) basal respiration, (B) ATP production, (C) spare capacity, (D) maximal respiration (E) 
proton leakage, and (F) non-mitochondrial respirations. The data was calculated from the 
average of the three time points for each treatment shown in Fig 3.32. Depending on the 
number of values that were removed due to error the different parameters have different 
numbers of values employed in their analysis (as shown in the figures). The histobars 
represent the mean and the error bar shows the SEM. Note that there was no significant 





Although, we tested PMA with Roscovitine, it was necessary to initially test PMA alone. 
Acute treatment with 1 M PMA failed to perturb the bioenergetics of synaptosomes (Fig 
3.34, Fig 3.35 A-D) with the extended 27oC assay employed with the Seahorse XFp flux 
analyser. 
 
Figure 3.34. The effect of 1 M PMA on the bioenergetics of synaptosomes using the Seahorse 
XFp analyser at 27oC. The experiment was done three times and the mean values represent 







Fig 3.35. The effect of 1 M PMA on (A) basal respiration, (B) ATP production, (C) spare 
capacity, and (D) maximal respiration. The data was calculated from the average of the three 
time points for each treatment and average data from the 3 independent experiments shown 




3.7.5 PMA with Roscovitine 
Acute treatment with 1 M PMA plus 100 M Roscovitine failed to perturb the 
bioenergetics of synaptosomes (Fig 3.36, Fig 3.37 A-F) with the Seahorse XFp flux 
analyser. 
 
Figure 3.36. The effect of 1 M PMA plus 100 M Roscovitine on the bioenergetics of 
synaptosomes using the Seahorse XFp analyser at 27oC. The experiment was done three times 
and the mean values represent an average of 9 independent measurements and error bars 
represent the SD. There is no significant difference between drug treated and control for any 









Figure 3.37. The effect of 1 M PMA plus Roscovitine on (A) basal respiration, (B) ATP 
production, (C) spare capacity, (D) maximal respiration, (E) Proton leakage, and (F) Non-
mitochondrial respiration. The data was calculated from the average of the three time points 
for each treatment and averaged the 3 independent experiments shown in Fig 3.36 (n=18 as 
some values were incorrect and removed). The histobars represent the mean and the error 




Although, we tested Go6983 plus Roscovitine, there was a need to check Go6983 alone 
first. Acute treatment with 1 M Go6983 failed to perturb the bioenergetics of 
synaptosomes (Fig 3.38, Fig 3.39 A-F) even with the extended 37oC assay employed with 
the Seahorse XFp flux analyser.  
 
Figure 3.38. The effect of 1 M Go 6983 on the bioenergetics of synaptosomes using the 
Seahorse XFp analyser at 37oC conditions. The experiment was done three times and the 
mean values represent an average of 9 independent measurements and error bars represent 







Figure. 3.39. The effect of 1 M Go 6987 on (A) basal respiration, (B) ATP production, (C) 
spare capacity, (D) maximal respiration, (E) proton leakage and (F) non-mitochondrial 
respiration. The data was calculated from the average of the three time points for each 
treatment shown in Fig 3.38 and average for the 3 independent exepriments. However, for 
some measurement, certain values were wrong and so were removed. The histobars represent 
the mean and the error bar shows the SEM. Note that there was no significant difference (P 






3.7.7 Go6983 with Roscovitine 
Acute treatment with 1 M Go6983 plus 100 M Roscovitine failed to perturb the 
bioenergetics of synaptosomes (Fig 3.40, Fig 3.41 A-F) even with the extended 
37oC assay employed with the Seahorse XFp flux analyser.  
 
Figure 3.40. The effect of 1 M Go 6983 plus 100 M Roscovitine on the bioenergetics of 
synaptosomes using the Seahorse XFp anyalyser at 37oC. The experiment was done three 
times and the mean values represent an average of 7 independent measurements and error 
bars represent the SD. Note that there was no significant difference (P > 0.05) in the data 







Figure 3.41. The effect of 1 M Go6983 plus 100 M Roscovitine on (A) basal respiration, (B) 
ATP production, (C) spare capacity, (D) maximal respiration, (E) Proton leakage, and (F) 
Non-mitochondrial respiration in synaptosomes. The histobars represent the mean and the 
error bar shows the SEM. Note that there was no significant difference (P>0.05) in the data 







3.7.8 JASP plus Roscovitine 
Treatment with 2.5 M JASP alone had no effect on the bioenergetics (see Fig 6.28 and 
6.29) and furthermore, treatment with 2.5 M JASP plus 100 M Roscovitine failed to 
perturb the bioenergetics of synaptosomes when assay performed at 24oC (Fig 3.42, Fig 
3.43 A-F). 
 
Figure 3.42. The effect of 2.5 M JASP plus 100 M Roscovitine on the bioenergetics of 
synaptosomes. The experiment was done 3 times and the mean values represent an average 
of 8 independent measurements and error bars represent the SD. Note that there was no 







Figure. 3.43. The effect of 2.5 M JASP plus 100 M Roscovitine on (A) basal respiration, (B) 
ATP production, (C) spare capacity, (D) maximal respiration, (E) proton leakage and (F) non-
mitochondrial respiration. The histobars represent the mean and the error bar shows the 








3.7.9 Cys A plus Roscovitine 
Treatment with 1 M Cys A plus 100 M Roscovitine failed to perturb the bioenergetics 
of synaptosomes when assay performed at 24oC (Fig 3.44, Fig 3.45 A-F). 
 
Figure 3.44. The effect of 1 M Cys A and 100 M Roscovitine on the bioenergetics of 
synaptosomes. The experiment was done 3 times and the mean values represent an average 
of 9 independent measurements and error bars represent the SD. Note that there was no 







Figure 3.45. The effect of 1 M Cys A plus 100 M Roscovitine on (A) basal respiration, (B) 
ATP production, (C) spare capacity, (D) maximal respiration, (E) proton leakage and (F) non-
mitochondrial respiration. The histobars represent the mean and the error bar shows the 








3.8 Phosphorylation profiles of various sites in Syn I following 
Roscovitine treatment 
Earlier we have showed that 100 M Roscovitine treatment of synaptosomes allows HK5C 
and ION5C to evoke SP release. Roscovitine is a Cdk5 inhibitor, thus the HK5C or ION5C 
evoked SP release following application of this drug is proposed to be due to an attenuation 
of Cdk5 activity. However, a detailed understanding of how Cdk5 inhibition leads to the 
evoked SP release is not fully known. One of the methods used to investigate this is to 
study phosphorylated profiles of particular proteins that are speculated to be involved in 
the SP regulation. One such protein is Synapsin I (Syn I) and its phosphorylation can be 
studied using western blotting following the evoked release of the SP after Roscovitine 
treatment. 
3.8.1 Results 
To determine the effect of Cdk5 inhibition on the phosphorylated state of different sites 
on Syn I, synaptosomes were treated with Roscovitine (to block Cdk5) or 10 M KN-93 
(to block CaMKII) (i.e. Sumi et al, 1991) (shown previoslu to induce specitic action on 
synaptosomes (Bhuva, 2015; Singh, 2017)) in the first trial and Roscovitine or 2 M 
KT5720 (to block PKA) (i.e. Murray, 2008) ( shown previously to induce specific action 
on synaptosomes (Rostron, 2019)) in the second trial. Following such drug treatment, 
synaptosomes were subsequently stimulated with various stimuli (4AP5C, HK5C, and 
ION5C) for different time points (2s, 15s, 30 s and 120 sec) before being solubilised in 
NuPAGE sample buffer and subsequently used for western blotting. Note, in first trial, 
lane 1-4 of the blots contained samples with non-drug treated control, lane 5-8 samples 
treated with KN-93, and lane 9-12 samples treated with Roscovitine, whilst in second trial, 
1-4 contained samples with non-drug treated control, 5-8 contained samples treated with 
Roscovitine, and 9-12 contained samples pre-treated with KT5720. Since, major interest 
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in this study is the stimulation evoked SP release in the presence of Roscovitine, only non-
drug applied control vs Roscovitine conditions were subjected to analysis.   
Phosphorylation in all Western blots were determined by chemi-luminescence that 
detected phospho-specific sites on Syn I with densitometric analysis as mentioned in 
Chapter 2, and the range (for the blots that were tested at least twice) to measure the 
average changes in phosphorylation compared to the respective L0 condition, based on the 
number of experiments conducted. It is important to remember that 4AP5C stimulation 
evokes release of the RRP only even in the presence of Roscovitine, whilst HK5C and 
ION5C with Roscovitine treatment have been shown to release the RRP, the RP and the 
SP. The mechanism of ION5C evoking the release is distinct from HK5C as this ionophore 
by-passes Ca2+ channels and increase the Ca2+ level throughout the terminal whereas 
HK5C depolarises terminals and allow Ca2+ entry via the opening of voltage dependent 
Ca2+ channels.  
Previous studies have demonstrated that the phosphorylation of specific sites on Syn I are 
due to the action of distinct kinases. Ser-9 site is known to be phosphorylated by cAMP 
dependent kinases (PKA) (Yamagata and Neirn, 2015), Ser-553 by cyclic dependent 
kinases (Cdk) 1/5 (Cesca et al, 2010; Verstegen et al, 2014), and Ser-603 site by CaMK II 
(Sakurada et al, 2002).  
3.8.2 Phosphorylation of Syn I Ser-553 in vivo 
Syn I-Ser-553 site is phosphorylated by Cdk5, a kinase that is inhibited by Roscovitine 
treatment (Verstegen et al, 2014). Careful observation of the phospho-Ser-553 probed 
blots revealed that at 15 sec, there is a reduction in phosphorylation in Roscovitine treated 




Figure 3.46. The effect of 100 M Roscovitine treatment upon the phosphorylation Syn I on 
the Ser-553. A) 15 sec stimulation B) Reprobing of this blot for 15 sec with Pan-Syn I C) 30 
sec stimulation D) Reprobing of this blot for 30 sec with Pan-Syn I E) 120 sec stimulation F) 
Reprobing of this blot for 120 sec with Pan-Syn I. This is a representative blot (All blots N=2)  
Following a 30 sec stimulation, Roscovitine treated nerve terminal are appear to contain 
less phosphorylated Ser-553 Syn I compared to no drug treated sample (Fig 3.46 C). This 
was also evident after 120 sec stimulation, where a reduction in the specific 
phosphorylation site in the presence of Roscovitine treatment appears to be definite (Fig 
3.46 E). Note that in 30 sec (Fig 3.46 D) and 120 sec stimulated samples (Fig 3.46 F) re-
probed with pan Syn I demonstrates that total protein was greater in the Roscovitine treated 
conditions for some reason but this suggests that the reduction in phosphorylation could 
potentially be more significant following the application of Roscovitine. 
The results are not clear cut looking at the blots but one can normalise the Ser-553 
phosphorylation relative to the Pan-Syn I signal and then one compares all result to the 
basal condition. This will reveal only stimulus evoked change in the phosphorylated serine 
and will take in to account the change in total protein. Bar charts in Figure 3.47 A-C are 
showing semi-quantitative analysis of phospho-Ser-553 probed blots presented in Figure 
3.46. At early time points representing combined values of 2 sec and 15 sec, 
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phosphorylation following Roscovitine treatment was found to be reduced for 4AP5C 
stimulation, and for HK5C compared to non-drug treated samples. Such a decrease in Ser-
553 phosphorylation of Syn I following Roscovitine treatment compared to non-drug 
treated control appear to be enhanced at 30 sec and 120 sec as both time points show 
visibly lower phosphorylation in Roscovitine treated conditions compared to drug free 
control in all stimuli employed. Clearly, the phosphorylation of phospho-Ser-553 site on 
Syn I is reduced in the presence of Roscovitine compared to its absence and the following 
result may suggest that the well characterised action of this drug on Cdk5 activity is shown 
to be connected to inhibition of phosphorylation of Ser-553 on Syn I. This is a preliminary 
set of experiments and needs to be repeated more times in order to determine statistical 







Figure 3.47. The effect of 100 M Roscovitine upon Syn I Ser-553 phosphorylation following 
various stimulation for a) early time points (2 sec+15 sec) b) 30 sec c) 120 sec; N=4 A; N=2 in 
B and C. All results are normalised to the L0 control value. a) shows a reduction of 
phosphorylation following Roscovitine treatment under 4AP5C stimulation relative to non-
drug treated control, and HK5C with Roscovitine also shows some reduction compared to 
condition without Roscovitine treatment but these values were not significantly different. 
These differences become greater for longer stimulation periods and at b) 30 sec and c) 120 




3.8.3 Phosphorylation of Syn I Ser-9 in synaptosomes 
Roscovitine has been established to inhibit Cdk5 activity, although, it is possible that the 
drug induced increase of releasable SVs from the SV pools may also involve the 
phosphorylation of Syn I by other kinases, such as PKA or CaMK II. Therefore we have 
investigated phosphorylation profiles of Syn I at the sites other than Cdk5 site in stimulated 
terminals following Roscovitine treatment. PKA phosphorylates Syn I at Ser-9 site and 
with the careful observation of the blot probed with Phospho-Syn I Ser-9, the Roscovitine 
samples appear to contain more phosphorylated Ser-9 than the non-drug treated samples 
following a 2 sec stimulation (Fig 3.48 A), However, this may have actually been due to 
relatively more total protein contents in Roscovitine treated samples as the corresponding 
pan-Syn I blot appear darker (Fig 3.48 B). This finding cannot be explained since all 
samples were adjusted to the same protein concentration.  
At 15 sec stimulation, HK5C + Roscovitine and ION5C + Roscovitine conditions appear 
to be less phosphorylated compared to basal and 4AP5C stimulation with Roscovitine, and 
to their corresponding drug free control conditions (Fig 3.48 C). However, re-probing blots 
for pan-Syn-I revealed that the level of Syn-I protein contained in these two lanes were 
much less compared to other samples (Fig 3.48 D). Thus only by normalising the data to 
the pan-Syn I content can one make any interpretation.    
At 30 sec stimulation, there is little detectable increase of phosphorylation in Ser-9 
identified in the samples treated with Roscovitine relative to drug free control (Fig 3.49 
A-B). Following 120 sec stimulation there may be some Roscovitine induced increase in 
phosphorylation of Ser-9 for 4AP5C and ION5C stimulation compared to drug free 
samples. HK5C appear to induce lower Ser-9 phosphorylation in the Roscovitine treated 
samples, however this can be explained because pan-Syn-I blot indicates a lower amount 




Figure 3.48. The effect of 100 M Roscovitine treatment upon the phosphorylation of Ser-9 
in Syn I. A) 2 sec stimulation B) Pan-Syn I blot reprobed for the 2 sec stimulation C) 15 sec 
stimulation D) Pan-Syn I blot reprobed for the 15 sec stimulation. This is a representative 
blot (All blots are N=2).  
 
Figure 3.49. The effect of Roscovitine treatment upon phosphorylation of Ser-9 for Syn I. A) 
30 sec stimulation B) Pan-Syn I blot reprobed for the 30 sec stimulation C) 120 sec stimulation 
D) Pan-Syn I blot reprobed for the 120 sec stimulation condition. This is a representative blot 
(A is N=2; B is N=1).  
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Semi-quantitative analysis is presented as a bar charts in figure 3.50. There appears to be 
a stimulus dependent increase in phosphorylation of Ser-9 with the different stimuli 
releasing a maximum effect at different times. ION5C induces maximum early whilst 
4AP5C takes longer. At early time points, there appeared to be higher phosphorylation for 
the Roscovitine treated terminals compared to non-drug treated controls for 4AP5C and 
HK5C (Fig 3.50 A). At 30 sec (Fig 3.50 B), it may be that the difference between 4AP5C 
plus Roscovitine and HK5C plus Roscovitine conditions and non-drug treated control may 
still be larger and this is apparent still with same stimuli employed for 120 sec stimulation 
(Fig 3.50 C). However, it would appear that Roscovitine has no real effect on ION5C 
evoked changes in phospho-Ser-9 of Syn I. Again, this experiment has to be repeated 







Figure 3.50. The effect of 100 M Roscovitine treatment upon Syn I Ser-9 phosphorylation 
following various stimulation for a) early time points (2 sec+15 sec) b) 30 sec c) 120 sec; N=4 
for A and N=2 for B and C. All results are normalised to the L0 control value. a) The combined 
early time points show that phosphorylation was higher in the presence of Roscovitine relative 
to control for 4AP5C and HK5C stimulation. Such increase is time dependent as b) 30 sec 
with 4AP5C and HK5C in the presence of Roscovitine was higher compared to non-drug 
treated control and the values reach maximum at c) 120 sec 
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3.8.4. Phosphorylation of Syn I Ser-603 in nerve terminals 
The SP release can be stimulated following Roscovitine treatment and this may involve 
the activity of not only Cdk5 but other kinases that can phosphorylate Syn I, including 
CaMKII. CaMKII phosphorylates Syn I at Ser-603 site, and we can study the 
phosphorylation of this site following Roscovitine treatment. Roscovitine treatment 
appears to increase the phosphorylation of Syn I- Ser-603 site relative to non-drug treated 
control at (Fig 3.51 A), but as there is a difference in the pan-Syn I content (Fig 3.51 B), 
this probably can account for the difference (See Fig 3.51 A).  
At 15 sec, Roscovitine treatment has reduced the HK5C and ION5C evoked 
phosphorylation compared to non-drug treated control (Fig 3.51 C), however again this 
was due to the difference in the pan-Syn-I blot densities, such that total Syn-I protein 
contents in HK5C plus Roscovitine and ION5C plus Roscovitine found to be visibly lower 
compared to non-drug treated control samples with same stimulations applied (Fig 3.51 
D), 
However, 30 sec HK5C stimulation in Roscovitine treated samples does induce more 
phosphorylation of Ser-603 of Syn I than in the drug-free control (Fig 3.52 A-B). Such 
increase was also evident at 120 sec stimulation in Roscovitine treated samples compared 




Figure 3.51. The effect of 100 M Roscovitine treatment upon phosphorylation of Ser 603 of 
Syn I. A) 2 sec stimulation B) Pan-Syn I blot reprobed for the 2 sec stimulation C) 15 sec 
stimulation D) Pan-Syn I blot reprobed for the 15 sec stimulation. This is a representative 
blot (A and B are N=2; C and D are N=1)  
 
Figure 3.52. The effect of 100 M Roscovitine treatment upon the phosphorylation of Ser-603 
in Syn I. A) 30 sec stimulation B) Pan-Syn I blot reprobed for the 30 sec stimulation C) 120 
sec D) Pan-Syn I blot reprobed for the 120 sec stimulation. This is a representative blot (All 




Bar charts presented in figure 3.53 show the semi-quantitative analysis performed on the 
blots representative ones which are shown in figure 3.51 and 3.52. There appears to be 
some time dependent increase in phosphorylation of Ser-603 of Syn I in control terminals 
stimulation with 4AP5C and ION5C, although maximum for HK5C is achieved early on. 
According to these charts, at early time points (2 sec+15 sec), HK5C evoked and ION5C 
evoked phosphorylation in the presence of Roscovitine maybe slightly higher compared 
to drug free control condition and these stimuli produced phosphorylation that was higher 
compared to 4AP5C evoked phosphorylation in the presence of Roscovitine (Fig 3.53A). 
At 30 sec, 4AP5C plus Roscovitine and ION5C plus Roscovitine were similar to non-drug 
treated control with same stimuli employed. Although, HK5C evoked phosphorylation in 
the presence of Roscovitine was increased compared to when Roscovitine was absent (Fig 
3.53 B). At 120 sec (Fig 3.53 C), there were clear increases in Roscovitine treated 
conditions throughout all stimuli employed, and these were visibly higher than the non-
drug treated control conditions. All the data collected so far does seems to suggest that 
CaMK II is activated upon stimulation as Ca2+ enters the terminal activates CaMK II 
(represented by HK5C and ION5C showing higher phosphorylation than 4AP5C in the 
presence of Roscovitine) which then phosphorylates Syn I on Ser-603 site. It would appear 









Figure 3.53. The effect of Roscovitine upon the phosphorylation of Syn I Ser-603 following 
various stimulation for a) Early stimulation time points (2 + 15 sec) b) 30 sec stimulation c) 
120 sec stimulation; A is N=3; B and C are N=2. A) Phosphorylation induced by HK5C or 
ION5C in Roscovitine treated terminal was relatively higher than non-drug treated controls 
at combined early time points. Note both these cause higher [Ca2+]i entry than 4AP5C and 
at 2s stimulation, 4AP5C shows little increase of phospho-Ser 603 with or without Roscovitine 
pre-treatment. B) HK5C stimulation in Roscovitine treated synaptosomes evoked greater 
phosphorylation than drug free control at 30 sec stimulation whilst Roscovitine had negligible 
effect on changes in phosphorylation of Ser 603 induced by 4AP5C or ION5C. C) There was 
substantial increase in phospho-Ser 603 of Syn I in Roscovitine treated samples for all stimuli 














1 3.1-3.2 GLU HK5C Roscovitine 
(10 M,  
33 M,  
100 M, 
 200 M) 
Roscovitine treatment allowed HK5C 
to evoke further GLU release compared 
to control which is assumed to be from 
the SP.100 M Roscovitine treatment 
provided maximum SP release from the 
synaptosomes. 
2 3.3 GLU ION5C Roscovitine 
(100 M) 
100 M Roscovitine also allowed 
ION5C to evoke the SP release 




No change in [Ca2+]i identified for 
HK5C and ION5C stimulated terminals 
in the presence of 100 M Roscovitine 








Extra GLU release observed in 
Roscovitine treated terminals are not a 
result of the RRP and RP recycling, 










Higher [Ca2+]e perturbed extra release 
in Roscovitine treated terminal and it 













PMA only perturbed ION5C, not 
HK5C, evoked SP release in 
Roscovitine treated terminal and this 










 (50 nM), 
NIF  
(1 M) 
Ca2+ channel blockade perturbed 
HK5C evoked SP release in 
Roscovitine treated terminal. Although, 








Roscovitine allowed HK5C to evoke an 






(100 M),  
Cys A  
(1 M) 
Inhibition of PP2B and Cdk5 inhibited 
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Although it is still a preliminary result, 
Ser-553 (Cdk5 site) phosphorylation 
appears to be decreased in Roscovitine 
treated terminals whilst Ser-9 (PKA 
site) and Ser 603 (CaMKII site) 
phosphorylation appears to be 
increased. 




3.9.1 Roscovitine effect on the SP release 
The silent pool (SP) has been an enigma mainly due to the fact that it is not released under 
the normal physiological conditions which makes it difficult to study. Roscovitine, a Cdk5 
inhibitor, can be employed to allow further evoked release after the RRP and the RP have 
been fully exocytosed and this represents the SP (Kim and Ryan, 2010; Kim and Ryan, 
2013). Herein this study has used Roscovitine under different conditions and attempted to 
elucidate properties of the SP. Note that Kim and Ryan (2010) measured release by the 
electrophysiological recording of the postsynaptic response to GLU release from 
hippocampal cultured cells. We have reproduced their findings in cortical synaptosomes 
measuring directly the release of the GLU. 
The current study first showed that Roscovitine dose dependently induced extra release 
from the nerve terminal with the maximum effect being induced by 100 M while 200 M 
was unable to induce any further release. It has previously been established that HK and 
ION with 5 mM [Ca2+]e maximally release GLU from synaptosomes (see appendix A. 
1.1.1) which is considered to be representing the total release of the RRP and RP. However, 
Roscovitine treatment allowed HK5C to evoke significantly higher GLU release compared 
to non-drug treated control, which indicates that SV pools other than the RRP and RP is 
releasing. Therefore, this extra release was assumed to be from the SP. This study further 
tested ION5C as well and found it could also release the SP in the presence of Roscovitine. 
ION5C is an ionophore that bypasses any Ca2+ channel requirement, and this useful 
information suggests that the level of Ca2+ influx through channels might not play a pivotal 
role in the release of the SP (See below). Please note that Ashton and colleagues have 
shown that the RRP and RP have distinct biochemical properties that can help identify 
them (see Bhuva, 2015; Singh, 2017; Rostron, 2019) and it was hoped that difference 
between these and the SP could be determined. 
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The study further investigated the actual intracellular Ca2+ levels evoked in Roscovitine 
treated terminal by employing a Fura-2 assay. However whilst 100 M Roscovitine 
induces the SP to release, it does not affect HK5C evoked changes in [Ca2+]i. 
Even though this study obtained extra GLU release with Roscovitine and employing 
ION5C or HK5C as the stimulus, it was still debatable whether this release was actually 
from the SP as there was still a chance that the inhibition of Cdk5 might actually promote 
the recycling of the RRP and the RP and their re-release during the stimulus period. This 
could mean that the study was observing a recycling of these two pools rather than release 
of the SP. However, this was found not to be the case since even after the inhibition of 
recycling through perturbation of Dyn and clathrin, the SP release was observed.  
This study also tested if additional extracellular Ca2+ could induce further HK5C evoked 
release in the presence of Roscovitine. However, this was not the case as HK10C and 
HK20C in Roscovitine pre-treated terminal failed to release the SP. Thus higher 
extracellular Ca2+ levels do not support the release of the SP. Further investigation revealed 
that for both HK10C and HK20C, the evoked [Ca2+]i was found to be reduced compared 
to HK5C in the Roscovitine treated terminals. This is interesting because although higher 
extracellular calcium concentrations were present, the result indicates that the quantity of 
calcium going into the terminal (as measured by [Ca2+]i) was reduced which indicates 
that there is a certain concentration of calcium required to induce the SP release.  
An intriguing result of this study was that supra-maximally induced PKC could actually 
block the SP release evoked by ION5C in Roscovitine treated terminals. 1 M PMA - that 
supra-maximally induce PKC activation - was used and it was found that the SP release 
was perturbed for ION5C evoked GLU release in Roscovitine treated synaptosomes. It is 
noteworthy that, although previous investigations on SP release are relatively lacking, 
there are few studies demonstrated a link between PKC activation with regulation of the 
RRP and RP. Stevens and Sullivan (1998) showed that PMA activation of PKC elevates 
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the rate of the RRP refilling. Another study has reported that Platelet activating factor 
(PAF) increased the size of the RRP and the exocytosis rate of the RP through elevation 
of calcium within the terminal and PKC activation (Hammond et al, 2016). However, it is 
difficult to make a direct comparison due to the fact that the models employed were 
different, and the stimulation protocol varied between these two studies and the study 
outlined here.  
A similar experiment was also conducted using the PKC inhibitor, Go6983, instead of 
PMA but the SP was still released by HK5C in Roscovitine treated synaptosomes. This, 
in combination with the previous result where additional amounts of Ca2+ have perturbed 
the SP release, represents novel result whose precise mechanism awaits to be elucidated. 
The results using HK10C and HK20C under Roscovitine pre-treatment also were further 
investigated by employing Go6983. It was demonstrated that in the presence of Go6983, 
HK10C and HK20C was still unable to evoke the SP release in Roscovitine treated 
terminals whereas with HK5C, Go6983 did not prevent SP release in synaptosomes treated 
with Roscovitine. As in the Roscovitine treated terminal, HK10C and HK20C failed to 
support the SP release but Go6983 did not perturb the SP release, it would appear that the 
changes in [Ca2+]e does not act to perturb the SP by activating PKCs because otherwise 
Go6983 by blocking activation of such PKC should have allowed HK10C and HK20C to 
release the SP. 
Previously, Ashton’s group have found that N-type Ca2+ channel blockade with 1 M 
CONO fails to inhibit the HK5C evoked release of the RRP and the RP. In the repeat 
experiment performed herein it is re-shown that it does not perturb the RRP and the RP 
release, but it does stop the release of the SP when both Roscovitine and CONO are 
employed. This clearly demonstrated that the SP requires a certain amount of Ca2+ influx 
through the channel for it to be released but in this study, because the N-type Ca2+ channel 
has been blocked by CONO, the SP was not able to be exposed to sufficient Ca2+ and, 
thereby the SP release has been perturbed. Equivalent experiments were done for P/Q- and 
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L-type calcium channels. For P/Q-type channel, AGA was used whilst for L-type channel 
NIF was employed. In both conditions the result was similar to what was revealed in N-
type Ca2+ channel blockade experiment where the RRP and the RP were released as 
normally whilst the SP release was not supported. These data demonstrate that the presence 
of calcium channels is essential for normal SP release, however, this is not operated 
through particular type of channel.  
Actin stabilisation with JASP was found not to reduce the release of the RRP and RP (see 
chapter 6). Further, JASP pre-treatment did not prevent HK5C evoked SP in Roscovitine 
treated terminals. Thus, stabilisation of actin microfilaments does not appear to inhibit the 
release of the RRP, RP, or SP. 
It is clear from all the data obtained measuring the bioenergetics of synaptosomes that 
none of the drugs tested in the current research perturbed the energy producing capacity 
of the nerve terminals. Since there are no detrimental effects identified, it is concluded that 
the changes each drug may induce on synaptosomal exocytosis are not due to non-specific 
effects. This is an important point since perturbation of ATP levels will change the amount 
of Ca2+ - dependent exocytosis, [Ca2+]i and any evoked changes [Ca2+]i levels and it may 
possibly induce Ca2+ independent non-vesicular GLU release (Sobieski et al, 2017).  
3.9.2 Phosphorylation of Syn I following Roscovitine treatment 
We have presented the preliminary data of phosphorylation profiles of various sites in 
Phospho-Syn-I, including Ser-553 (Cdk 5 site), Ser-9 (PKA site), and Ser-603 (CaMKII 
site), in response to Roscovitine pre-treatment. As this drug allows HK5C and ION5C to 
evoke the SP of SVs from the nerve terminal, such phosphorylation results allow one to 
investigate a changes of Syn I phosphorylation when the SP is undergoing exocytosis. This 




Syn-I-Ser-553 site is known to be phosphorylated by Cdk5. Semi-quantitative analysis 
demonstrated that Cdk5 inhibition with Roscovitine has led to time-dependent decrease in 
phosphorylation at Ser-553 site compared to non-drug treated control. Benfenati’s group 
has demonstrated that the phosphorylation of Syn I with Cdk5 at Ser-551 (homologous 
site with Ser 553) site promoted its interaction with actin microfilament and they suggested 
that this leads to an elevation of SV interaction with F-actin, moves recycling SVs to the 
SP, and leads to reduction in releasable SVs in the recycling pool (Verstegen et al, 2014). 
In this study, Roscovitine treatment also led to the reduction in the phosphorylation of Syn 
I at Ser-553 site and this seems to have allowed the SP SVs being able to exocytose. 
Therefore, these results may suggest that inhibition of Cdk5 by Roscovitine led to a 
reduction in Cdk5 phosphorylation of Syn I, which allows the previously immobilised SVs 
now available for exocytosis, such that these previously immobilised SP SVs can now 
release their content. It is noteworthy that this result is from preliminary study and require 
a further investigation. 
However, we investigated whether there were other Syn I phosphorylation sites that could 
play a role in the release of the SP. A semi-quantitative analysis on blots probing for the 
phosphorylation of Ser-9 – a PKA site - demonstrated that such phosphorylation was found 
to be elevated following Roscovitine treatment relative to non-drug treated control for 
4AP5C and HK5C but not ION5C. Although these are still preliminary results, it is 
possible to suggest that these two former stimuli, by activating Ca2+ channels at the AZ, 
can activate PKA in some way (perhaps via calmodulin dependent adenylate cyclase). 
Indeed, PKA phosphorylation on Syn I has been highlighted in several studies to promote 
exocytosis by regulating the dissociation of the protein from the SV membrane and 
enhance the recycling of the SVs (Hosaka et al, 1999; Bonanomi et al, 2005). Indeed, a 
mutation of Ser-9 so this site could not be phosphorylated, resulted in an absence of this 
enhancement of release (Flumara et al, 2004). Menegon et al (2006) also reported that 
phosphorylation of Syn I by PKA promotes dissociation of Syn I from SVs, and facilitates 
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the rate of SV exocytosis under sustained stimulation. These authors suggested PKA 
mediated SV exocytosis is primarily caused by calmodulin (CaM)-dependent activation of 
cAMP pathways activated by increased [Ca2+]i rather than the direct activation of CaM 
kinases by Ca2+. Therefore, there clearly can be causes talk between cAMP- and CaM-
dependent cascades which can regulate Syn via its PKA site to modulate SV exocytosis 
(Menegon et al, 2006). 
Syn I is also a substrate of CaMKII at the Ser-603 site. Previous studies have indicated 
that some of Syn I effects were abolished by CaMKII mediated phosphorylation. Syn I 
reversibly anchors the SVs to the actin cytoskeleton of the nerve terminal, promoting 
polymerisation and bundling of actin filaments and forming ternary complex, but CaMKII 
phosphorylation of Syn I abolishes the formation of this network (Llinas et al, 1985, 1991; 
Petrucci and Morrow, 1987; Valtorta et al, 1991; Ceccaldi et al, 1995; Wang et al, 2008). 
Herein, stimulus evoked increase in the phosphorylation of Ser-603 which is increased by 
Roscovitine and these changes are most distinct after 120 sec of stimulation. Interestingly, 
the CaMKII site appears to show the best Ca2+ dependent stimulation evoked 
phosphorylation increase. At 2s 4AP5C induced less of an increase in phospho-Ser-603 
than either HK5C or ION5C and although there appears to be greater amounts of this 
phosphorylation, after 120 sec stimulus, 4AP5C is still less than HK5C or ION5C at 
inducing Syn I Ser-603 phosphorylation. This fits in with the known greater induced 
increase in [Ca2+]i with the latter two stimuli. Overall, it is possible that a further increase 
in phosphorylation of the Ser-603 site in Syn I may be associated with Roscovitine 
treatment and so this may also be related to the support for evoked release of the SP. 
Although, it is not clear whether decrease in Cdk5 expression and increase in CaMKII 
phosphorylation at Syn I are correlative. Again, these are preliminary data and further 
research is required. 
It is important to remember that 4AP5C is incapable of inducing the release of the SP in 
Roscovitine treated terminals so it is likely that any changes seen with 4AP5C may not be 
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related to release of the SP. For the phosphorylation of Ser-553, 4AP induces slightly less 
than HK5C which is slightly less than ION5C. However, Roscovitine reduces this 
phosphorylation to a level not too dissimilar for all these stimuli. Thus, perhaps it is the 
larger decrease of phosphorylation induced by HK5C or ION5C in Roscovitine treated 
terminals which can free the SP SVs and allow them to be released. However, 4AP5C may 
allow such SP SVs to be released from their attachments but there is insufficient increase 
in [Ca2+]i to actually cause these to exocytose. 
Intriguingly, by 120 sec all 3 stimuli have increased 2-fold the phosphorylation of Ser-9 
on Syn I but, whereas Roscovitine can increase this to 3-fold for both 4AP5C and HK5C, 
there is no change for ION5C. As mentioned earlier, this could be related to the activation 
of voltage dependent Ca2+ channels by 4AP5C and HK5C (ION5C does not act via such 
channels) and subsequent activation of calmodulin dependent adenylate cyclase, increase 
in cAMP locally and specific activation of PKA. However, as HK5C and ION5C induced 
SP release in Roscovitine treated terminals, then this phosphorylation site may not 
contribute to the SP release, similar are what can be made for the phosphorylation of Ser-
603. HK5C and ION5C induced a larger increase in phosphorylation at this site in 
Roscovitine treated terminals. Thus the larger increase may be important for SP SVs to 
undergo exocytosis. 
3.10 Future research 
This study requires further research on several areas in order to elucidate various properties 
of the SP. Future experiments include investigating the reversibility of Roscovitine, any 
PKA involvement in Roscovitine induced SP exocytosis, and additional repeat of western 





3.10.1 Reversibility of Roscovitine 
In this thesis, we have been able to induce the SP of SVs following Roscovitine treatment 
but we have not studied the exocytosis of the SP utilising FM dyes. In order to conduct 
FM 2-10 Styryl dye release assay on the SP, all SV from the nerve terminal have to be pre-
released, labelled with the dye and then such SVs must then recycle into the terminal. 
Subsequently, evoked release is induced and fluorescence changes as measured (See 
chapter 2.4 of method section). However, this experiment is probably only viable if 
Roscovitine effect can be reversed after the pre-treatment and pre-stimulation. This is 
because Cdk5 inhibition may perturb the recycling of the labelled SVs or the subsequent 
mode of exocytosis. However, as the reversibility of Roscovitine is not yet been 
established, the mode of the SP exocytosis is unable to be investigated. This would be 
interesting data because it would reveal the mode of the exocytosis that SP SV undergo 
which would then partially reveal some of the proteins that are involved in SP regulation 
and may indicate further distinct properties of the SP compared to the other two pools.  
3.10.2 PKA Dependency of SP release 
It has been found that PKC activity was able to regulate the SP release. Another essential 
kinase is PKA which is known to contribute heavily to the regulation of neurotransmission 
(see some results in chapter 5). PKA is present at nerve terminals, and it is known to 
phosphorylate serine and threonine residues. It can be activated by increasing cAMP levels 
(Seino and Shibasaki, 2005; Park et al, 2014). It is capable of regulating exocytosis of SVs 
via the regulation of the phosphorylated state of various protein, including Syn I (Fiumara 
et al, 2004; Menegon et al, 2006) and as Syn I may regulate the SP release (see 
phosphorylation results) (Orenbuch et al, 2012; Verstegen et al, 2014), PKA is a potential 




3.10.3 Repeat western blot experiment with same drug treatments 
Due to the lack of time available for further experiments, the current study is reporting 
results from two independent experiments. A minimum of three independent experiments 
are required to produce statistically significant results, and so we are unable to prove the 
significance of the changes reported. Additional experiments with an equivalent drug 
treatment will need to be conducted and the resulting values need to be combined with 
those herein to clarify the results. It is for this reason that these results are not included as 
a separate chapter. However, it was felt that it was important to demonstrate the strategy 
being employed to determine the molecular mechanism of Roscovitine.  
3.11 Conclusion 
This chapter has shown Roscovitine, a Cdk5 inhibitor, can allow the SP to be released 
following HK5C or ION5C stimulation and utilising this fact an investigation has been 
performed on how the properties of SP changes dependent on various other drug 
treatments. However, higher [Ca2+]e with the HK stimulus (HK10C or HK20C) blocked 
the SP release from Roscovitine-treated terminals but a reduction in evoked [Ca2+]i data 
in Roscovitine treated terminals also blocked the release of the SP. This demonstrates that 
the SP requires a specific level of [Ca2+]i for it to be released.  
Activation of PKC, but not inhibition, was found to perturb the ION5C evoked SP release 
in Roscovitine-treated terminals. Likewise, the N-type Ca2+ channel blocker CONO 
prevented the HK5C-evoked SP release in Roscovitine-treated synaptosomes. However, 
similar results were also found when P/Q-type channels were blocked with AGA or when 
L-type channels were blocked with NIF. Thus, all these channels may have an important 
role in the SP regulation. Actin stabilisation with JASP did not perturb release of the SP, 
indicating that stabilisation of microfilaments does not prevent release of any pool. 
127 
 
It is, therefore, concluded that the SP of GLU containing SVs was induced to release GLU 
following treatment with Roscovitine, but such release was controlled by levels of [Ca2+]i, 
by entry of Ca2+ through three types of Ca2+ channels and by PKC activation.   
Additionally, the preliminary data of western blotting experiments has shown that Cdk5 
inhibition with Roscovitine might have led to decrease in phosphorylation at Ser-553 site 
(Cdk5 site) whilst increase of phosphorylation was observed at Ser-9 (PKA site) and Ser-
603 (CaMK II site). Accordingly, it would appear that Roscovitine supported release of 
the SP may involve phospho-Syn I activity which include inhibition of the Cdk5 
phosphorylation site and enhancement of the PKA and CaMK II phosphorylation sites. 
Although, it is not clear whether these two phenomena of positive and negative effect of 
Roscovitine on phosphorylated profiles of Syn-I are correlative. Additionally, it is also 
noteworthy that PKA phosphorylation was discovered by several researches to contribute 
to the dispersion of Syn I from SVs whilst CaMKII phosphorylation was implicated in the 
dissociation of actin microfilament and Syn I, thus inhibition of Cdk5 action with 
Roscovitine might have promoted phosphorylation at both ends of the actin-synapsin-
synaptic vesicles network leading to increasing availability of SVs to exocytose. Clearly, 
these experiment are worthy to be repeated several more times as it could potentially lead 








Chapter 4:  






Chapter 3 demonstrated that Roscovitine – through Cdk5 inhibition – enabled HK5C or 
ION5C to evoke the SP of SVs to release. Considering the complexities of release of SVs 
from all the pools, it is likely that other pathways besides the Cdk5 pathway may evoke 
the release of the SP. Herein, Fluoxetine has been investigated to see whether it could 
trigger the extra release from the SP in synaptosomes. 
Fluoxetine was designed as a selective serotonin reuptake inhibitor (SSRI) and it is one of 
the most prevalently prescribed drugs for the treatment of depression (Prozac). The exact 
pathology of depression is yet to be fully elucidated, but the disruption in the serotonergic 
pathway has been widely acknowledged as a potential candidate. This is because the SSRI 
drugs, including Fluoxetine, that were assumed to target on the serotonergic pathway were 
found to relieve some of the major symptoms of depression (Rahn et al, 2015; Hamilton 
et al, 2016; Clevenger et al, 2018). SSRIs operate through blocking the uptake of serotonin 
following its release, and this consequently increases the level of the monoamine in the 
brain in drug treated patients (Dale et al, 2015). However, the association between synaptic 
transmission and the pathology of depression requires further investigation. Recently, 
studies have suggested that ketamine, an NMDA antagonist, produces rapid antidepressant 
responses in patients who were resistant to typical antidepressant treatments. Ketamine 
rapidly stimulates synaptogenesis and reverses the synaptic deficits caused by chronic 
stress, and such a result suggests that there are associations between synaptic transmission 
and the pathology of major depressive disorder (MDD), this led to the synaptogenic 
hypothesis of depression (Duman and Aghajanian, 2012). 
If it is the case that manipulation of synaptic transmission has a contribution on depression 
phenotype, it could also imply that a regulation of the exocytosis of the pools including 
the SP may potentially be associated with the development of depression. Jung et al (2014) 
studied the action of 1 M of Fluoxetine on exocytosis from hippocampal cultured cell. 
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This treatment led to an increase in the size of the recycling pool of SVs by apparently 
allowing some SP SVs to contribute to release. This finding is significant because it has 
suggested that the pharmacological mechanism of this antidepressant could potentially 
involve an elevation of the SV release of non-monoamine transmitters, and importantly, 
such release involves mobilisation and release of the SP. In this chapter, the aim was to 
test whether Fluoxetine could release the SP of GLU containing SVs in the synaptosomal 
model used herein. It is noteworthy that the experimental model used in this study is 
cerebral cortical terminals, and these are 80% glutamatergic.  
4.2 Establish optimum condition for Fluoxetine to allow HK5C 
evoked SP release.  
4.2.1 5 min incubation with various doses of Fluoxetine 
In Chapter 3, Roscovitine induced extra release from the SP was investigated and 
maximum SP release was established by treating synaptosomes for 5 min at 37oC with 
various concentrations of the drug (10 M, 33 M, 100 M, 200 M). In this chapter, the 
study aimed to elucidate whether Fluoxetine could release - same as Roscovitine – the SP 
and what conditions were needed to allow maximum SP release. 
Synaptosomes were pre-treated with different concentrations (1 M, 200 nM, 100 nM, 50 
nM) of Fluoxetine for 5 min incubation time and the GLU release evoked by HK5C was 
measured. For 1 M Fluoxetine treatment, the HK5C evoked release appeared to be 
reduced compared to non-drug treated control and, therefore this concentration has not 
only failed to induce the SP of SVs to exocytose, but may have also perturbed some release 




Figure 4.1. 1 M Fluoxetine treatment for 5 min in 37oC failed to allow HK5C evoked SP 
release. HK5C evoked GLU release in terminals treated with 1 M Fluoxetine compared to 
non-drug treated controls. Data are mean ± SEM, N=5 independent experiments; Although 
the drug may actually reduce the release, this was not statistically significant (P >0.05).  
As 1 M Fluoxetine did not allow HK5C evoked release of the SP, the concentration of 
the drug was lowered to 200 nM and the HK5C evoked GLU release measured. However, 
this failed to allow extra release and the release was quite similar to control condition (Fig 
4.2). Note in some of these preliminary studies only one experiment was performed for 
each drug concentration. It was argued that any concentration that induced the SP would 




Figure 4.2. 200 nM Fluoxetine treatment for 5 min in 37oC failed to allow HK5C evoked SP 
release. HK5C evoked GLU release in terminals treated with 200 nM Fluoxetine compared 
to non-drug treated terminals. Data are mean ± SEM, Note as there was no obvious difference 
we did not repeat this experiment.  
100 nM (Fig 4.3) and 50 nM (Fig 4.4) Fluoxetine were also tested in preliminary 
experiments, but both conditions produced similar amount of HK5C evoked release of the 
RRP and RP compared to non-drug treated condition and no SP release was apparent. Thus, 
in these preliminary experiments, 5 min treatment with Fluoxetine failed to trigger any 





Figure 4.3. 100 nM Fluoxetine treatment for 5 min in 37oC failed to allow HK5C evoked SP 
release. HK5C evoked GLU release in 100 nM Fluoxetine pre-treated terminals compared to 
non-drug treated terminals. Data are mean ± SEM, N=1 independent experiment.  
 
Figure 4.4. 50 nM Fluoxetine treatment for 5 min in 37oC failed to allow HK5C evoked SP 
release. HK5C evoked GLU release in terminals treated with or without 50 nM Fluoxetine. 




4.2.2 20 min incubation with various doses of Fluoxetine 
In the previous sets of experiment, the samples were treated with Fluoxetine for 5 min but 
with all concentrations employed HK5C failed to evoke any significant release of the SP. 
Thus, this drug may take longer to exhibit its action and we noted that Jung et al (2014) 
incubated for 20 min with the drug instead of 5 min. Thus, the Fluoxetine incubation time 
was extended from 5 min to 20 min.  
Again samples were pre-treated with range of Fluoxetine concentrations (1 M, 200 nM, 
60 nM, 40 nM, 20 nM, 5 nM) for 20 min and subsequently the release evoked by HK5C 
was measured using the GLU assay.  
There was no significant increase in the release identified at majority of the concentrations, 
instead, at 1 M, the control was higher compared to drug-treated condition (Fig 4.5). 
Figure 4.5. 1 M Fluoxetine treatment for 20 min in 37oC reduced the HK5C evoked GLU 
release HK5C evoked GLU release following an extended 20 min incubation at 37oC with 1 
M Fluoxetine compared to non-drug treated control. Data are mean ± SEM, N=3 
independent experiments; P<0.05.  
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Performing a single experiment for 200 nM (Fig 4.6) and 100 nM (Fig 4.7), still suggested 
that in the control conditions HK5C evoked more release than drug-treatment conditions 
although the difference appeared to be smaller compared to 1 M Fluoxetine (Fig 4.5). 
Clearly, it would appear that 1 M, 200 nM, and 100 nM is perturbing some HK5C evoked 
release from the recycling pool and definitely not allowing any SP release.  
 
Figure 4.6. 200 nM Fluoxetine treatment for 20 min in 37oC perturb some HK5C evoked 
release from the recycling pool and not allowing any SP release. HK5C evoked GLU release 





Figure 4.7. 100 nM Fluoxetine treatment for 20 min in 37oC perturb some HK5C evoked 
release from the recycling pool and not allowing any SP release. HK5C evoked GLU release 
following 100 nM Fluoxetine pre-treatment for 20 min at 37oC. Data are mean ± SEM, N=1 
independent experiment. 
A lower concentration of Fluoxetine, 60 nM, did not perturb the HK5C evoked release 
since it was similar to that for non-drug treated control (Fig 4.8) so RRP and RP SVs were 
not being prevented from release but neither was the SP being allowed. As this was near 
to the concentration of 40 nM (see below) which did cause extra release we repeated this 




Figure 4.8. 60 nM Fluoxetine did not perturb the HK5C evoked RRP and RP release but 
neither was the SP being allowed. HK5C evoked GLU release in terminals treated 60 nM 
Fluoxetine pre-treatment with extended incubation for 20 min at 37oC compared to non-drug 
treated control. Data are mean ± SEM, N=3 independent experiments; P >0.05. 
With 40 nM Fluoxetine, the HK5C evoked release was found to be significantly higher 
than the control (Fig 4.9). This was also the case for 20 nM (Fig 4.10), although, the release 
appeared to be slightly lower compared to 40 nM (Fig 4.11) (did not show a difference 
statistically but chose to use 40 nM Fluoxetine from data in Fig 4.9). However, at 5 nM, 
Fluoxetine treatment did not induce any more HK5C evoked release compare to the non-
drug treated condition (Fig 4.12). We have repeated this to ensure that truly 5 nM was not 




Figure 4.9. 40 nM Fluoxetine treatment for 20 min at 37 oC show significantly higher HK5C 
evoked release compared to the control. HK5C evoked GLU release following an incubation 
with 40 nM Fluoxetine for 20 min at 37oC compared to non-drug treated control. Data are 
mean ± SEM, N=11 independent experiments. Note drug treated condition was significantly 
higher than control (P<0.05). 
 
Figure 4.10. 20 nM Fluoxetine treatment for 20 min at 37 oC show significantly higher HK5C 
evoked release compared to the control HK5C evoked GLU release following 20 nM 
Fluoxetine incubation of 20 min at 37oC. Data are mean ± SEM, N=7 independent 




Figure 4.11. 40 nM Fluoxetine treated terminal show slightly higher HK5C evoked release 
compared to 20 nM Fluoxetine terminal, HK5C evoked GLU release following 20 nM 
Fluoxetine and 40 nM Fluoxetine incubation for 20 min at 37oC. Data are mean ± SEM, N=7-
11 independent experiments; P >0.05. 
 
Figure 4.12. 5 nM Fluoxetine did not perturb the HK5C evoked RRP and RP release but 
neither was the SP being allowed HK5C evoked GLU release with 5 nM Fluoxetine pre-
treatment following incubation for 20 min at 37oC. Data are mean ± SEM, N=4 independent 
experiments; P >0.05 
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It is evident from the results that Fluoxetine has a biphasic effect on HK5C evoked release 
with 100 nM or more inhibiting some of the release whilst 40 nM induces greater 
additional release due to evoking the SP. Therefore, the 40 nM Fluoxetine was employed 
in later studies. These results demonstrate that one has to determine precisely the 
Fluoxetine concentration in the synaptosomal model to allow one to study the SP, it should 
be noted that in hippocampal culture cells 1 M was required whilst herein we only needed 
40 nM. However, Jung et al (2014) also found a biphasic action of Fluoxetine on that 8 
M was also shown to inhibit evoked release (Jung et al, 2014). 
The effect of 40 nM Fluoxetine with extended incubation time (20 min) was compared to 
5 min treatment of 100 M Roscovitine on HK5C evoked release (Fig 4.12). The two 
drugs were found to induce an equivalent amount of release. Considering 100 M 
Roscovitine has been previously found to induce the maximum SP release in the previous 
chapter (See Ch 3), the result clearly showcased that 40 nM Fluoxetine with 20 min 
incubation time has successfully evoked the SP exocytosis. 
Figure 4.13. 40 nM Fluoxetine with 20 min incubation time show similar release to 100 mM 
Roscovitine with 5 min incubation. HK5C evoked GLU release following 5 min pretreated 
terminals with 100 M Roscovitine or 40 nM Fluoxetine treatment for 20 min at 37oC. Data 
are mean ± SEM, N=3 independent experiments; P >0.05. 
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4.2.3 Dual treatment of Fluoxetine with Roscovitine produced 
equivalent amount of SP release 
We have established that 20 min incubation with 40 nM Fluoxetine allows HK5C to trigger 
SP exocytosis to an apparent maximum amount. However, we investigated whether HK5C 
could evoke even more release from the SP. In these experiments, synaptosomes were 
incubated for 20 min at 37oC with no-drug (control), Roscovitine (for last 5 min of the 20 
min incubation or Fluoxetine for 20 min with Roscovitine added for the last 5 min). By 
including synaptosomes with both 40 nM Fluoxetine and 100 M Roscovitine, 
Roscovitine on its own  allowed HK5C to evoke SP release as previously identified (Fig 
4.14a) and when it was dual treated with Fluoxetine, there was still extra release evoked 
by HK5C compared to control (Fig 4.14b). Importantly, the amount of this extra release 
was equivalent to that induced by HK5C with only Roscovitine was treated (Fig 4.14c). 
Thus there was no further extra release evoked by HK5C following the double drug 
treatment. This could mean that 40 nM Fluoxetine treatment induces the maximum release 
of the SP release or it could imply that Roscovitine and Fluoxetine share a similar pathway 
































































































































































































































































































4.3 The effect of Fluoxetine on HK5C evoked [Ca2+]i 
Previously in this chapter, 20 min of incubation with 40 nM and 20 nM Fluoxetine was 
found to enable HK5C to induce the SP release. However, it was also identified that 1 M 
Fluoxetine treatment led to a reduction in HK5C evoked release by not only not allowing 
the SP release but also inhibited some release from the recycling pool consisting of the 
RRP and the RP. An investigation was, therefore, performed to see whether such effects 
were due to changes in evoked  [Ca2+]i using the Fura-2 assay. The sample was pre-
treated with 1 M Fluoxetine and HK5C evoked [Ca2+]i was measured.1 M Fluoxetine 
treatment appeared to reduce the HK5C evoked  [Ca2+]i compared to the control (Fig 
4.15). Therefore, it would be appeared that 1 M Fluoxetine is reducing the release through 
blocking the entry of calcium into the nerve terminal following application of HK5C (see 
discussion). 
 
Figure 4.15. 1 M Fluoxetine treatment reduced the HK5C evoked [Ca2+]i. The change in 
[Ca2+]i induce by HK5C comparing control and 1 M Fluoxetine. Data are mean ± SEM, N=3 
independent experiments; more experiments would be needed to prove this statistically. 
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4.4 Fluoxetine did not induce recycling and re-release of the RRP 
and RP 
Research from Ashton’s group has indicated that neither HK5C nor ION5C can 
induce more than one round of release of the RRP and RP, this mean that there are 
no recycling, reloading, and re-release of the SVs from their pool in the presence 
of these stimuli. Nevertheless, there was still a possibility that Fluoxetine, through 
unknown pathway, could enable the recycling, reloading, and re-release (see 
similar arguments for Roscovitine action in chapter 3). This is important because 
it could mean that the release we have observed may be derived from the recycled 
RRP and RP instead of the SP. In order to ascertain this is not the case, we 
pharmacologically disabled recycling machineries; 160 M Dynasore for Dyn-
dependent pathway and 15 M Pitstop2TM for clathrin-dependent pathway. 
Comparing non-drug treated control condition vs Fluoxetine plus Dynasore (Fig 
4.16 a) clearly revealed that 40 nM Fluoxetine was still allowing HK5C evoked 
release of SP when Dyn-dependent recycling pathways have been blocked. 
Pitstop2TM treated synaptosomes also still allow 40 nM Fluoxetine to support 
HK5C evoked SP release (Fig 4.16 b). Overall this confirms that the extra HK5C 







































































































































































































































































































4.5 ION5C evoked SP release  
4.5.1 40 nM Fluoxetine supports ION5C evoked SP release 
The results so far employing Fluoxetine involved studying HK5C evoked release of the 
SP. Another type of stimulus that we often employ in our study to trigger exocytosis of 
SVs is ION. In contrast to HK5C, ION is an ionophore which bypasses calcium channels 
and increased the Ca2+ level throughout the nerve terminal, therefore it works through a 
different pathway from HK5C. Thus, it was important to ascertain that Fluoxetine can also 
release the SP employing ION5C stimulation. ION5C evoked exocytosis following 40 nM 
Fluoxetine treatment (20 min at 37oC) was also able to induce the release of the SP (Fig 
4.17).  
 
Figure 4.17. 40 nM Fluxoetine supports ION5C evoked SP release. ION5C evoked GLU 
release in 40 nM Fluoxetine pre-treated terminals compared to non-drug treated control. 
Data are mean ± SEM, N=6 for control and N=4 for Fluoxetine independent experiments. 





4.5.2 Fluoxetine did not induce recycling and re-release of the RRP 
and RP under ION5C stimulation 
As for HK5C evoked extra release following 40 nM Fluoxetine treatment, we also tested 
that Fluoxetine’s effect on ION5C evoked release was not due to recycling, reloading, and 
re-release of the RRP and RP by pharmacologically blocking SV recycling with Dynasore 
and Pitstop2TM. ION5C evoked release in control vs 160 M Dynasore plus 40 nM 
Fluoxetine (Fig 4.18a) or in control vs 15 M Pitstop2TM plus 40 nM Fluoxetine (Fig 4.19a) 
were measured. It was evident from the results that under both the Dynasore treated 
conditions and Pitstop2TM treated conditions, Fluoxetine was still able to support the 
release of the SP evoked by ION5C stimulation. Clearly, this extra release is not due to 
recycled RRP and RP SVs. These results are more apparent when Fluoxetine treated 
condition was compared to either Fluoxetine plus Dynasore (Fig 4.18b) or Fluoxetine plus 

























































































































































































































































































































































































































































































































































































































































































































4.6 Bioenergetics results 
4.6.1 5 min incubation with Fluoxetine concentrations 
Bioenergetics of the 1 M Fluoxetine treated samples were measured with Seahorse XFp 
flux analyser. The purpose of this experiment was to clarify the drug does not have an off-
target effect which perturbs the bioenergetics of nerve terminals. Specifically, Fluoxetine 
induced effect on the release is not derived from disruption in bioenergetics of the 
synaptosomes. In fact, as1 M Fluoxetine was found to block some of the release from the 
RRP and RP, there is a chance that this effect may be derived from disturbance of 
bioenergetics in the terminals whereby there is less energy to support SV exocytosis. 
The sample was pre-treated with 1 M Fluoxetine for 5 min at 37oC and then its oxygen 
consumption rate was measured during serial injections of oligomycin, FCCP, and 
rotenone/antimycin. This procedure has allowed various parameters to be measured; basal 
respiration, ATP production, spare capacity, maximum respiration, proton leakage, and 
non-mitochondrial respiration. Note this method was already outlined in more detail in 
Chapter 3. However, the acute treatment with 1 M Fluoxetine for 5 min has failed to 




Figure 4.20. The reduction identified in HK5C evoked GLU release of nerve terminal treated 
with 1 M Fluoxetine for 5 min was not a result of disturbance in bioenergetics. The effect of 
1 M Fluoxetine treatment on the bioenergetics of synaptosomes compared to non-drug 
treated control. The experiment was done three times and the mean values represent an 







Figure 4.21. The reduction identified in HK5C evoked GLU release of nerve terminal treated 
with 1 M Fluoxetine for 5 min was not a result of disturbance in mitochondrial functions. 
The effect of 5 min 1 M Fluoxetine incubation at 37oC on various parameters measured on 
synaptosomes; (A) basal respiration, (B) ATP production, (C) spare capacity, (D) maximal 
respiration, (E) Proton leakage, and (F) Non-mitochondrial respiration. The histobars 
represent the mean and the error bar shows the SEM. There is no signifcnant difference (NS) 





4.6.2 The effect of 20 min Fluoxetine incubation on synaptosomal 
bioenergetics 
Synaptosomes were initially pre-treated with range of Fluoxetine concentrations for 5 min 
but have failed to evoke any SP exocytosis (see ch 4.2.1). Therefore, the incubation time 
with the drug has extended to 20 minutes. Consequently, a 20 min pre-treatment of the 
drug also had to be tested to see whether it has an impact on bioenergetics of the sample. 
The acute treatment of the sample with 1 M Fluoxetine for 20 min, which did inhibit 
some of the release of the RRP and RP, failed to produce any significant difference on any 
of the bioenergetic parameters (Fig 4.22, Fig 4.23 A-E). We argue that as 1 M Fluoxetine 
failed to perturb the bioenergetics parameters, then clearly a lower concentration (40 nM) 
would not as this drug concentration is even less likely to have secondary effect. 
 
Figure 4.22. The reduction identified in HK5C evoked GLU release of nerve terminal treated 
with 1 M Fluoxetine for 20 min was not a result of disturbance in bioenergetics. The effect 
of extended incubation of 1 M Fluoxetine (20 min at 37oC) on the bioenergetics of 
synaptosomes. The experiment was done two times and the mean values represent an average 





Figure 4.23. The reduction identified in HK5C evoked GLU release of nerve terminal treated 
with 1 M Fluoxetine for 20 min was not a result of disturbance in mitochondrial functions. 
The effect of 20 min 1 M Fluoxetine pre-incubation time on synaptosomes bioenergetics 
parameters; (A) basal respiration, (B) ATP production, (C) spare capacity, (D) maximal 
respiration, (E) Proton leakage, and (F) Non-mitochondrial respiration. The histobars 
represent the mean and the error bar shows the SEM. Note although only 2 independent 
synaptosomes preparations were used, the sample in individual wells were treated as 
independent. Using this one can show that there was no significant difference (P>0.05) 













1 4.1-4.4 GLU HK5C Fluoxetine 
(1 M, 200 
nM, 100 nM, 
50 nM) 
5 min incubation of synaptosomes in 
37oC with Fluoxetine failed to allow 
HK5C to evoke SP release. Instead, 1 




GLU HK5C Fluoxetine 
(1 M, 200 
nM, 100 nM, 
60 nM, 40 
nM, 20 nM, 
5 nM) 
20 min incubation with 1 M, 200 nM, 
100 nM, appears to reduce the HK5C 
evoked GLU release compared to 
control. However, 40 nM and 20 nM 
Fluoxetine allowed an extra release with 
40 nM providing the maximal release.  




Treatment of the terminal with 
Roscovitine combined with Fluoxetine 
allowed HK5C to evoke an extra release. 
Importantly, Roscovitine alone and 
Roscovitine plus Fluoxetine conditions 
showed a similar amount of GLU 
release, shows that Fluoxetine is 
allowing maximum evoked SP release, 
and it also suggest that Fluoxetine and 
Roscovitine might operate in similar 
pathway to allow an extra SVs to be 
available. 
4 4.15 Fura-2 HK5C Fluoxetine 
(1 M) 
20 min treatment of synaptosomes with 1 
M Fluoxetine was found to perturb 
some release from the RRP and RP 
potentially due to reduction in [Ca2+]i 
following Fluoxetine treatment.  








An extra HK5C evoked release observed 
in 40 nM Fluoxetine treated terminal is 
not a result of recycling of the RRP and 
RP. 
6 4.17 GLU ION5C Fluoxetine 
(40 nM) 
40 nM Fluoxetine with 20 min 
incubation also allows ION5C to evoke 
an extra release. 
7 4.18-
4.19 






An extra ION5C evoked release 
following 40 nM Fluoxetine treatment is 




Bio  Fluoxetine 
(1 M) 
1 M Fluoxetine treatment for both 5 
min and 20 min incubation in 37oC failed 
to perturb any of the bioenergetics 
parameters. This may suggest that some 
perturbations of the RRP and RP release 
observed in both incubation times are not 
due to the disturbance of bioenergetics of 
synaptosomes. 




Selective serotonin reuptake inhibitors (SSRIs) are the most prevalently used 
antidepressants. They are suggested to work through blocking the uptake of exocytosed 
serotonin into the presynaptic terminal, which consequently increase the serotonin levels 
in the brain of the patient with depression. Fluoxetine is an SSRI and it has been found 
from the study of Jung et al (2014) that under the therapeutic dosage (1 M), it is capable 
of mobilising the GLU containing SVs from the SP in hippocampal cultured cell. In the 
research model used herein (i.e synaptosomes for cerebral cortical cell), 80% of terminals 
utilised GLU as their neurotransmitter and we, therefore, investigated whether Fluoxetine 
could also evoke the release of the SP in this model. 
4.7.1 GLU Assay 
Synaptosomes were pre-treated with various concentrations of Fluoxetine for 5 min at 
37oC and HK5C evoked GLU release was subsequently measured. Whilst 1 M Fluoxetine, 
may reduce the release compared to the control condition, overall, none of the Fluoxetine 
concentrations employed were able to successfully allow HK5C to evoke the SP to 
exocytose. Therefore, the Fluoxetine incubation time was extended to 20 min and the 
synaptosomes were, again, pre-treated with different concentrations of Fluoxetine and its 
HK5C evoked GLU release was subsequently induced and measured. 1 M Fluoxetine 
treatment for 20 min at 37oC significantly reduced HK5C evoked release compared to the 
control, indicating that this concentration of the drug reduced normal release rather than 
increasing it. Both 200 nM and 100 nM Fluoxetine also reduced the exocytosis of GLU 
containing SVs although the reduction was not as great as with 1 M. With 60 nM 
Fluoxetine there was neither an inhibition or stimulation effect on HK5C evoked release 
so this release was to an equivalent level with the control, representing the normal release 
of the RRP and the RP. However, remarkably at 40 nM Fluoxetine, a significantly increase 
in HK5C evoked SV release was found. The amount of release was clearly above the non-
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drug treated condition and, therefore, such treatment appears to have induced a release of 
SVs derived from a pool distinct from the RRP and the RP; this release can be assumed to 
be from the SP. The SP was also evoked by HK5C following 20 nM Fluoxetine treatment, 
but the level of extra release seems to be slightly lower compared to 40 nM. A 5 nM drug 
treatment release appeared to be equivalent to the control so there was no extra release; 
this concentration of drug probably had no effect on any pathway. This would suggest that 
60 nM Fluoxetine may have both inhibiting action and a stimulatory action that cancel 
each other out. Overall, maximum release of the SP was observed by 40 nM Fluoxetine 
incubation for 20 min incubation prior to stimulation.  
Even though a 20 min 40 nM Fluoxetine treatment at 37oC appeared to allow the SP to be 
release, there was still a potential that the drug, by an unknown mechanism, may have 
promoted recycling, reloading, and re-releasing of the RRP and RP pool. This possibility 
was investigated through pharmacologically inhibiting the recycling, with Dynasore and 
Pitstop2TM. The results clearly demonstrated that the extra release observed was from the 
SP of SVs as both conditions prevented recycling pathways of the RRP and the RP but 
Fluoxetine was still able to allow HK5C to induce extra release. 
Having established that 40 nM Fluoxetine incubation for 20 min at 37oC appeared to make 
available the SP following stimulation, it was found that this treatment also allowed 
ION5C to evoke the SP and this was also not a result of recycling, reloading, and releasing 
as the stimulus was still able to induce an extra release under Dynasore and Pitstop2TM 
treatment. As these stimuli work by distinct means future experiments must help to 
ascertain the commonalities of their action on the SP. 
4.7.2 FURA-2 Assay 
It was apparent that the HK5C evoked [Ca2+]i has been reduced following the treatment 
with 1 M Fluoxetine compared to non-drug treated condition. Thus, it would be appear 
that 1 M Fluoxetine is reducing the level of calcium entering the nerve terminal and this 
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may consequently lead to a reduction, this could also possibly explain the reduced release 
in terminals treated with 100 nM and 200 nM ([Ca2+]i was not measured for this). Indeed, 
our observation could explain why Fluoxetine was dose-dependently reduced the level of 
release in the study by Jung et al (2014). This study used range of concentrations (0.9, 4.5, 
9, 18 M) of Fluoxetine and found out that the drug above the therapeutic dose (1 M) 
were dose-dependently inhibiting the neurotransmission (Jung et al, 2014) (see earlier 
comments about differences in the dose required between synaptosomes and hippocampal 
cultured cells). Intriguingly, in some other cases Fluoxetine has been found to increase the 
Ca2+ entry. For instance, Charles et al (2017) reported that Fluoxetine induces an elevation 
in the cytosolic Ca2+ concentration and eventually results in necrosis of the cancer cell. 
They have claimed that this showcases the potential of Fluoxetine to be used in the cancer 
therapy (Charles et al, 2017). However, the study used 100 M Fluoxetine which is much 
higher than used herein or used by Jung et al (2014). Nevertheless, results from other 
studies and the data obtained in current study demonstrate that Fluoxetine may require 
changes in [Ca2+]i levels under certain circumstance and this could be investigated further 
in the future.  
4.7.3 Bioenergetics  
It is clear from the bioenergetic results that neither 5 min incubation nor a 20 min 
incubation with 1 M Fluoxetine, disturbed the bioenergetics of the nerve terminals. These 
results confirm that the observed Fluoxetine induced effect on synaptic neurotransmission 
are not due to disturbance of synaptosomal bioenergetics. Furthermore, it also ensures that 
reduction in release of the recycling pool (RRP or RP) induced through 1 M Fluoxetine 
treatment is not a consequence of the off-target effect of the drug on energetic integrity of 




4.8 Future Studies 
4.8.1 Mechanism of Fluoxetine induced SP release 
This chapter has successfully established that 20 min incubation with 40 nM Fluoxetine is 
capable of allowing the SP to be released from synaptosomes following stimulation. There 
are several future studies that are required, including elucidating the exact mechanism of 
Fluoxetine that allows the evoked triggering of the SP release. SSRI drugs are believed to 
work through blocking serotonin uptake to into terminals, thereby, increasing the 
monoamine level in the synaptic cleft. However, the result from current study could 
suggest that the antidepressant effect of Fluoxetine may also involve glutamatergic 
neurotransmission, and furthermore, that SP exocytosis may contribute such 
antidepressant activity. The exact cause of depression is yet not fully understood but a 
widely accepted view is a lack of serotonin levels within the brain since the SSRI drugs, 
such as Fluoxetine, have managed to improve the symptoms of the patients. However, in 
this current study, Fluoxetine can allow extra exocytosis of GLU containing SVs from 
glutamatergic nerve terminals. Thus, it is possible that part of the antidepressant effect of 
drug may be derived from increasing the number of NT vesicles that can be stimulated to 
release and these effects would not be restricted to serotonergic terminals.  
Indeed, it has been reported theoretically that the antidepressant effect of Fluoxetine may 
not be restricted to causing serotonin uptake inhibition. For instance, Bymaster et al (2002) 
has demonstrated that Fluoxetine induced an elevation in the extracellular level of 
dopamine and on norepinephrine in the hypothalamus, cortex and prefrontal cortex 
(Bymaster et al, 2002). Previously it was reported that Fluoxetine inhibited 4AP evoked 
GLU release from the cerebral cortical synaptosomes mainly through attenuation of P/Q 
type calcium channels (Wang et al, 2003).  This result differs from herein as we use higher 
[Ca2+]e and stimuli that release both the RRP and the RP. Fluoxetine was also found to be 
able to regulate neuroplasticity even under the condition where 5HT transporters were 
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absent (Levy et al, 2019). Clearly, further investigations on the precise mechanism of 
Fluoxetine allowing evoked SP exocytosis in synaptosomes may help elucidate the 
complete pharmacology of Fluoxetine and this may help in the further understanding the 
pathology of the depression. Such advances may help accelerate the development on future 
treatment options for a patients suffering from depression. As to whether serotonergic 
pathways have contributed to the extra GLU release that can be induced need to be studied, 
one could investigate whether other SSRIs could support release on SP or investigate 
whether activation of presynaptic serotonin receptor could do this. Currently, this seems 
unlikely as compared to glutamatergic terminals there are very few serotonergic terminals 
to release enough serotonin to act on all glutamatergic terminals and this assumes that 
these all contain presynaptic serotonin receptors. 
4.8.2 Ca2+ dependency of Fluoxetine induced SP release 
This chapter has shown that 1 M Fluoxetine treatment (in both 5 and 20 min incubation) 
failed to support HK5C evoked SP release but it perturbed some release from the other 
recycling pools. Such treatment reduced the HK5C evoked [Ca2+]i. Thus, it is likely that 
1 M Fluoxetine treatment prevents some of the SVs from the recycling pools (RRP and 
RP) from releasing due to the attenuation of calcium entry into the nerve terminal.  In 
chapter 3 the Roscovitine action to support the evoked SP release, it has been shown that 
SP exocytosis involved the regulation of calcium entry. Further, treatment of the samples 
with PMA, a PKC activator, perturbed the Roscovitine induced ION5C evoked SP release, 
as did increasing the extracellular calcium level ([Ca2+]e)by using HK10C and HK20C. 
Thus, future experiments should include studying Fluoxetine with PKC regulating drugs, 
including PMA (PKC activator) and Go6983 (PKC inhibitor), and also employing higher 
[Ca2+]e. 
In the Roscovitine chapter, we have shown that inhibition of three distinct types of calcium 
channel blocks the Roscovitine action on HK5C evoked SP release but there was no 
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specificity observed as specific inhibition of each types of channel with toxins showed a 
similar result in that there was perturbation of the SP release. For Fluoxetine, some studies 
have implicated P/Q type calcium channels is in its action (Wang et al, 2003) whilst others 
have shown that Fluoxetine inhibits both L-type and N-type calcium channels (Deak et al, 
2000). On the other hand, it has been reported that major depression disorders involve L-
type calcium channel (Bhat et al, 2012) and others suggest that SSRI modulate synaptic 
plasticity through inhibition of L-type calcium channel and that this action was actually 
independent of 5-HT transporters (Norman et al, 2018; Alboghobeish et al, 2019). 
Therefore, it will be interesting to investigate whether Fluoxetine action on regulating the 
availability of the SP might involve the presence of various calcium channels, and 
importantly, if such action occurred through specific Ca2+ channels.  
4.8.3 Reversibility of Fluoxetine 
The use of FM 2-10 dye to study SP exocytosis has not been performed herein. This is 
because in order to load up the SP SVs with dye, one would have to pre-treat the terminals 
with either Fluoxetine or Roscovitine so that the SP is released and so could be labelled 
with the Fluorescence dye and following recycling, one would have labelled such SP SVs. 
However, Fluoxetine or Roscovitine would be needed to allow HK5C or ION5C to evoke 
the release of FM dye from the exocytosing SP of SVs. This may be complicated if such 
drugs can effect parts of the SV recycling cycle such that one may not be able to label SP 
SVs by this method. Possibly if drug actions are reversible then one could allow SP to be 
labelled and recycled and then re-load the drug; one could use one drug for pre-stimulation 
and the other drug for stimulation. 
The mode of the Fluoxetine triggered SP exocytosis has yet to be established. Two modes 
of release, KR and FF, operate through distinctive machineries, and thus exploration into 
the mode of SP release may also help with elucidating the exact properties of exocytosis 
from such vesicles. It is noteworthy that Ashton’s group has previously observed that 
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under non-drug treated conditions, stimulation with 4AP5C released only the RRP of SVs, 
with roughly half being via a KR mechanism and half being through FF during controls 
(see appendix Fig A5). ION5C and HK5C on the other hand, releases RRP exclusively by 
KR, and the RP exclusively by FF (see appendix 1). Further, Tsien’s group has reported 
that the mode of the release is dependent on position of the SVs with long-dwelling 
vesicles more likely to undergo the KR mode of the release (Park et al, 2012). Therefore, 
in the future study, one may be able to utilise FM 2-10 release assay and Fluoxetine to 
discover the mode of SP exocytosis. 
4.8.4 Phosphorylation 
The preliminary phosphorylation experiments on specific phosphorylation sites on Syn I 
has tried to correlate specific sites with release of the SP (see chapter 3). Clearly, an 
analogous study should be performed in which the SP is able to be released following 40 
nM Fluoxetine treatment. 
4.9 Conclusion 
In conclusion, a 20 min incubation at 37oC with 40 nM Fluoxetine provided the best 
condition for future studies for both HK5C and ION5C evoked SP release. 1 M 
Fluoxetine treatment resulted in a decrease of the release. This may due to this reducing 









Mode of Release: Role of Dynamin, 






There are finite numbers of SV in the nerve terminal, thus after exocytosis, vesicles must 
be recycled and prepared for the subsequent round of release. Therefore, vesicle recycling 
is vital to refill the pre-synaptic SV pools, sustaining transmitter release during continuous 
stimulation, and maintaining presynaptic morphological and structural integrity. In 
response to the dynamics of vesicle reutilisation, it has been argued that exocytosis can 
occur by at least two different mechanisms; full-collapse fusion (FF), and Kiss-and-run 
(KR) fusion. In FF, the FP quickly dilates/expands, which leads to complete flattening of 
the vesicle into the planar surface of the target membrane and which may lead to the lipid 
and protein contents of the vesicle mixing with that of the PM. In KR, the vesicle release 
its neurotransmitters through a narrow fusion pore, whilst maintaining its morphological 
shape (Alabi and Tsien, 2013) and subsequently the pore recloses and vesicle regains its 
integrity. 
These two fusion modes are distinctive to each other, especially in the way transmitter is 
exocytosed and the details of subsequent retrieval and reuse. Heuser and Reese have 
established a role for FF and clathrin-mediated endocytosis (CME) in vesicle cycling. In 
small terminals of CNS neurons, FF leaves vesicle components on the plasma membrane 
for ~15 sec on average before the membrane and protein are retrieved by CME at 
perisynaptic zone (Heuser and Reese, 1973, 1989).  
The biggest distinction of KR from FF is a rapid endocytic kinetics and the small size of 
the fusion pore formed during exocytosis. The recycling process after FF requires proteins 
such as clathrin and Dyn. Clathrin is a triskelion shaped scaffold protein, which through 
collaboration with adaptor proteins, invaginates the membrane containing vesicular 
components into clathrin-coated pits. These coated pits present on the PM for short 
duration, 1-2 sec, forming a narrow neck made out of lipids and/or proteins. This neck 
subsequently has to be detached from the membrane and the following role is performed 
165 
 
by Dyn (Rizzoli and Jahn, 2007). Dyn is a 100-KDa lipid-binding GTPase. It helps to 
pinch off the coated pit from the PM by oligomerising around the neck of clathrin pits in 
spirals. Dyn is a mechanoenzyme and during guanosine triphosphate (GTP) hydrolysis, its 
structural conformation changes, and this produces tension on the vesicle neck, 
consequently, destabilise the structure and this eventually leads to scission of the neck and 
consequently release of the coated vesicles (Hinshaw and Schmid, 1995; Sweitzer and 
Hinshaw, 1998; Hinshaw, 2000; Anantharam et al, 2011). If the coated vesicles has been 
formed from the SV content then as this vesicles moves away from the PM, clathrin and 
other scaffold proteins dissociate and the vesicle re-acidifies so it can subsequently refilled 
with NT. Clearly, Dyn has an important role in exocytosis and the regulation of the FP. 
However, it has been suggested that under specific stimulation conditions the regulation 
of the FP during KR can also be regulated through Dyn (Graham et al, 2002).  
Along with Dyn, several other proteins are suggested to play a role in the regulation of the 
exocytotic mode including NM-II (Chan et al, 2010; Papadopulos, 2017). Myosin is a 
motor protein that has been reported to be involved in controlling the availability of 
secretory granules. In the chromaffin cells, Myosin V and several members of NM-II gene 
family are expressed. Myosin V is known to be involved in the mobilisation of chromaffin 
granules from interior space of the cell to the periphery site, and following the arrival of a 
stimulus, it dissociates from the granules. NM-II motor function can be regulated by the 
phosphorylation of the regulatory light chain subunits. With the Ca2+ entry, MLCK is 
activated and this kinase phosphorylate NM-II to regulate its motor function, this is 
therefore a calcium dependent function (Chan et al, 2010). In the study on chromaffin cells 
from Neco et al (2002), Myosin was found to actively transport chromaffin granules into 
the sub-plasmalemmal area in the early stage of the exocytosis. It was established in this 
study that NM-II is pre-dominantly abundant in the cell periphery and, it was therefore, 
concluded that such a subtype may be contribute to the early events of exocytosis (Neco 
et al, 2002). In a subsequent study, this group further reported that NM-II may also be 
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involved in a later phase of exocytosis by regulating the kinetics of exocytotic pore 
expansion (Neco et al, 2004). Later, they suggested that NM-II works as a molecular motor 
on the FP expansion whose dilation is hindered when phosphorylation sites on NM-II are 
perturbed (Neco et al, 2008).  
Doreian et al (2008) have claimed that under low stimulation conditions, actin regulates 
the KR mode of release, and that following an increase in stimulation, the actin cortex gets 
disrupted and this leads to a switch of the mode to FF. Importantly, they discovered that 
NM-II activation is involved in the cytoskeleton-dependent regulation of the fusion mode 
as perturbation of NM-II led to continuous KR mode even under elevated stimulation 
(Doreian et al, 2008). Pharmacological disruption of the F-actin- NM-II network with 
Blebbistatin (inhibits NM-II ATPase activity) and JASP (stabilises actin microfilaments) 
has led to a slower single vesicle fusion kinetics and increased the distance between 
vesicles and the fusion site. This suggest that such interaction may have a key role in 
localisation of the SVs at AZ in nerve terminals and also may regulate the speed of the 
fusion events occurring (Vilanueva et al, 2012). 
We have discussed these proteins in some detail because the experiments in this chapter 
investigate the contribution of some of these molecules in the regulation of the mode of 
exocytosis. 
5.2 The effect of the Dyn inhibitor MITMAB on the mode of release 
Dyn is known to regulate the KR mode of SV exocytosis. Dynasore is a drug used to block 
GTPase activity of Dyn and pharmacologically inhibits its action. It has been previously 
found that Dynasore treatment has led to the switch of mode from KR to FF for the RRP 
of SVs under certain stimulation conditions (Bhuva, 2015, Singh, 2017; see appendix 1 
Fig A7). This clearly tells us that Dyn does indeed have a role in one type of KR release. 
However, it is unknown whether Dyns that are already present on membranes regulate the 
KR mode of exocytosis or whether Dyn has to translocate to the membrane during 
167 
 
exocytosis and only then regulate the exocytotic mode. This can be tested by using the 
drug MITMAB. MITMAB prevents Dyn translocating from the cytosol to membranes, i.e. 
it stops Dyn binding to membrane (i.e. Quan et al, 2007; Linares-Clemente et al, 2015). 
This drug prevents Dyn binding to phospholipids in membranes because it perturbs the 
pleckstrin homology (PH) domain present in Dyn. The use of MITMAB should reveal 
whether Dyn has to be translocated to membranes to regulate the mode or whether Dyn 
already on membrane can do this. 
5.2.1 MITMAB does not change the HK5C, ION5C, 4AP5C evoked 
GLU release 
Synaptosomes were pre-treated with 30 M MITMAB (5 min at 37oC) and subsequently 
GLU release evoked by three different stimuli (4AP5C, HK5C, ION5C) was measured. It 
is apparent from the results obtained that MITMAB treatment did not affect the release 
induced by 4AP5C (Fig 5.1a), HK5C (Fig 5.1b) or ION5C (Fig 5.1c). Note that 4AP5C 
only evokes release from RRP whilst HK5C and ION5C can trigger the release from both 
the RRP and RP, thus, these results prove that MITMAB does not change the amount of 





Figure 5.1. MITMAB does change the amount of release from either the RRP or RP. Evoked 
GLU release induced by a) 4AP5C b) HK5C c) ION5C in control and 30 M MITMAB 
treated terminals. Data are mean ± SEM, N=3 independent experiments. Note that there were 
no significant difference (P>0.05) in release amounts between drug treated and non-drug 
treated terminals for any of the stimuli employed. 
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5.2.2 MITMAB does not interfere with Dyn dependent KR 
pathway 
MITMAB has been found not to affect the GLU release induced by the three stimuli 
employed. Therefore, we tested if it has any impact on the mode of the release by using 
the FM dye release assay. Synaptosomes were loaded with FM 2-10 dye, treated with 
MITMAB and FM dye release was evoked by HK5C and ION5C. Clearly, MITMAB does 
not affect the amount of FM dye release evoked by either HK5C (Fig 5.2a) or ION5C (Fig 
5.2b) and, therefore, there is no mode switching to FF as there is no extra dye release. This 
implies that inhibition of Dyn translocation to membranes by MITMAB did not affect the 
Dyn dependent KR pathway normally activated by ION5C (appendix 1 Fig A5), which 
means that Dyn already present on membrane must regulate the KR mechanism. As HK5C 
works on the NM-II dependent KR pathway (appendix 1 Fig A5, A8, A9) one might have 






Figure 5.2. No mode switching to FF has been found following MITMAB treatment in either 
stimuli employed. FM 2-10 dye release evoked by a) HK5C b) ION5C in the presence or 
absence of 30 M MITMAB. Data are mean ± SEM, N=4 independent experiments. Note that 
there were no significant difference (P>0.05) between control and MITMAB treated condition 
for both HK5C and ION5C evoked release. 
5.2.3 MITMAB does not perturb calcium entry evoked by HK5C 
or ION5C 
Changes in intracellular calcium level ([Ca2+]i) were measured to make sure calcium entry 
induced by the stimuli has not been changed by the drug treatment. Synaptosomes were 
pre-treated with MITMAB and stimulated with HK5C (Fig 5.3) and ION5C (Fig 5.4) 




affected by the drug treatment, as the [Ca2+]i was similar in control and drug treated 
terminals. From such results we can conclude that MITMAB does not stop the Dyn 
dependent KR release, and does not interfere with the Dyn mediated KR mode. 
 
Figure 5.3. HK5C evoked [Ca2+]i was not changed with MITMAB treatment. [Ca2+]i induce 
by HK5C in control and 30 M MITMAB treated terminals. Data are mean ± SEM, N=3 
independent experiments; There is no significant difference (P>0.05) for the data points for 
the 2 conditions.  
 
Figure 5.4. ION5C evoked [Ca2+]i was not changed with MITMAB treatment.[Ca2+]i 
induced by ION5C in control and 30 M MITMAB treated terminals. Data are mean ± SEM, 
N=3 independent experiments; There is no significant difference (P>0.05) between drug-free 
and drug-treated terminals. 
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5.3 Inhibition of endogenous PKA perturbs the Dyn dependent KR 
mechanism for the RRP SVs but not the NM-II dependent KR 
pathway 
Dyn I has a key role in regulation of a KR mode of exocytosis. However, an exact 
mechanism of this regulation is not understood. SV endocytosis can be regulated by a set 
of proteins that collectively are termed dephosphins. The dephosphins are phosphorylated 
in nerve terminals, whilst they are dephosphorylated during endocytosis, and their 
subsequent rephosphorylation after endocytosis is vital for regulation of SV recycling and 
thus synaptic transmission. Dyn I is one of these dephosphins and during endocytosis, it is 
dephosphorylated by calcineurin and subsequently gets re-phosphorylated at certain serine 
residues (Robinson, 1991; Robinson et al, 1994; Simillie and Cousin, 2005; Graham et al, 
2007). Thus, it is important to investigate the role of phosphorylation of Dyn in regards to 
the contribution of this protein to the KR mode of release.  
Originally, PKC was shown to be a major kinase phosphorylating Dyn (Robinson, 1991, 
1992, Powell et al, 2000) and Ashton’s group has recently highlighted some evidence for 
PKC dependent Dyn I phosphorylation regulating the mode of release, although, such data 
also indicated other kinases maybe involved (Bhuva, 2015; Singh, 2017). Protein kinase 
A (PKA) could be one such kinase that could regulate the Dyn activity. PKA is activated 
following rise of cytosolic cyclic-AMP (cAMP) levels, it is present in nerve terminals, and 
it phosphorylates serine and threonine residues of target proteins. Thus, it could potentially 
regulate the mode of exocytosis by the phosphorylation of Dyn I at specific sites (Nguyen 
and Woo, 2003; Seino and Shibasaki, 2005; Park et al, 2014). Herein, we investigated the 




5.3.1 PKA inhibition with KT5720 does not affect GLU release 
evoked by 4AP5C, HK5C or ION5C. 
Before studying the mode of exocytosis, one needed to establish whether PKA inhibition 
could affect the GLU release itself. Synaptosomes were treated with the PKA inhibitor, 
KT5720 (Murray, 2008), and GLU released with various stimuli (4AP5C, HK5C, and 
ION5C) was subsequently measured. 2 M KT5720 failed to modify the amount of GLU 





Figure 5.5. PKA inhibition does not affect GLU release evoked by either stimuli employed. 
GLU release evoked by a) 4AP5C b) HK5C c) ION5C in control and 2 M KT5720 treated 
terminals. Data are mean ± SEM, N=3 independent experiments. However, there was no 




5.3.2 KT5720 treatment switches 4AP5C and ION5C induced 
release to FF but HK5C induced mode of the release remains 
unchanged 
FM dye release experiments were performed for all three stimuli following PKA inhibition 
with KT5720. Intriguingly, for 4AP5C (Fig 5.6a) and ION5C (Fig 5.6b) there is an 
increase in FM dye release and this indicates that the RRP SVs have been fully switched 
to a FF mode. However, for HK5C (Fig 5.6c) stimulation, there was no extra release and 
the FM dye release was similar to the non-drug treated control, indicating that the drug 
treatment has not switched the RRP mode. From previous work, it is known that 4AP5C 
and ION5C evoke KR release through a Dyn-dependent pathway, whilst HK5C acts 
through a NM-II dependent pathway (Bhuva, 2015; Singh, 2017; see appendix 1). 
Therefore, these results might suggest that PKA inhibition with KT5720 switches the Dyn 





Figure 5.6. PKA inhibition switches 4AP5C and ION5C induced release to FF but HK5C 
induced mode of release was unchanged. FM dye release evoked by a) 4AP5C b) ION5C c) 
HK5C in the presence or absence of 2 M KT5720. Data are mean ± SEM, N=4 (a, c) and 5 
(b) independent experiments. There was a significant difference (P<0.05) between control and 
KT5720 treated conditions for 4AP5C and ION5C evoked release but there was no significant 
difference (P>0.05) for HK5C evoked release (Note that significance measured for 
representative time points throughout time course i.e. every 10 sec). 
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In fact, similar results were previously obtained after synaptosomes were treated with 
Dynasore, which inhibits the GTPase activity of Dyn. In this case, the Dyn dependent KR 
was switched to a FF mode (such results are shown in Fig 5.7 so one can compare to Fig 
5.5 and Fig 5.6). Whilst, Dynasore treatment did not affect the GLU release for all stimuli 
(Fig 5.7 a-c), it was apparent that 4AP5C (Fig 5.7 d) and ION5C (Fig 5.7 e) evoked FM 
dye amount increased due to a release were switch to FF of the RRP whilst HK5C (Fig 5.7 
f) evoked dye release remain unchanged. Results from KT5720 experiments, in 
combination with these Dynasore results, demonstrate that the PKA inhibition perturbs the 
distinct KR mode depending on which stimulus has been employed. One can hypothesise 
that the inhibition of endogenous PKA leads to a switch of the Dyn dependent KR to FF, 







Figure 5.7. GLU and FM dye results when Dyn is inhibited produce similar result to when 
PKA is inhibited. GLU release evoked by a) HK5C b) ION5C c) 4AP5C and FM dye release 
evoked by d) HK5C e) ION5C f) 4AP5C evoked FM dye release in the control or 160 M 
Dynasore treated terminals. Data are mean ± SEM of numerous experiments. Note for GLU 
release there was no significant difference (P>0.05) between control and Dynasore treated 
conditions on for any stimulus. For FM-dye assay, HK5C evoked release was unchanged but 
ION5C and 4AP5C evoked release were significantly changed compared to controls. Note this 
figure was supplied by A.Ashton and was included so one can compare to the previous 2 
figures. It is actually the same figure as A7 that in appendix 1. However, it was included here 





5.4 Conditions under which HK5C evokes Dyn dependent KR of 
the RRP depends upon active endogenous PKA 
The hypothesis is that the inhibition of endogenous PKA leads to a switch of the Dyn 
dependent KR to FF, thus, HK5C action on NM-II KR is not perturbed. This can be further 
verified if HK5C is switched so that it acts on the Dyn dependent pathway instead of the 
NM-II dependent pathway. Fortunately, we can switch the action of HK5C as it was 
previously observed that PKC inhibition with Go6983 changed the pathway HK5C work 
through to induce a release, such that HK5C is now working through Dyn dependent 
pathway instead of NM-II dependent pathway (Bhuva, 2015; Singh, 2017; see appendix 1 
Fig A 11 and A12).  
5.4.1 KT5720 had no effect on HK5C evoked GLU release in 
Go6983 treated synaptosomes 
Synaptosomes were pre-treated with Go6983 and KT5720 and subsequently HK5C 
evoked GLU release was measured. The GLU release was not perturbed under this dual 
drug treatment as the levels of release were virtually the same as for the non-drug treated 





Figure 5.8. KT5720 had no effect on HK5C evoked GLU release in Go6983 treated 
synaptosomes. HK5C evoked GLU release from control and 1 M Go6983 plus 2 M KT5720 
treated terminals. Data are mean ± SEM, N=4 independent experiments; P <0.05 is used as a 
sign of significant difference. However, there was no significant difference of release between 
control and Go6983 plus KT5720 treated terminals. 
 
5.4.2 HK5C evoked FM dye release switch to FF in terminals co-
treated with Go 6983 and KT5720 
It was previously hypothesised that HK5C evoked KR release is unchanged because PKA 
inhibition only affects Dyn dependent pathway. Go6983 treatment causes HK5C 
stimulation to stop operating through NM-II dependent pathway and switch to Dyn 
dependent pathway for the KR of the RRP. Indeed, it was found that pre-treatment with 
Go6983 and KT5720 has led to an increase in HK5C evoked FM dye release 
demonstrating a change of the RRP SVs releasing mode from KR to FF (Fig 5.9). Such 
results confirm the suggestion that PKA only affects the Dyn dependent KR pathway since 
HK5C working through the Dyn dependent pathway is also switched to FF just like for 
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ION5C and 4AP5C; this also indicates that FM results were not limited to a particular 
action of a specific stimulus.  
 
Figure 5.9. Dual treatment of synaptosomes with Go6983 and KT5720 switches HK5C evoked 
FM dye release to FF. HK5C evoked FM dye release in the presence of 1 M Go6983 plus 2 
M KT5720 compared to non-drug treated control. Data are mean ± SEM, N=4 independent 
experiments; Note that there were significant difference of release between control and double 
drug treated conditions (P<0.05). 
 
5.5 The effect of Calcium channel blockers on NM-II and Dyn 
dependent regulation of RRP SV mode 
Specific calcium channel dependencies of the release mode is an important area to address. 
A.Ashton’s group has previously observed that at least one KR mode of exocytosis is 
dependent on L-type calcium channel. Various voltage dependent calcium channels were 
blocked by pre-incubating synaptosomes; 1 M NIF blocked L-type channels; 1 M 
CONO blocked N-type channels; 50 nM AGA blocked P/Q-type channels. In these 
preliminary observations it was found that HK5C evoked [Ca2+]i decreased after blocking 
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all of these types of calcium channel (AGA, CONO, NIF) (Fig 5.10 a-c). However, no 
calcium channel inhibitors have actually perturbed HK5C evoked GLU release (Fig 5.10 
d-f); this indicates that despite a reduction in HK5C evoked [Ca2+]i there was still 
sufficient Ca2+ entering to enable the RRP and RP SVs to exocytose. However, for HK5C 
evoked FM 2-10 dye release there was only extra FM dye release – because the KR mode 
of the RRP has switched to FF - for L-type calcium channel blockade (Fig 5.10 i), whilst 
P/Q-type (Fig 5.10 g) and N-type (Fig. 5.10 h) channel inhibition did not perturb the KR 
mode evoked by HK5C. Overall, it was initially concluded that the KR of the RRP is pre-
dominantly regulated through L-type calcium channels. However, it has now been realised 
that this result actually applies to the NM-II dependent KR pathway as it utilises HK5C 
which works through this pathway. ION5C acts through the Dyn dependent pathway, but 
as ION5C is an ionophore that bypasses the calcium channel requirement, one could not 
utilise this stimulus to investigate the Dyn dependent pathway. However, it is possible to 
investigate Dyn dependent pathway using HK5C under conditions in which it works via 
this pathway by inhibiting PKC (see above). PKC inhibition with Go6983 changes the 













Figure 5.10. L-type Ca2+ channel regulates NM-II dependent KR pathway. HK5C evoked 
changes in a-c) [Ca2+]i d-f) GLU, and g-i) FM dye in the absence or presence of 50 nM AGA, 
1 M CONO, and 1 M NIF. Data are mean ± SEM; P>0.05 for a, b, c, i and P<0.05 for d, e, 
f, g, h. Note that there was a significant difference between NIF treated condition and control 
for FM dye release representing the switch of releasing mode from KR to FF following L-type 
calcium channel inhibition. Note this data was produced by A.Ashton and is included here for 
comparison with HK5C stimulation in the presence of Go6983. It could have been included 
in the appendix but it was felt that it was easier to compare this with Fig 5.11, 5.12 and 5.13 











































































































5.5.1 HK5C evoked [Ca2+]i is reduced by specific calcium channel 
blockers in Go6983 treated terminals 
Inhibition of P/Q-type (Fig 5.11 a), N-type (Fig 5.11 b), or L-type (Fig 5.11 c) calcium 
channels in Go6983 treated terminals resulted in the reduction of HK5C evoked [Ca2+]i 
compared to terminals just treated only with Go6983. These data are similar to results 
shown above (Fig 5.10 a-c), and this suggests that the presence of Go6983 does not change 



















































































































































































































































































5.5.2 Calcium channel inhibition did not affect the HK5C evoked 
GLU release in Go6983 treated terminals 
P/Q-type calcium channel inhibition with AGA (Fig 5.12 a) in the presence of Go6983 did 
not perturb the HK5C evoked GLU release as the release amount was similar to that in 
terminals only treated with Go6983. This was also found when N-type calcium channels 
were blocked with CONO (Fig 5.12 b) or when L-type calcium channels were blocked 
with NIF (Fig 5.12 c). These data are similar to that previous found in terminals not treated 
with Go6983 (Fig 5.10 d-f). Thus the PKC inhibition does not produce variation on the 

































































































































































































































































































5.5.3 P/Q type calcium channel inhibition changed Dyn dependent 
HK5C evoked release from KR mode to FF 
HK5C evoked FM dye release was measured in synaptosomes treated with Go6983 and 
each type of calcium channel blocker. In the presence of AGA with Go6983 (Fig 5.13 a), 
HK5C evoked FM dye release was significantly increased, whilst inclusion of CONO (Fig 
5.13 b) or NIF (Fig 5.13 c) produced virtually the same amounts of release relative to 
treatment with Go6983 alone (control). These data demonstrate that under Go6983 
treatment, when HK5C is now regulating Dyn dependent KR mode, only P/Q-type calcium 
channel inhibition has led to the changing of the releasing mode from KR to FF. Thus, it 
would appear that the Dyn dependent KR mode is regulated by P/Q-type calcium channels. 
Taken together, these results in combination with the data obtained from condition in the 
absence of Go6983, wherein HK5C is regulating NM-II dependent KR mode, allows one 
to propose that NM-II dependent KR is regulated through L-type calcium channel whilst 
P/Q-type calcium channel is mediating Dyn dependent KR mode. This is extremely 
important as these two distinction between these 2 KR modes may indicate that they are 



































































































































































































































































































































































































5.5.4 Go6983 treatment does not interfere with switching of the 
RRP mode 
HK5C evoked FM dye release was discovered to only increase when L-type calcium 
channels is inhibited, whilst in the presence of Go6983 only perturbation of P/Q-type 
calcium channels have produced similar phenomenon. These results can be interpreted as 
that when HK5C is regulating KR through NM-II dependent pathway, L-type calcium 
channel is required, but when HK5C is regulating through Dyn dependent pathway, P/Q-
type calcium channel is needed. Nevertheless, there is still a possibility that PKC inhibition 
might interfere with switching of the RRP mode, meaning the result might not represent 
the calcium channel dependent regulation of the releasing modes. 
Luckily, this can be checked using Okadaic acid (OA), a phosphatase inhibitor that has 
been found to increase the SV mobility in the terminal (i.e. Betz and Henkel, 1994). It was 
also shown to switch all RRP SVs exocytosis from a KR to a FF mode (Bhuva, 2015; 
Singh, 2017; see also appendix 1 Fig A5, A6). OA inclusion in Go6983 treated 
synaptosomes vs Go6983 alone control have revealed that there was an increase in the FM 
dye release in the presence of OA (Fig 5.14), reflecting that treatment with OA has 
changed the RRP SV mode to undergo FF. Clearly, Go6983 does not interfere with OA 
induced FF mode. Furthermore, OA treatment still allows FF of the RRP in Go6983 treated 
terminals treated with CONO (Fig 5.15), and NIF (Fig 5.16). Lastly, comparison between 
Go6983 plus OA versus Go6983 plus OA plus AGA (Fig 5.17) shows that OA and AGA 
work on the same RRP SVs as both treatments induced maximum release of the FM dye, 
confirming there is no additivity of effect when both treatments are applied and indicating 




Figure 5.14. OA treatment switches FM dye release mode to FF. HK5C evoked FM dye release 
in terminals treated with 1 M Go6983 (control) or 1 M Go6983 plus 0.8 M OA. Data are 
mean ± SEM, N=3 independent experiments; P<0.05. 
Figure 5.15. The RRP SVs can be switched to FF when OA is included in Go6983 plus 
CONO treated termianls. HK5C evoked FM dye release in the presence of 1 M Go6983 
(control) or 1 M Go6983 plus 0.8 M OA plus 1 M CONO. Data are mean ± SEM, N=1 




Figure 5.16. The RRP SVs can be switched to FF when OA is included in Go6983 plus NIF 
treated termianls. HK5C evoked FM dye release in the presence of 1 M Go6983 (control) or 
1 M Go6983 plus 0.8 M OA plus 1 M NIF. Data are mean ± SEM, N=1 independent 
experiments; This is a representative experiment. 
 
Figure 5.17. Synaptosomes treated with Go6983 plus AGA were already releasing in FF mode. 
HK5C evoked FM dye release in the presence of 1 M Go6983 plus 0.8 M OA or 1 M 
Go6983 plus 50 nM AGA. Data are mean ± SEM, N=2 independent experiments. Note that 





Several drugs have been employed in this chapter whilst investigating the properties of the 
exocytotic mode; MITMAB, KT5720; Go6983; AGA; CONO; NIF; OA. It is important 
to ascertain that these drugs do not have non-specific off-target effects that may disturb 
the bioenergetics of the nerve terminals. We carried out an XF Cell Mito stress test using 
the Seahorse XFp machine on each drug treated condition. Through comparison with non-
drug treated condition, such protocols can reveal whether a drug treatment had any impact 





The acute treatment with 30 M MITMAB for 5 min failed to significantly disturb any of 
the parameters except from a small effect on non-mitochondrial respiration (Fig 5.18, Fig 
5.19 a-f) which has nothing to do with the normal mitochondrial respiratory capacity. 
 
 
Figure 5.18. Synaptosomal bioenergetics were unaffected by 30 M MITMAB treatment. 
The effect of 30 M MITMAB on the bioenergetics of synaptosomes. The experiment was 
done three times and the mean values represent an average of 9 independent measurements 







Figure 5.19. 30 M MITMAB treatment did not perturb most of bioenergetics parameters 
measured as it looks similar to those for the controls. The effect of a 5 min pre-incubation 
with 30 M MITMAB on (A) basal respiration, (B) ATP production, (C) spare capacity, (D) 
maximal respiration, (E) Proton leakage, and (F) Non-mitochondrial respiration in 








Treatment with KT5720 had a small effect on basal respiration, however, all other 
parameters remained at similar level with the non-drug treated condition (Fig 5.20, Fig 
5.21 a-f) and as such this drug does not really perturb the nerve terminals. 
 
Figure 5.20. Synaptosomal bioenergetics were unaffected by 2 M KT5720 treatment. The 
effect of 2 M KT5720 on the bioenergetics of synaptosomes performed at 37oC. The 
experiment was done three times and the mean values represent an average of 9 










Figure 5.21. 2 M KT5720 treatment did not perturb most of bioenergetics parameters 
measured as it looks similar to those for the controls.The effect of 2 M KT5720 on (A) 
basal respiration, (B) ATP production, (C) spare capacity, (D) maximal respiration, (E) 
Proton leakage, and (F) Non-mitochondrial respiration in synaptosomes. The histobars 








5.6.3 Go6983 plus KT5720 
Treatment with Go6983 alone has been shown in chapter 3 to have no effect on the 
bioenergetics (see Fig 3.38 and 3.39). The dual treatment of 1 M Go6983 with 2 M 
KT5720 did not disturb any of the bioenergetics parameters of the synaptosomes (Fig 5.22, 
Fig 5.23 a-f). 
 
Figure 5.22. Synaptosomal bioenergetics were unaffected by dual treatment of 1 M Go6983 
and 2 M KT5720. The effect of 1M Go6983 plus 2 M KT5720 on the bioenergetics of 
synaptosomes. The experiment was done three times and the mean values represent an 








Figure 5.23. 1 M Go6983 and 2 M KT5720 dual treatment did not perturb any 
bioenergetics parameters measured as it looks similar to those for the controls. The effect of 
1M Go6983 plus 2 M KT5720 on (A) basal respiration, (B) ATP production, (C) spare 
capacity, (D) maximal respiration, (E) Proton leakage, and (F) Non-mitochondrial 








5.6.4 Go6983 plus AGA 
Treatment of synaptosomes with both 1 M Go6983 and 50 nM AGA failed to 
significantly change any of the parameters (Fig 5.24, Fig 5.25 a-f). 
 
Figure 5.24. Synaptosomal bioenergetics were unaffected by 1 M Go6983 and 50 nM AGA 
dual treatment. The effect of 1M Go6983 plus 50 nM AGA on the bioenergetics of 
synaptosomes. The experiment was done three times and the mean values represent an 










Figure 5.25. 1 M Go6983 and 50 nM AGA dual treatment did not perturb any 
bioenergetics parameters measured as it looks similar to those for the controls. The effect of 
1M Go6983 plus 50 nM AGA on (A) basal respiration, (B) ATP production, (C) spare 
capacity, (D) maximal respiration, (E) Proton leakage, and (F) Non-mitochondrial 








5.6.5 Go6983 plus NIF 
Bioenergetics of synaptosomes are unaffected by the double treatment of 1 M Go6983 
and 1 M NIF as none of the parameters measured were significantly changed compared 
to control following the drug treatment (Fig 5.26, Fig 5.27 a-f).  
 
Figure 5.26. Synaptosomal bioenergetics were unaffected by 1 M Go6983 and 1 M NIF dual 
treatment. The effect of 1M Go6983 plus 1M NIF on the bioenergetics of synaptosomes. 
The experiment was done three times and the mean values represent an average of 9 






Figure 5.27. 1 M Go6983 and 1 M NIF dual treatment did not perturb any bioenergetics 
parameters measured as it looks similar to those for the controls. The effect of 1M Go6983 
plus 1M NIF on (A) basal respiration, (B) ATP production, (C) spare capacity, (D) 
maximal respiration, (E) Proton leakage, and (F) Non-mitochondrial respiration in 









The acute treatment with OA slightly affected basal respiration of the synaptosomes, 
however all the other parameters were remained at the similar level with control condition 
(Fig 5.28, Fig 5.29 a-f) and overall the synaptosomes were very similar in the drug treated 
and non-treated terminals. 
 
Figure 5.28. Synaptosomal bioenergetics were unaffected by 0.8 M OA treatment. The 
effect of 0.8 M OA on the bioenergetics of synaptosomes. The experiment was done three 
times and the mean values represent an average of 6 independent measurements and error 






Fig 5.29. 0.8 M OA treatment did not perturb most of bioenergetics parameters measured 
as it looks similar to those for the controls. The effect of 0.8 M OA on (A) basal respiration, 
(B) ATP production, (C) spare capacity, (D) maximal respiration, (E) Proton leakage, and 
(F) Non-mitochondrial respiration in synaptosomes. The histobars represent the mean and 








5.6.7 Go6983 plus OA 
The acute treatment of synaptosomes with 1 M Go6983 plus 0.8 M OA failed to disturb 
any of the bioenergetics parameters (Fig 5.30, Fig 5.31 a-f). 
 
Figure 5.30. Synaptosomal bioenergetics were unaffected by 1 M Go6983 and 0.8 M OA 
dual treatment. The effect of 1M Go6983 plus 0.8M OA on the bioenergetics of 
synaptosomes. The experiment was done two times and the mean values represent an 









Figure 5.31. 1 M Go6983 and 0.8 M OA dual treatment did not perturb any bioenergetics 
parameters measured as it looks similar to those for the controls. The effect of 1M Go6983 
plus 0.8M OA on (A) basal respiration, (B) ATP production, (C) spare capacity, (D) 
maximal respiration, (E) Proton leakage, and (F) Non-mitochondrial respiration in 




















Inhibition of Dyn translocation with 
MITMAB treatment produced no 
difference in all assays employed. 
This means, Dyn, already present on 
membrane, regulates the KR 
mechanism of exocytosis. 










Inhibition of endogenous PKA with 
KT5720 perturbs the Dyn dependent 
KR (stimulated with ION5C) 
mechanism for the RRP SVs but not 
the NM-II dependent KR pathway 
(stimulated with HK5C). Similar 
results were previously found when 
Dyn was inhibited with Dynasore 
and stimulated with various stimulus. 
Thus, the hypothesis was made 
predicting that the inhibition of 
endogenous PKA leads to a switch of 
the Dyn dependent KR to FF, which 
explains why HK5C action on NM-II 
KR is not perturbed. 
3 5.8-5.9 GLU, 
FM, 
Fura-2 
HK5C KT5720 (2 
M), Go6983 
(1 M) 
Go6983 was used to switch HK5C to 
work through Dyn dependent KR 
pathway instead of NM-II dependent 
KR pathway. It was found that pre-
treatment with Go6983 and KT5720 
changed the mode of release to FF, 
confirming the suggestion that PKA 
only affect the Dyn dependent KR 
pathway. It also indicates that FM 
results were not limited to a 







HK5C CONO (1 M), 
AGA (50 nM), 
NIF (1 M), 
Go6983 (1 
M), OA (0.8 
M) 
HK5C evoked FM dye release was 
discovered to only increase when L-
type calcium channels is inhibited, 
whilst in the presence of Go6983, 
only perturbation of P/Q-type 
calcium channels have produced 
similar phenomenon. These results 
may imply that L-type is required for 
NM-II dependent KR pathway whilst 
P/Q-type is needed for Dyn 
dependent KR pathway. This was 
also ascertained using OA. 
5 5.18-
5.31 
Bio  All drugs tested 
in this chapter 
Under any drug treatment, the 
bioenergetics parameters were 
virtually at the similar level to that of 
the control, meaning no disturbance 
of bioenergetics from the drugs 
employed were identified.  





The mode of release is dependent on various protein activities. For instance, when a SV is 
releasing in a KR mode, fission of the FP should be performed so that the vesicle does not 
fully flatten into the membrane. This fission maybe involve Dyn activity. Dyn may aid in 
the scissoring of the FP formed between SV and PM by oligomerising into a spiral around 
the FP as it does for forming clathrin pits in CME following FF. However Dyn’s precise 
role in KR has not been elucidated. Several lines of evidence have found that in the absence 
of Dyn, the KR mode of exocytosis is attenuated. In this chapter, investigation into several 
properties of the mode of release of the RRP have been described. We have employed 
several drugs, such as as MITMAB, KT5720, Go6983, AGA, CONO, NIF, and OA to 
explore how activity of various proteins could affect the regulation of the mode.  
5.7.1 MITMAB 
Dyn is important in regulating one type of KR mode for SV exocytosis. For investigation 
of the role of this protein, Dynasore, which blocks GTPase activity of Dyn and thereby 
pharmacologically inhibit its action, can be used. It has been previously found by Ashton’s 
group that Dynasore treatment has led to switch of Dyn dependent mode from KR to FF, 
demonstrating pivotal role of Dyn in controlling the KR mode of the release. However, it 
was unclear whether Dyn had to translocate to a membrane compartment (either the PM 
or the vesicle membrane) prior to the fusion or whether Dyn already present on the 
membrane could regulate the mode. MITMAB is a drug that stops Dyn translocating from 
cytosol to membranes by stopping Dyn binding to the phospholipid in membranes (Quan 
et al, 2007). Therefore this drug was employed to test whether it would interfere with the 
Dyn dependent KR mode of exocytosis. MITMAB treatment was found not to affect the 
GLU release stimulated using HK5C, ION5C, and 4AP5C. Further, it was clear that the 
drug does not interfere with Dyn dependent KR pathway when FM dye release was 
measured. In addition, MITMAB treatment had negligible effects on evoked [Ca2+]i. 
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These finding suggest that Dyns are not required to translocate to a membrane 
compartment from the cytosol prior to SV exocytosis of the RRP via KR. These results do 
not indicate where exactly Dyn is localised to mediate the FP closure – during Dyn 
dependent KR - but some of the potential locations include the membrane of the SVs 
themselves or at the PM in the AZ. In unpublished observations, A.Ashton has shown that 
MITMAB does prevent the recycling of those SV that undergo FF indicating that the drug 
is active (as was shown by Quan et al, 2007). 
5.7.2 PKA 
Clearly, Dyn can play a role in the regulation of a KR mode of the RRP of SVs as inhibiting 
its GTPase activity induces Dyn dependent KR to switch to FF. Thus it is important to 
investigate processes that allowed Dyn to regulate the mode of release. Dyn is a substrate 
of numerous kinases, and one approach that could be undertaken would be the 
investigation of which kinases may cause switch in the Dyn dependent KR mode. Apart 
from PKC (see thesis by Bhuva, 2015; Singh, 2017) PKA could potentially regulate Dyn 
I activity as regards KR. Towards this, we employed KT5720, an inhibitor of endogenous 
PKA, to investigate the mode of release. 4AP5C and ION5C evoked FM dye releases were 
significantly increased in the presence of KT5720, reflecting the changes of mode from 
KR to FF. However, HK5C evoked release remained unchanged. These data demonstrate 
that PKA inhibition does not affect HK5C evoked FM dye release. This is intriguing 
because it is known that ION5C regulates KR through a Dyn dependent pathway whilst 
HK5C works via a NM-II dependent pathway. Thus, it would appear that endogenous PKA 
activity only affects the Dyn dependent KR pathway and not the NM-II dependent KR 
mode. This interpretation is due to the fact that HK5C evoked FM dye release is not 
affected when Dyn is inhibited with Dynasore, whilst 4AP5C and ION5C evoked release 
is switched to FF. This idea was further tested by measuring HK5C evoked FM dye release 
in the presence of Go6983 as when PKC is inhibited, HK5C now regulate the KR mode 
of the RRP SVs through the Dyn dependent pathway. Treatment of synaptosomes with 
211 
 
Go6833 plus KT5720 did not affect the HK5C evoked GLU release but such conditions 
increased the FM dye release relative to control, meaning the RRP SVs mode of release 
had switched from KR to FF. Thus, this proves that whilst KT5720 does not regulate the 
NM-II mode of exocytosis when HK5C regulates the KR mode via the Dyn dependent 
pathway PKA inhibition can regulate this latter mode. Clearly, PKA activity only affects 
Dyn dependent KR mode but not the NM-II dependent KR mode.  
5.7.3 Calcium channel dependency of KR 
Extracellular and intracellular calcium levels have been long considered as one of the 
major mediators for the KR mode of exocytosis (Neher and Sakaba, 2008). Thus it was 
obvious to consider the link between changes in calcium levels and the releasing mode. 
Calcium enters the nerve terminal through voltage-gated calcium channels (VGCC), and 
subsequently initiates neurotransmission. VGCC, therefore, have an important role in 
neurotransmission via regulation of intracellular calcium levels (Catterall, 2011). 
Preliminary research from A.Ashton’s group had shown that inhibition of each type of 
calcium channels with specific toxin (AGA for P/Q-type, CONO for N-type, NIF for L-
type) has determined that whilst inhibition of N-type and P/Q-type calcium channels does 
not affect the HK5C evoked FM dye release, disabling L-type channel function has led to 
dramatic increase in the HK5C evoked FM dye release. Thus, it was concluded that L-type 
calcium channel regulate the KR mode of release of the RRP. However, this result applies 
only to NM-II dependent KR mode since HK5C usually works through this pathway. 
Hence, there was a possibility that when KR is regulated through Dyn dependent pathway, 
another type of channel might be involved. Although, ION5C acts through the Dyn 
dependent KR mode, this ionophore bypasses the role of calcium channels and so cannot 
be employed for such investigation. However, a PKC inhibitor, Go6983, induces HK5C 
to operate through the Dyn dependent pathway, so we can measure HK5C evoked FM dye 
release in Go6983 treated terminals in the presence of the various calcium channel 
blockers. Intriguingly, whilst the treatment with any of the specific Ca2+ channel blockers 
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does not affect the HK5C evoked GLU release in Go6983 treated terminals, only AGA 
treatment led to an increase in the HK5C evoked FM dye release in such terminals. This 
data indicates that when HK5C evoked RRP SV release has changed to the Dyn dependent 
pathway, only P/Q type calcium channel inhibition can switch the mode. Overall, such 
results suggest that the NM-II dependent KR mode is regulated through L-type calcium 
channel whilst Dyn dependent release is regulated by P/Q type calcium channel. OA 
treatment, a drug that is known to switch the RRP SVs to FF for either mode of release, 
confirmed that Go6983 treatment does not prevent switching of the RRP mode. Thus, the 
difference in Ca2+ channel requirement for Dyn and NM-II dependent KR may indicate 
that these operates as two distinct KR processes rather than one that can be acted upon by 
these two proteins.  
5.7.4 Bioenergetics 
Bioenergetics experiments were done on drugs employed in this chapter using Seahorse 
XF analyser, and it was established that under any drug treatment, the bioenergetics 
parameters were virtually at the similar level to that of the control. These results imply that 
there were no disturbances of bioenergetics for such drug treatments used in this chapter, 
proving that the data we have obtained in this chapter are not due to non-specific effects 
of the drug on bioenergetics integrity. This is an important aspect of the study because it 
indicates that any drug induced actions are purely due to their effect on the release and it 
is not on disturbance of bioenergetics within the terminal. 
5.8 Conclusion 
In conclusion, various properties of the mode of the RRP of SVs have been studied in this 
chapter. Inhibition of translocation of Dyn from cytosol to membranes with MITMAB 
was found not to interfere with Dyn dependent KR mode. Thus, this demonstrates that 
Dyns are already present on membranes (either on SV or the PM) prior to exocytosis of 
vesicles at the AZ fusion site. Furthermore, inhibition of endogenous PKA activity only 
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affected Dyn dependent KR mode, revealing that PKA only regulate the KR mode of 
release through Dyn dependent pathway but not NM-II dependent pathway. Lastly, Dyn 
dependent KR mode was found to be regulated through P/Q-type calcium channel, and 
this in combination with previous results showing NM-II dependent pathway is regulating 
KR through L-type calcium channels, represents a calcium channel specificities in KR 














The Effect of Actin Cytoskeleton 
Disassembly and Stabilisation on the 




The actin cytoskeleton may contribute to the regulation of the mode of exocytosis and to 
the release of the distinct pools of SVs. The cytoskeleton is involved in virtually every cell 
biological process in eukaryotes, ranging from cell division and motility to vesicle 
trafficking. The cytoskeleton is mainly composed of three types of protein filaments; actin, 
microtubules, and intermediates filaments (Dillon and Goda, 2005). The actin cytoskeleton 
is a main structural component of both pre- and postsynaptic components of the synapse. 
However, the precise role of the actin cytoskeleton in neurotransmission is yet to be fully 
elucidated. In regulated exocytosis, it was proposed to work either positively or negatively 
and this depended upon the secretory system under examination (Porat-Shliom et al, 2012). 
At the centre of the bouton terminal where SVs are distal from the AZ region of the PM, 
actin appears to interact with short filaments of Syn I, forming an actin-Syn I-SV 
meshwork. It has been suggested that it is this meshwork that sequesters the SVs that are 
distal to the AZ. Following elevated neuronal activity, phosphorylation of Syn I at specific 
sites may cause the disattachment and freeing of the SV and these mobilised SVs can 
replenish the RRP. At the AZ, actin is suggested to have dual functions. It might direct the 
arriving SVs and allow them to dock at the AZ, thereby positively controlling the size of 
the RRP. It could also form a physical and molecular barrier for priming reactions required 
for SNARE mediated exocytosis, and this may prevent facile fusion of vesicles (Cingolani 
and Goda, 2008).  
The actin cytoskeleton is also proposed to interact with Dyn and myosin in the regulation 
of neurotransmission (Papadopulos, 2017). In the case of Dyn, Gu et al (2010) reported 
that short actin filaments promoted Dyn self-assembly in vitro through direct Dyn -actin 
interaction. Such assembled Dyn was able to displace the capping protein (CP) gelsolin 
(Gsn) from barbed ends of actin filaments, and this resulted in the elongation of such 
filaments (Gu et al, 2010). Kessels et al (2001) reported that in vitro the mammalian F-
actin binding protein (Abp1) links the actin cytoskeleton to Dyn through its SH3 domain. 
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Excitingly, the actin cytoskeletal scaffold, in association with Dyn, contributes to the 
closing dynamics of exocytotic fusion pores measured in PC12 cells (Kessels et al, 2001). 
Others have suggested that actin can regulate the vesicular fraction released in an extended 
KR mode (Trouillon and Ewing, 2014).  
Regarding vesicle release, actin is proposed to form an actomyosin complex with NM-II 
to provide the force to drive exocytosis to completion (Nightingale et al, 2012; Porat-
Shliom et al, 2013). Further, it was found that a F-actin cell cortex plays a key role in 
stabilising the KR fusion under lower stimulation frequency, and under higher stimulation 
frequency, the actin cortex dependent FF mode of release was disrupted. These authors 
have indicated that, an absence of NM-II or MLCK under increased stimulation frequency 
inhibited the FP dilation and sustained the granule in KR mode of exocytosis (Doreian et 
al, 2008).  
In the previous chapter of this thesis, we have reported that KR modes of SV exocytosis 
can be associated with Dyn and NM-II activities. As both these can associate with the actin 
cytoskeleton as highlighted above, this justifies the exploration of the actin cytoskeleton 









6.2 The effect of disassembly of actin cytoskeleton on the evoked 
release and mode of exocytosis 
6.2.1 LAT inhibits the release of the RP but not the RRP 
To establish an effect of actin disassembly on neurotransmission, we have pre-treated the 
synaptosomes with Latrunculin (LAT), and measured HK5C, ION5C, and 4AP5C evoked 
GLU releases. LAT disrupts the organisation of microfilament by binding to the actin 
monomer and preventing them from polymerising (i.e. Coue et al, 1987; Richard et al, 
2004). HK5C evoked release was significantly lower compared to control, meaning actin 
disassembly caused some reduction in the release (Fig 6.1a), LAT also caused a reduction 
of ION5C evoked release (Fig 6.1 b). Intriguingly, 4AP5C evoked release was unchanged 
following actin disassembly (Fig 6.1 c). As 4AP5C is a stimulus that work exclusively on 













































































































































































































































































































































6.2.2 LAT does not inhibit the FM dye release relative to control 
LAT did not perturb the total FM dye content compared to control (appendix 3) proving 
that both the RRP and RP were still labelled with dye following microfilament disassembly. 
Furthermore, HK5C and ION5C (Fig 6.2) evoked FM dye release appears similar in LAT 
and non-drug treated terminals. However, it was shown above that the RP is not released 
in the presence of LAT and yet this is the pool that normally releases the FM dye because 
it undergoes FF. Normally the RRP does not release FM dye since it undergoes KR. Thus 
we have the situation that RRP SVs are being exocytosed and yet FM dye is also being 
released. This leads to the conclusion that disassembling actin microfilaments with LAT 
switches the RRP SVs to a FF mode of exocytosis. Okadaic acid (OA) (i.e. Bialojan and 
Takai, 1988) can switch the RRP SVs to FF (see earlier chapter and appendix 1) but 
application of OA to LAT treated terminals did not induce any further dye release clearly 




















































































































































































































































































































Figure 6.3. Actin disassembly allowed RRP to release in FF mode. HK5C evoked FM dye 
release in control or 15 M LAT plus 0.8 M OA treated synaptosomes. Data are mean ± 
SEM, N=7 independent experiments; P <0.05 for significance. However, there was no 
significant difference of release between control and LAT plus OA treated terminals. 
 
6.2.3 The action of LAT on evoked [Ca2+]i 
Disassembly of actin with LAT inhibits RP release and leads to the RRP SVs switching to 
a FF mode of exocytosis for both HK5C and ION5C stimulation. One reason this could 
occur is that disassembly of the actin cytoskeleton may reduce the evoked [Ca2+]i.There 
was a significant drop in HK5C evoked [Ca2+]i in LAT treated relative to control 
terminals (Fig 6.4). In contrast, ION5C evoked [Ca2+]i was similar in drug free and drug 
treated terminals (Fig 6.5). Thus the action of LAT on ION5C evoked GLU containing SV 
RP release and its action on ION5C evoked FM dye release from the RRP SVs are not 
related to any changing in evoked [Ca2+]i. However, the action of LAT on HK5C evoked 
GLU and FM release could be explained by changing in [Ca2+]i levels. Since, HK5C acts 
through NM-II dependent KR pathway for the RRP whilst ION5C operates via the Dyn 
dependent KR pathway for such vesicles, this could suggest that whilst intact actin 
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microfilaments could have a direct effect on the Dyn dependent KR mode (via regulation 
of the closure of the FP) this cytoskeletal component may not have direct effect on the 
NM-II dependent KR mode.  
Figure 6.4. Actin disassembly reduce HK5C evoked [Ca2+]i. Change in [Ca2+]i induced by 
HK5C in control and 15 M LAT treated terminals. Data are mean ± SEM, N=3 independent 








Figure 6.5. ION5C evoked [Ca2+]i is unaffected by actin disassembly. Change in [Ca2+]i 
induced by ION5C in control and 15 M LAT treated terminals. Data are mean ± SEM, N=4 
independent experiments. Note that there was no significant difference (P>0.05) between 
control and LAT treated terminals. 
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6.2.4 Higher [Ca2+]e did not rescue the LAT induced inhibition of 
evoked RP exocytosis 
It was evident in the above section that changes in HK5C evoked [Ca2+]i maybe involved 
in the LAT induced inhibition of the RP evoked by this stimulation. An obvious question 
was whether using higher [Ca2+]e, one could prevent the effect of LAT. Therefore, HK20C 
evoked GLU release from synaptosomes was determined in the presence of LAT, but this 
stimulus failed to overcome the LAT block of the RP (Fig 6.6).  
It is possible that our results demonstrate two separate actions of LAT, one involving 
inhibiting action of the drug on the release of the RP SVs, and another action that can 
regulate the mode of release. Therefore, future experiments would measure HK20C 
evoked FM dye release in the LAT treated synaptosomes.  
 
Figure 6.6. Higher [Ca2+]e did not rescue the LAT induced inhibition of evoked RP exocytosis. 
HK20C evoked GLU release in control and 15 M LAT treated terminals. Data are mean ± 
SEM, N=6 independent experiments, P <0.05 was considered as a significant difference. LAT 




6.2.5 PKC inhibition reversed LAT effect on HK5C evoked release 
It is clear that LAT treatment produced varying results depending on the stimulus 
employed. This might suggest that the effect of the actin cytoskeleton could depend upon 
on whether Dyn or NM-II are regulating the FP during KR of the RRP SVs. HK5C 
normally acts on the NM-II dependent KR but inhibiting PKCs with Go6983 allows this 
stimulus to act on the Dyn dependent pathway instead (as discussed in earlier chapters). 
Thus, HK5C evoked release in Go6983 treated terminals in the presence or absence of 
LAT was measured.  
PKC inhibition with Go6983 actually prevented the LAT induced reduction in the release 
as Go6983 (which behaves same as non-drug treated samples) and Go6983 plus LAT 
revealed no significant difference in HK5C evoked GLU release (Fig 6.7). It was also 
found that HK5C evoked FM dye release (Fig 6.8) and HK5C evoked [Ca2+]i (Fig 6.9) 
that were previously changed by pre-treatment with LAT were no longer affected 
following PKC inhibition with Go6983. If LAT regulated the FP of RRP SV KR similarly 
for both HK5C and ION5C, then one might have expected that HK5C would work on the 
Dyn dependent pore in response to PKC attenuation with Go6983, whereas this does not 
appear to be the case even though ION5C acting on the Dyn dependent pore is sensitive 
to disassembly of microfilament. One possible interpretation is that the action of LAT on 
HK5C evoked release involves in some way the activation of PKCs since when these are 




Figure 6.7. PKC inhibition reversed LAT effect on HK5C evoked GLU release. HK5C evoked 
GLU release in 1 M Go6983 or 1 M Go6983 plus 15 M LAT treated terminals. Data are 
mean ± SEM, N=5 independent experiments. Note Go6983 plus LAT condition showed no 
significant difference (P>0.05) to Go6983 alone. Note that Go6983 treatment has been 
previously shown by Ashton’s group not to effect HK5C evoked GLU release compared to 
non-drug treated samples.  
 
Figure 6.8. PKC inhibition reversed LAT effect on HK5C evoked FM dye release. HK5C 
evoked FM dye release from 1 M Go6983 or 1 M Go6983 plus 15 M LAT treated terminals. 
Data are mean ± SEM, N=3 independent experiments. Note that there was no significant 
difference (P>0.05) in release between Go6983 and Go6983 plus LAT treated terminals. Note 
that Ashton and colleagues have previously shown that there is no difference in FM dye 




Figure 6.9. PKC inhibition reversed LAT effect on HK5C evoked [Ca2+]i. Change in [Ca2+]i 
induced by HK5C in 1 M Go6983 and 1 M Go6983 plus 15 M LAT treated terminals. 
Data are mean ± SEM, N=4 independent experiments; Note that these is no significant 
difference (P>0.05) in the change in [Ca2+]i between Go6983 and Go6983 plus LAT treated 
terminals. Also note that previously Ashton and colleagues showed that Go6983 did not 
perturb HK5C evoked [Ca2+]i  relative to non-drug treated control. 
An important control for these experiments is to test whether LAT induces its effects when 
ION5C is the stimuli and Go6983 treatment is also used, if this is the case, then it is clear 
that the LAT effect is different for the two distinct stimuli. Indeed, ION5C evoked GLU 
release in the synaptosomes treated with LAT plus Go6983 compared to Go6983 treatment 
alone clearly demonstrated that when PKCs are inhibited, LAT perturbed the ION5C 
evoked release of the RP of GLU containing SVs (Fig 6.10). Recently, Ashton and his 
colleagues have checked whether LAT could switch the ION5C evoked Dyn dependent 
RRP KR to FF when PKCs were blocked. Disassembly of the microfilaments did switch 
the mode even in the presence of Go6983. This highlights a big difference in the action of 




Figure 6.10. PKC inhibition failed to reverse LAT effect on ION5C evoked GLU release. 
ION5C evoked GLU release in 1 M Go6983 and 1 M Go6983 plus 15 M LAT treated 
terminals. Data are mean ± SEM, N=4 independent experiments. Note that there was 
significant difference in release (P<0.05) between Go6983 plus LAT condition and Go6983 
alone.  
 
6.3 Stabilisation of Actin 
Disassembly of the actin cytoskeleton with LAT was shown to have effects on SV 
exocytosis and on release of distinct pools. However, it is possible that stabilisation of 
actin microfilament may also have an effect. Jasplakinolide (JASP) can be applied to 
promote actin stabilisation. It stimulates actin filament nucleation, thereby promoting actin 
polymerisation (i.e. Bubb et al, 1994, 2000). Thus, by performing the equivalent 
experiment to LAT, we can investigate how stabilisation of actin would impact on the 




6.3.1 Actin stabilisation does not affect evoked GLU and FM dye 
release, nor evoked [Ca2+]i 
Synaptosomes were pre-treated with JASP and HK5C evoked GLU release, FM 2-10 dye 
and [Ca2+]i were measured. GLU release was found not to be affected in response to actin 
stabilisation (Fig 6.11). Thus, whilst actin disassembly prevents the release of the RP, actin 
stabilisation with JASP does not affect the release of this pool. There was no difference in 
HK5C evoked FM 2-10 dye release between control and JASP treated condition (Fig 6.12) 
and since the RP of SVs are undergoing exocytosis this would suggest that stabilisation of 
actin microfilaments does not prevent RRP SVs from undergoing KR. When HK5C 
evoked [Ca2+]i was measured it was found that JASP treatment actually increased the 
[Ca2+]i induced by the stimulus (Fig 6.13). 
 
Figure 6.11. Actin stabilisation does not affect HK5C evoked GLU release. HK5C evoked 
GLU release in control and 2.5 M JASP treated terminals. Data are mean ± SEM, N=4 






Figure 6.12. Actin stabilisation does not affect HK5C evoked FM dye release. HK5C evoked 
FM dye release in control and 2.5 M JASP treated terminals. Data are mean ± SEM, N=7 
independent experiments. Note that there was no apparent significant difference (P>0.05) in 
the release between control and JASP treated synaptosomes. 
 
Figure 6.13. Actin stabilisation increase HK5C evoked [Ca2+]i. HK5C evoked [Ca2+]i in 
control and 2.5 M JASP treated terminals. Data are mean ± SEM, N=6 independent 
experiments; Note that the JASP application has actually led to significant increase (P<0.05) 
in the [Ca2+]i. 
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ION5C evoked GLU and FM2-10 release and [Ca2+]i were also measured in the presence 
of JASP. JASP did not perturb the ION5C evoked release of the RRP and RP of GLU 
containing SVs (Fig 6.14) nor did it affect the release of FM2-10 dye (Fig 6.15). Finally, 
stabilisation of actin microfilaments did not perturb the ION5C evoked [Ca2+]i (Fig 6.16). 
This indicates that the Dyn dependent KR mode of the RRP SVs can still occur when actin 
microfilaments are stabilised such that you neither get disassembly nor assembly of such 
filament.  
 
Figure 6.14. Actin stabilisation does not affect ION5C evoked GLU release. ION5C evoked 
GLU release in control and 2.5 M JASP treated terminals. Data are mean ± SEM, N=3 






Figure 6.15. Actin stabilisation does not affect ION5C evoked FM dye release. ION5C evoked 
FM dye release in control and 2.5 M JASP tested terminals. Data are mean ÷ SEM, N=3 
independent experiments. Note that there was no significant difference (P>0.05) in the release 
between control and JASP treated synaptosomes. 
 
Figure 6.16. Actin stabilisation does not affect ION5C evoked [Ca2+]i. ION5C evoked 
[Ca2+]i in control and 2.5 M JASP treated terminals. Data are mean ± SEM, N=6 
independent experiments; P>0.05; Note that there was no significant difference in the release 
between control and JASP treated terminals. 
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6.3.2 JASP treatment reverse LAT’s action 
As synaptosomes were found to be releasing normally after JASP treatment, this enabled 
one to check whether any LAT action is truly due to disassembly of actin microfilaments. 
This is because prior stabilisation of microfilaments with JASP prevents subsequent 
disassembly of such filament by LAT. Synaptosomes were pre-treated with JASP prior to 
LAT addition and then GLU release was evoked by HK5C or ION5C. HK5C (Fig 6.17) 
and ION5C (Fig 6.18) evoked GLU release consisted of the exocytosis of the RRP and RP 
of SVs after the stabilisation of the actin cytoskeleton indicating that LAT no longer could 
disassemble such microfilaments. This proves that the previous effects of LAT were due 
to disassembly of such filaments and were not due to a non-specific secondary effect of 
this drug. 
 
Figure 6.17. Actin stabilisation reverses LAT effect on HK5C evoked GLU release. HK5C 
evoked GLU release in control and 2.5 M JASP plus 15 M LAT treated terminals. Data are 
mean ± SEM, N=3 independent experiments; P<0.05 for significance. Note that JASP plus 





Figure 6.18. Actin stabilisation reverses LAT effect on ION5C evoked GLU release ION5C 
evoked GLU release in control and 2.5 M JASP plus 15 M LAT treated terminals. Data are 
mean ± SEM, N=4 independent experiments. There is no significant difference (P>0.05) 
between control and JASP plus LAT treated terminals indicating that stabilisation of 
microfilaments prevents their disassembly by LAT. 
6.3.3 LAT does not perturb the HK5C evoked calcium entry in the 
presence of JASP 
Next, we wanted to see how evoked [Ca2+]i is affected when LAT is applied to the nerve 
terminal following JASP pre-treatment. A comparison between LAT alone vs JASP plus 
LAT condition shown that in the latter condition HK5C produced a significantly higher 
[Ca2+]i, implying that truly actin disassembly does reduce the HK5C evoked changes in 
calcium level but this is prevented by JASP treatment (Fig 6.19b). Indeed, as we saw with 
JASP alone, there is a slight increase in the HK5C evoked [Ca2+]i in the presence of both 
drugs (Fig 6.19a).  






























































































































































































































































































































































































6.3.4 JASP treatment prevents LAT action on evoked FM dye 
release 
The action of LAT in inducing a switch in the RRP SVs from KR to FF for both HK5C 
and ION5C may not have been due to disassemble of the actin microfilament. However, 
this was checked by preventing LAT’s action by pre-treatment with JASP. As such 
treatment allowed the RP SVs to be released, we measured the FM dye release under such 
condition. JASP treatment appeared to prevent LAT action on HK5C evoked FM dye 
release (Fig 6.20) or ION5C evoked dye release (Fig 6.21). 
 
Figure 6.20. Actin stabilisation prevents LAT action on HK5C evoked FM dye release. HK5C 
evoked FM dye release in control and 2.5 M JASP plus 15 M LAT treated terminals. Data 
are mean ± SEM, N=7 independent experiments; P <0.05 for significant difference. Note that 







Figure. 6.21 Actin stabilisation prevents LAT action on ION5C evoked FM dye release. 
ION5C evoked FM dye release in control and 2.5 M JASP plus 15 M LAT treated terminals. 
Data are mean ± SEM N=3 independent experiments. Note that there was no significant 




However, whilst the FM dye release looks similar to the control release in these conditions 
(Fig 6.20, Fig 6.21), one could argue that this is also the case for LAT alone and so we 
needed to show that following JASP plus LAT, the RP is releasing via FF and the RRP is 
releasing via KR whereas for LAT alone, the RP is not releasing and the RRP is releasing 
via FF. Fortunately, it is possible to test whether the RRP is releasing by KR or FF by also 
treating the synaptosomes with OA since this drug will switch the RRP undergoing KR to 
FF (as discussed earlier) whereas it will have no effect on dye release if the RRP is already 
releasing by FF. 
Indeed, JASP plus LAT plus OA was found to allow HK5C (Fig 6.22a) or ION5C (Fig 
6.23a) to evoke more FM dye release compared to control, similarly, this further exhibited 
more HK5C evoked (Fig 6.22b) or ION5C evoked (Fig 6.23 b) FM dye in terminal treated 
with LAT plus JASP. Finally, the triple treated terminals exhibited more FM dye release 
evoked by HK5C (Fig 6.22c) or ION5C (Fig 6.23 c) then in LAT plus OA treated 
synaptosomes. 
These results are convincing because it indicates that JASP prevents the LAT from 
removing the RP of SVs and that these undergo normal FF, whilst RRP of the SVs now 
undergo KR. This is demonstrated by a comparison between JASP plus LAT and JASP 
plus LAT plus OA treated terminals, in which more release was measured in the latter 
treatment condition. Likewise, it is clear that LAT does remove the RP from releasing and 
switches the RRP to FF since LAT plus OA produces no extra release evoked by either 
stimuli. Very recently, it was shown by A.Ashton’s group that this inclusion of OA with 
any of these other treatments did not change the amount of HK5C or ION5C evoked GLU 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































The Synaptosomes were treated with 15 M LAT for 5-10 min at 37oC in order to allow 
actin microfilament disassembly. However, such treatment failed to disturb any of the 
bioenergetics parameters measured, confirming that the drug does not have non-specific 
effect on the bioenergetics (Figure 6.24, Figure 6.25a-f). 
 
Figure 6.24. Synaptosomal bioenergetics were unaffected by 15 M LAT treatment.The 
effect of 15 M LAT on the bioenergetics of synaptosomes. The experiment was conducted 
twice and the mean values represent an average of 6 independent measurements and error 
bars represent the SD.   
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Figure 6.25. 15 M LAT treatment did not perturb any bioenergetics parameters measured 
as it looks similar to those for the controls. The effect of 15 M LAT on (A) basal 
respiration, (B) ATP production, (C) spare capacity, (D) maximal respiration, (E) Proton 
leakage, and (F) Non-mitochondrial respiration in synaptosomes. The histobars represent 








6.4.2 Go6983 plus LAT 
The double drug treatment of synaptosomes with Go6983 and LAT failed to perturb in any 
of the bioenergetics parameters measured (Figure 6.26, Figure 6.27 a-f). 
 
Figure 6.26. Synaptosomal bioenergetics were unaffected by dual treatment of 1 M Go6983 
and 15 M LAT treatment. The effect of 1 M Go6983 plus 15 M LAT treatment on the 
bioenergetics of synaptosomes compared to nondrug treated control. The experiment was 
conducted three times and the mean values represent an average of 8 independent 




Figure 6.27. 1 M Go6983 and 15 M LAT double treatment did not perturb any 
bioenergetics parameters measured as it looks similar to those for the controls. The effect of 
1 M Go6983 plus 15 M LAT on (A) basal respiration, (B) ATP production, (C) spare 
capacity, (D) maximal respiration, (E) Proton leakage, and (F) Non-mitochondrial 
respiration of synaptosomes compared to non-drug treated terminal. The histobars 









Treatment of synaptosomes with 2.5 M JASP for 10-20 min at 37oC was found to produce 
a slight difference in non-mitochondrial respiration compared to control. However, the 
change was minor and it failed to disturb any of the other bioenergetics parameters (Figure 
6.28, Figure 6.29 a-f). 
 
Figure 6.28. Synaptosomal bioenergetics were unaffected by 2.5 M JASP treatment. The 
effect of 2.5 M JASP on the bioenergetics of synaptosomes. The experiment was conducted 
three times and the mean values represent an average of 6-7 independent measurements and 
error bars represent the SD; P>0.05.   
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Figure 6.29. 2.5 M JASP treatment did not perturb most of bioenergetics parameters 
measured as it looks similar to those for the controls. The effect of 2.5 M JASP on (A) 
basal respiration, (B) ATP production, (C) spare capacity, (D) maximal respiration, (E) 
Proton leakage, and (F) Non-mitochondrial respiration in synaptosomes compared to non-








6.4.4 JASP plus LAT 
Synaptosomes were pre-treated with 2.5 M JASP for 20 min at 37oC and LAT (for the 
last 10 min of this incubation). Such conditions failed to disturb any of the bioenergetics 
parameters measured (Figure 6.30, Figure 6.31 a-f) 
 
Figure 6. 30. Synaptosomal bioenergetics were unaffected by 2.5 M JASP and 15 M LAT 
double treatment. The effect of 2.5 M JASP plus 15 M LAT treatment on the 
bioenergetics of synaptosomes. The experiment was conducted three times and the mean 
values represent an average of 8 independent measurements and error bars represent the 
SD; P>0.05.   
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Figure 6.31. 2.5 M JASP and 15 M LAT double treatment did not perturb any 
bioenergetics parameters measured as it looks similar to those for the controls. The effect of 
2.5 M JASP plus 15 M LAT treatment on (A) basal respiration, (B) ATP production, (C) 
spare capacity, (D) maximal respiration, (E) Proton leakage, and (F) Non-mitochondrial 
respiration in synaptosomes compared to non-drug treated control. The histobars represent 







6.4.5 LAT plus JASP plus OA 
The Triple drug treatment of synaptosomes with 2.5 M JASP for 10 min at 37oC followed 
by a further 10 min at 37oC with 15 M LAT and 0.8 M OA failed to produce any changes 
in the bioenergetics parameters of the treated terminals. Note that last 3 points were not 
present for one of the experiment and so these values could not be averaged. Consequently, 
protein leakage and non-mitochondrial respiration values are missing (Figure 6.32, Figure 
6.33). 
 
Figure 6.32. Synaptosomal bioenergetics were unaffected by 15 M LAT, 2.5 M JASP and 
0.8 M OA triple treatment. The effect of 15 M LAT plus 2.5 M JASP plus 0.8 M OA on 
the bioenergetics of synaptosomes. The experiment was conducted twice and the mean 
values represent an average of 6 independent measurements and error bars represent the 
SD. Note that last three points were not present in one of the experiments, and thus these 
values were not averaged.  
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Figure 6.33. 2.5 M JASP, 15 M LAT and 0.8 M OA triple drug treatment did not 
perturb any bioenergetics parameters measured as it looks similar to those for the controls. 
The effect of triple drug treatment of 2.5 M JASP plus 15 M LAT plus 0.8 M OA on (A) 
basal respiration, (B) ATP production, (C) spare capacity, (D) maximal respiration in 
synaptosomes compared to non-drug treated control. The histobars represent the mean and 































The mode of RRP release has changed to FF 









LAT treatment reduced the HK5C evoked 
[Ca2+]i but not ION5C evoked [Ca2+]i . Thus 
the action of LAT on ION5C evoked GLU 
containing SV RP release and its action on 
ION5C evoked FM dye release from the RRP 
SVs are not related to any changing in evoked 
[Ca2+]i. Although, the action of LAT on HK5C 
evoked GLU and FM release could be explained 
by changing in [Ca2+]i. 
4 6.6 GLU HK20C LAT (15 
M) 
Higher [Ca2+]e did not rescue the LAT effect on 













PKC inhibition prevented the LAT induced 
effect in all release parameters for HK5C but 
not ION5C. One possible interpretation is that 
the action of LAT on HK5C evoked release 
involve in some way the activation of PKCs, 
since when these are blocked, the drug did not 










(2.5 M)  
Actin stabilisation does not affect evoked GLU, 












JASP treatment reverse LAT’s action on evoked 
GLU release and evoked [Ca2+]i. This proves 
that the previous effects of LAT were due to 
disassembly of such filaments and were not due 











- JASP treatment prevented LAT action on 
HK5C evoked FM dye release or ION5C 
evoked dye release.  
- OA was used to test whether RRP is 
releasing by KR or FF. Indeed, OA 
inclusion to JASP plus LAT condition was 
found to evoke more FM dye release 
compared to control and in terminal treated 
with LAT plus JASP. 
- Also, the triple treated terminals exhibited 
more evoked FM dye release compared to 
LAT plus OA treated synaptosomes. These 
results indicate that JASP prevents the LAT 
from removing the RP of SVs and that 
these undergo normal FF, whilst RRP of the 
SVs now undergo KR.  
- Likewise, it is clear that LAT does remove 
the RP from releasing and switches the 
RRP to FF  
9 6.24-
6.33 
BIO  All drugs 
tested  
Majority of bioenergetics parameters in drug 
treated synaptosomes were unaltered compared 
to control.  




In this chapter, we have investigated the role of the actin cytoskeleton on regulating both 
the release of the SV content and SV mode of exocytosis. We have investigated this using 
ION5C (a stimuli known to induce Dyn dependent KR) and HK5C (a stimuli known to 
induce NM-II dependent KR) to stimulate on terminals in which LAT treatment has 
induced actin disassembly or in terminal in which microfilament have been stabilised by 
JASP pre-treatment.  
6.5.1 Effect of actin disassembly on the release of SV pools and on 
the exocytotic mode 
Disassembly of actin with LAT was found to inhibit some HK5C and ION5C evoked GLU 
release. As GLU released by 4AP5C stimulation was not perturbed, it would appear that 
LAT perturbs the RP release but not the RRP release. However, such drug treatment would 
appear not to inhibit any FM dye release (note the RRP and RP are labelled normally with 
the dye). This result is misleading because we know that the RP, that normally releases 
FM2-10 dye because it undergoes FF, is not being released. Therefore, the dye release 
measured must be from RRP undergoing FF, whereas under control conditions the RRP 
does not release the dye since it undergoes KR. The conclusion must be that following the 
disassembly of actin microfilament with LAT, RRP SVs evoked to release by HK5C or 
ION5C are switched to FF. Proof for this was provided by the fact that OA added to LAT 
treated terminals did not allow any HK5C or ION5C evoked the further FM dye release 
indicating that the RRP was already releasing through the FF mode of exocytosis. 
[Ca2+]i evoked by HK5C stimulation, but not that evoked by ION5C, was reduced in 
LAT treated synaptosomes. This indicates that the action of LAT in blocking ION5C 
evoked RP release and on switching the ION5C release of the RRP to FF are not related 
to the change in ION5C evoked [Ca2+]i whilst the results for HK5C may be explained by 
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a reduction in the HK5C evoked  [Ca2+]i. This leads to the idea that whilst actin 
microfilaments could have a direct effect on the Dyn dependent KR mode (induced by 
ION5C stimulation) by regulating the closure of the FP, this cytoskeleton might not have 
a direct effect on the NM-II dependent KR mode (triggered by HK5C stimulation) and the 
results could be simply due to a reduction in evoked [Ca2+]i. However, the use of a higher 
[Ca2+]e level (20 mM) by employing a HK20C stimulus failed to reverse the action of LAT 
on the block of the RP. Note Ashton and colleagues have demonstrated that the RRP SV 
undergoing KR depends on the [Ca2+]i (A.Ashton et al, unpublished) and, indeed, this 
explains why 4AP5C only induces some KR since it does not induce a high enough 
[Ca2+]i (see appendix 1 Fig A5 and A6). Furthermore, too low of [Ca2+]i is unable to 
release the RP of SVs as determined with 4AP5C (appendix 1 Fig A1, A5, and A6) 
We tried to establish whether it could be that the actin cytoskeleton effects seen depend 
on whether Dyn or NM-II are regulating the FP because Go6983 causes HK5C to act on 
the Dyn dependent pathway. We measured HK5C evoked release in Go6983 treated 
terminals in the presence or absence of LAT. If LAT exerted its effects on the FP similarly 
for both HK5C and ION5C stimuli then one might expect that HK5C would work on the 
Dyn dependent pathway following PKC blocking with Go6983 in a similar manner to 
ION5C. However, this was not the case and it would appear that the effect of LAT on 
HK5C evoked release involves in some way the activation of PKCs, because following 
blockade of these enzymes, LAT failed to affect the release of the RP and the mode of 
exocytosis of the RRP. However, for the ION5C stimulation LAT still induced the changes 
expected in terminals also treated with Go6983 treatment. Therefore, it would appear that 





6.5.2 The effect of stabilisation of the actin cytoskeleton on the 
release of the pools of SVs and on their release mode 
We employed JASP, a drug that promotes the stabilisation of actin microfilaments, to test 
how it would affect the pools of SVs and their mode of release. JASP was found not to 
perturb HK5C or ION5C evoked GLU release or FM dye release. Intriguingly, JASP pre-
treatment led to a slight increases in HK5C evoked [Ca2+]i. We also checked whether 
stabilisation of actin microfilaments (by pre-treatment with JASP) could prevent the 
actions of LAT. This test demonstrates whether any LAT action is truly due to 
microfilament disassembly. After the actin cytoskeleton is stabilised by JASP, LAT no 
longer exert any action as both HK5C and ION5C evoked GLU release of both the RRP 
and the RP of SVs. Thus, the action of LAT in blocking the evoked release of RP was truly 
due to the disassembly of actin microfilaments. Furthermore, it was apparent that actin 
disassembly did reduce the HK5C evoked [Ca2+]i because JASP reversed this action of 
LAT. In fact, there was a slight elevation in the HK5C evoked [Ca2+]i in the presence of 
both drugs to a similar extent to that seen with JASP alone. Although, FM dye release 
evoked by HK5C or ION5C appeared to be similar to control release in JASP plus LAT 
treated terminals but unlike LAT treatment alone, it was assumed that this was due to the 
RP being released by FF whilst the RRP is releasing KR. We treated synaptosomes with 
OA to prove this, as if the RRP was undergoing KR it should now switch to FF and so 
more dye would be released. By comparing synaptosomes treated with JASP plus LAT 
with or without OA, the results clearly demonstrated that JASP stops the LAT removing 
the RP of SVs and that these undergo normal FF, whilst RRP of SVs now undergo KR but 
OA switches this. Likewise, it was apparent that LAT treatment does remove the RP from 
releasing and switches the RRP to FF since the pre-treatment with LAT followed by OA 
does not allow any further FM dye release. Whilst we can suggest that actin microfilaments 
may play a role in the Dyn mediated closure of the KR FP, we actually cannot make a 
conclusion about the role of this cytoskeletal component for NM-II mediated KR because 
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LAT actually perturbs the HK5C stimulus. One possible future experiment would be to 
switch ION5C action to the NM-II pathway by including 40 nM PMA in the experiment 
(previously shown by Asthon’s group e.g. Bhuva, 2015; Singh, 2017; see appendix 1 Fig 
A14 and A15). Then one could measure the effect of LAT on this stimulus. This maybe 
complicated because of the suggestion that PKCs themselves maybe affected by LAT. 
6.5.3 Bioenergetics 
The Drug treatments employed in this chapter include LAT, Go6983, JASP, LAT plus 
JASP, LAT plus JASP plus OA. Although, the results obtained from performing such drug 
treatments appeared to be specific and could be explained by action on the pools and 
modes of SVs, it was important to ascertain that none of these drug treatment induced non-
specific effects. One possible non-specific action could be to perturb the bioenergetics of 
the terminals as this would clearly Affect SV release. We tested this using Seahorse XFp 
analyser and the mito stress test. By carrying out such measurements, we found that the 
majority of bioenergetics parameters in drug treated synaptosomes were unaltered 
compared to non-drug treated terminals. Any changes seen were very minor and unlikely 
to affect the SV exocytosis. Overall, such data confirm that the effects of all drug 
treatments identified in this chapter were not from detrimental effects of the drugs on the 
bioenergetics of the synaptosomes. 
6.6 Conclusion 
In conclusion, the role of the actin cytoskeleton in regulating both the release of SV pools 
and the exocytotic mode of such vesicles has been investigated in this chapter. 
Disassembly of actin microfilament with LAT was discovered to inhibit the HK5C and 
ION5C evoked RP release, and it was also shown to change the mode of RRP release from 
KR to FF. However, whilst LAT treatment led to a significant reduction in HK5C [Ca2+]i 
this did not perturb ION5C stimulation of [Ca2+]i. This could mean that whilst the actin 
microfilaments could have a direct effect on the Dyn dependent KR mode (induced by 
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ION5C stimulation) regarding to the closure of the FP, actin microfilament might not have 
a direct effect on the NM-II dependent KR mode (triggered by HK5C stimulation). A 
difference in the action of LAT with these 2 stimuli was further shown by dual treatment 
with LAT and Go6983 (that inhibits PKCs) because whilst this did not prevent the action 
of microfilament disassembly on ION5C evoked events it totally reversed any action of 
LAT on HK5C evoked GLU release, FM dye release, and [Ca2+]i. This suggests that the 
actual mechanism whereby HK5C induces SV exocytosis may be perturbed by disrupting 
actin microfilaments.  
Actin stabilisation with JASP was also tested. In contrast to disassembly, stabilisation of 
actin was found not to reduce HK5C or ION5C evoked GLU release or disturb the mode 
of SV exocytosis as measured by FM dye release. JASP treatment was also found to 
antagonise LAT effect, proving the actions of LAT measured were truly due to 
disassembly of microfilaments. This result with JASP is interesting as it means that neither 
the release of the pools or the modes of exocytosis require changes in actin assembly at 
the point of SV fusion. This is because, by stabilising microfilament, no new microfilament 






















Synaptic transmission is the basis of neuronal networking and disturbances of this process 
are associated with the pathophysiology of numerous neuronal and psychiatric disorders. 
Therefore, it is important to elucidate the molecular mechanism of synaptic vesicle (SV) 
exocytosis. SVs are small, electron-lucent vesicles that are clustered at presynaptic 
terminal. They store neurotransmitters and release them by calcium triggered exocytosis 
(Takamori, 2009). In the nerve terminal, they are organised in three distinct pools; readily 
releasable pool (RRP), reserve pool (RP), and silent pool (SP) (Tsien and Alabi, 2012). 
Despite the importance of these pools, understanding about their properties are far from 
fully understood. Herein we have investigated various properties of SV pools in synaptic 
transmission, including the SP exocytosis following Roscovitine (Cdk5 inhibitor) (Chapter 
3) or Fluoxetine (SSRI drug) (Chapter 4) treatment, and also the effect of PKA and 
Calcium channels (Chapter 5), and the actin cytoskeleton (Chapter 6) on properties of the 
SV exocytotic modes. 
7.1.1 Roscovitine 
The SP is known to contain the majority of the SVs in certain type of experimental models, 
such as rodent hippocampal cultured cells. Interestingly, despite this characteristic, the SP 
rarely contributes to neurotransmission under normal physiological conditions (Sudhof, 
2004). The reason why such a large number of SVs, that could theoretically take part in 
the synaptic transmission, are reluctant to release has been a major question.  
Recently, Kim and Ryan (2010) used the Cdk5 inhibitor, Roscovitine, to successfully 
induce an extra release of SVs from mammalian hippocampal cell cultures and such 
release is from the SP. These authors have reported that treatment with Roscovitine 
allowed a 100-AP stimulation to trigger release of virtually all of the SVs in the terminal. 
They concluded that Cdk5 inhibition has increased the size of the available SV pool by 
allowing SP SVs to now become releasable (Kim and Ryan, 2010, 2013). We have now 
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employed Roscovitine to investigate the properties of the SP rat cerebral cortical 
synaptosomes. 
Roscovitine treatment dose dependently increased the evoked GLU release from the nerve 
terminals with the maximum effect being identified at 100 M. Under the stimulation 
conditions employed (HK5C or ION5C) the synaptosomes only undergo one round of SV 
release. However, under conditions where the SV recycling machineries were 
pharmacologically blocked with Dynasore and Pitstop2TM, Roscovitine still triggered extra 
release with the stimuli. This means that the release observed has occurred from SVs from 
a different pool other than the RRP and the RP, and this must be the SP. ION5C stimulation 
could also release the SP in the presence of Roscovitine, and as ION5C is an ionophore 
that bypasses any Ca2+ channel requirement, such result suggests that the level of Ca2+ 
influx through specific channels might not play an important role in the release of the SP 
providing there is a sufficient increase in [Ca2+]i. Indeed, whilst 100 M Roscovitine 
allows the HK5C to evoke the SP release, it does not affect the evoked [Ca2+]i. 
Although it was clear that [Ca2+]i was unchanged with the treatment of Roscovitine, it was 
possible that additional [Ca2+]e could induce further release in the presence of Roscovitine 
i.e. the condition being used did not maximally release the SP. This was found not to be 
the case as following Roscovitine pre-treatment HK10C and HK20C was actually unable 
to release the SP, indicating that higher [Ca2+]e actually does not support the release of the 
SP. Intriguingly, the evoked [Ca2+]i was reduced with HK10C or HK20C stimulation 
following Roscovitine treatment compared to that induced by HK5C, clearly there are 
some very precise requirements involving changes in [Ca2+]i that are involved in the 
regulation of the SP release. There was also some specific PKC requirements as 
determined by using PMA and Go6983. Supramaximal activation of PKC with 1 M PMA 
actually blocks the SP release evoked in Roscovitine treated terminals. However, 
inhibition of PKCs by Go6983 did not prevent the SP being released by HK5C in 
Roscovitine treated synaptosomes. However, HK10C and HK20C evoked release in the 
259 
 
presence of both Roscovitine and Go6983 failed to release the SP indicating that the higher 
[Ca2+]e was not activating PKCs to the same extent as 1 M PMA since otherwise, as PKCs 
are blocked, one might have expected the SP to be released. All the experiments outlined 
in this paragraph are novel and the precise mechanisms involved will need to be elucidated 
in the future.  
We next investigated whether SP release is dictated by specific types of voltage dependent 
Ca2+ channel. For this, toxins targeting and blocking specific types of Ca2+ channels were 
employed (CONO for N-type Ca2+ channels, AGA for P/Q type Ca2+ channels, NIF for L-
type Ca2+ channels). It was apparent from the results that SP release requires a certain 
amount of Ca2+ influx through Ca2+ channels and SP exocytosis was perturbed by blocking 
any of these three types of Ca2+ channel. Thus, in rat cortical synaptosomes the SP 
regulated by entry of Ca2+ through voltage dependent Ca2+ channels but there is no one 
specific channel linked to this release. This may have been predicted as ION5C bypasses 
these channels but allows the SP to release in Roscovitine treated terminals. 
The actin cytoskeleton has been suggested to play a role in regulation of synaptic 
transmission via scaffolding the SVs (Cingolani and Goda, 2008; Porat-Shliom et al, 2012). 
The actin cytoskeleton must restrain the mobility of SVs, so that they remain distal from 
the AZ; a feature that overlaps with the reluctant release of the SP (Dillon and Goda, 2005). 
Therefore, the actin cytoskeleton might contribute to the SP regulation. Actin 
microfilaments were stabilised with JASP in Roscovitine treated terminals and HK5C still 
evoked release of the SP. Therefore, actin stabilisation with JASP was found not to affect 
the SP exocytosis. This is intriguing since it is clear that the actin microfilaments cannot 
act as barrier to unattached SP SVs, Roscovitine could still physically disattach the SVs 
from this cytoskeleton and such vesicles maybe now available for release. 
Roscovitine treatment has been established in this study to allow HK5C and ION5C to 
evoke the SP exocytosis and this presumably involves Cdk5 inhibition. However, a precise 
mechanism of how inhibition of Cdk5 has led to the SP release is unknown. Cdk5 is a 
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kinase that has numerous substrates in the nerve terminal, such as Syn I. Benfenati’s group 
has previously reported that Cdk5 phosphorylation of Syn I at Ser-551 site restrains the 
mobility of the SVs through association with actin cytoskeleton (Verstegen et al, 2014). 
Therefore, it is possible that Syn I phosphorylation might have been modified following 
Cdk5 inhibition with Roscovitine, and this allows previously immobilised SVs to 
exocytose. To investigate this, the specific phosphorylation of certain sites on Syn I were 
explored using western blotting experiments. 
Semi-quantitative analysis of Syn I phospho-Ser-553 probed blots indicated that 
Roscovitine may have reduced the phosphorylation of this site. Additionally, phospho-
Ser-9 and Ser-603 probed blots have shown increased phosphorylation following 
Roscovitine application relative to drug free control. Thus, it would be appear that 
Roscovitine treatment leads to decreased phosphorylation of Syn I at Ser-553 site, whereas 
Ser-9 and Ser-603 site phosphorylation increases, and these changes may allow the stimuli 
to evoke the SP exocytosis. Importantly, in the previous literature it was shown that Cdk5 
phosphorylation restricts the mobility of SVs by anchoring it with actin cytoskeleton 
(Verstegen et al, 2014), whereas PKA and CaMK II phosphorylation dissociates Syn I 
with SVs, thereby facilitate the SV exocytosis (Llinas et al, 1985, 1991; Petrucci and 
Morrow, 1987; Valtorta et al, 1991; Ceccaldi et al, 1995; Menegon et al, 2006; Wang et 
al, 2008). Therefore, results from current study match with findings from previous 
research. However, careful comparison between 4AP5C induced changes and HK5C and 
ION5C induced changes may highlight that the PKA site Ser-9 might not be involved (as 
ION5C does not change this phosphorylation in Roscovitine treated terminals) and that 
large changes in phosphorylation of Ser-553 and Ser-603 are required because 4AP5C can 
induce some change. As this is still preliminary data, many more repeasts of these 





Roscovitine treatment and subsequent stimulation with HK5C and ION5C have 
successfully induced the SP release. Nevertheless, considering the complexity of 
neurotransmission, it is unlikely that Cdk5 inhibition is the only approach that would allow 
one to study this pool of SVs. Hence, we attempted to find an alternative method that could 
allow the SP of SVs to be released extra release. One of the possible candidate was 
Fluoxetine, a commonly prescribed antidepressant drug. Recently, Jung et al (2014) 
reported that 1 M Fluoxetine increased the size of the recycling pools at the expense of 
the SP, in hippocampal cultured cells. Thus, we have tested whether Fluoxetine could also 
support the release of glutamatergic SVs from the SP. 
Synaptosomes were treated with various concentrations (1 M, 200 nM, 100 nM, and 50 
nM) of Fluoxetine for 5 min and its GLU release was evoked by HK5C. None of the 
concentrations applied were found to allow HK5C to evoke an extra release, and in fact 1 
M Fluoxetine actually inhibited some release. This was analogous to the finding that 8 
M Fluoxetine inhibited release in the study by Jung et al (2014). Synaptosomes were 
then treated with different concentrations (1 M, 200 nM, 100, nM, 50 nM, 40 nM, 20, 
nM, and 5 nM) of Fluoxetine for an extended period of incubation (20 min) to determine 
if this provided better conditions. The release was still reduced with 1 M Fluoxetine as it 
was with 200 nM and 100 nM Fluoxetine, indicating that these dosages of the drug perturb 
release. Remarkably, 40 nM Fluoxetine induced extra evoked release of GLU as did 20 
nM, although this was a smaller effect. However, 5 nM failed to effect evoked release. 
Therefore, it would appear that maximum release of the SP was produced following 40 
nM Fluoxetine treatment for 20 min at 37oC prior to stimulation. A comparison with 100 
M Roscovitine treatment demonstrated that 40 nM Fluoxetine treatment allowed HK5C 
to evoke a similar amount of SP release. Further, dual treatment of Roscovitine and 
Fluoxetine was found not to induce any further increase in release, confirming that the 
262 
 
maximum release of the SP has been achieved. 40 nM Fluoxetine can also allow ION5C 
to evoke the SP release so again this suggests that the action of Fluoxetine is independent 
of any specific voltage dependent Ca2+ channels. 
Even though this study obtained extra evoked GLU release with Fluoxetine using ION5C 
or HK5C stimuli, there was still a possibility that the drug, through unknown mechanism, 
might actually promote a recycling of the RRP and RP and the re-release during the 
stimulus period. So that this study was observing a recycling of these two pools rather than 
release of the SP. However, this was found not to be the case since even after the inhibition 
of the recycling machineries involving Dyn and clathrin, Fluoxetine was still able to allow 
ION5C and HK5C to evoke the SP release. 
40 nM Fluoxetine with 20 min incubation was found to be an ideal condition to allow 
evoked release of the SP release. However, there was a noticeable decrease in the evoked 
release when 1 M Fluoxetine was applied, indicating that this concentration of the drug 
is perturbing some release from the RRP and RP. One of the possible explanations for 
perturbation of release following 1 M Fluoxetine treatment may be due to a reduction in 
evoked [Ca2+]i. Indeed, 1 M Fluoxetine application did reduce evoked [Ca2+]i 
compared to non-drug treated control, suggesting that an inhibition effect derived from 1 
M Fluoxetine treatment may be from a reduction in the evoked [Ca2+]i level. 
7.1.3 Effect of PKA and Calcium channel on regulation of SV 
releasing modes 
From previous research in Ashton’s group, it was established that regulation of releasing 
modes is dependent on various protein activities (Bhuva, 2015; Singh, 2017). Herein we 
are discussing the regulation of releasing modes dependent on activities of various proteins; 
Dyn, PKA, and Ca2+ channels.  
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Dyn plays an important role in the regulation of some type of KR mode of exocytosis as 
inhibition of its GTPase activity with Dynasore has shown to change the mode to FF. 
However, it was unknown whether Dyn has to be translocated to a membrane compartment 
prior to SV fusion or whether Dyn already present on such membranes regulates the KR 
mode of exocytosis. This was investigated using MITMAB, a drug that inhibits the 
translocation of Dyn from the cytosol to membranes as it prevents membrane binding. 
Evoked GLU and FM dye release and [Ca2+]i were found to be unchanged following 
MITMAB treatment compared to non-drug treated control, indicating that his drug does 
not interfere with the Dyn dependent KR pathway. These results suggests that Dyn that is 
already present on membranes can regulate the mode of release. In recent experiment 
(Ashton et al, unpublished), it was shown that MITMAB can prevent the recycling of those 
SVs undergoing FF. Thus, as previously characterised, this CDE does require Dyn to bind 
to membrane. Further, it also proves that MITMAB is active. 
Dyn is a substrate of PKC but, although it is speculated that PKC mediated Dyn I 
phosphorylation regulates the KR mode, it was hard to block changes in site specific 
phosphorylation in Dyn using PKC inhibitors. Thus, other kinases may also play a role 
(Singh, 2017). Dyn I is also proposed to be phosphorylated by other kinases, including 
PKA. Thus, we tested whether absence of endogenous PKA activities induced by its 
inhibition by KT5720 would affect the releasing mode. 4AP5C and ION5C evoked FM 
dye releases were found to be increased following KT5720 treatment, demonstrating that 
the mode of release has changed from KR to FF. Intriguingly, KT5720 treatment did not 
perturb the KR mode of the RRP evoked by HK5C. Such results are identical to what 
occurs when Dynasore inhibits the Dyn dependent KR mode. Thus, it would appear that 
endogenous PKA inhibition is only affecting the Dyn dependent KR mode, whereas HK5C 
evoked release operating through NM-II dependent pathway is not affected by the 
treatment with KT5720. Excitingly one can change HK5C to act on the Dyn dependent 
KR by inhibiting PKCs with Go6983. Under such circumstance, KT5720 can now switch 
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the HK5C evoked RRP SVs from KR to FF. Clearly, the Dyn dependent but not NM-II 
dependent KR has a requirement for endogenous PKA activity. 
In a preliminary study from A.Ashton’s group, it was discovered that HK5C evoked FM 
dye release from the RRP was induced following L-type Ca2+ channel inhibition, 
suggesting that the KR mode is regulated through L-type Ca2+ channels. However, this 
data only applies to the NM-II dependent KR pathway since HK5C works through this 
pathway. ION5C is the stimulus that acts on the Dyn dependent KR mode but as this 
stimulus bypasses Ca2+ channel requirements, one cannot use this stimuli to investigate 
possible specific Ca2+ channel requirement. Since Go6983 can change the HK5C to work 
through Dyn dependent KR, we measured HK5C evoked FM dye release in the presence 
of Go6983 with different Ca2+ channel inhibitors. Intriguingly, only the P/Q type 
Ca2+channel inhibitor, AGA, changed the releasing mode of the RRP SVs from KR to FF, 
whereas, CONO (N-type Ca2+ channel inhibitor) and NIF (L-type Ca2+ channel inhibitor) 
failed to induce any changes in mode of release. Importantly, these results demonstrate 
that the NM-II dependent KR is regulated by L-type Ca2+ channels whilst the Dyn 
dependent KR mode is mediated through P/Q-type Ca2+ channels. This result has now led 
us to the idea that rather than us studying one KR mode that can be regulated by either 
Dyn or NM-II (dependent on the stimulation conditions) we are studying two independent 
KR modes: one regulated by Dyn and P/Q type channels and one regulated by NM-II and 
L-type channels. As these channels may be localised to distinct regions on the AZ, it could 
be that these two modes occur at distinct regions herein. This may also now explain 
difference in certain properties e.g. PKA’s maybe localised near to the Dyn dependent KR 
SVs and regulated this but not near the NM-II dependent KR SVs.  
7.1.4 Effect of Actin cytoskeleton on the releasing mode 
At the AZ, the actin cytoskeleton is suggested to have a dual function. It might direct the 
arriving SVs to dock at the AZ, thereby positively controlling the size of the RRP. It could 
265 
 
also form a physical and molecular barrier for priming reaction, and thereby prevent facile 
fusion of vesicles (Cingolani and Goda, 2008; Porat-Shliom et al, 2012). The actin 
cytoskeleton can interact with Dyn and NM-II (Papadopulos, 2017) suggesting the 
possibility of its role as a regulator of Dyn and NM-II dependent KR mode. Herein, we 
have investigated the properties of KR mode depending on the actin cytoskeleton activity. 
Actin microfilament disassembly due to LAT treatment prevented the release of RP GLU 
containing SV. If LAT does not perturb the modes of release, then one should expect the 
HK5C or ION5C should induce little FM dye because RRP normally undergoes KR so it 
does not release the dye and the RP SVs are blocked. However, HK5C and ION5C released 
FM dye and this was comparable to that found in non-drug treated controls. A possible 
explanation is that actin disassembly switches the RRP SVs to a FF mode. This idea was 
found to be correct because OA – which normally switches the RRP SVs to FF failed to 
produce any further FM dye release in LAT treated terminals, indicating that the RRP had 
been switched to the FF mode of exocytosis by disassembling actin microfilaments. 
These results would initially suggest that both the Dyn dependent FP closure for KR and 
the NM-II dependent FP closure for KR may also require intact microfilaments. These 
may help to close the FP. However, we have found some difference between HK5C and 
ION5C that means that both KR modes FP may not both be directly affected by 
microfilament. HK5C evoked [Ca2+]i levels were found to be reduced following 
disassembly of actin cytoskeleton, suggesting that a reduction in [Ca2+]i level by 
microfilament of this cytoskeleton component may explain the switch of the RRP KR to 
FF and further, this could also explain why there is no release from the RP. However, actin 
disassembly action on ION5C evoked RP release and on ION5C RRP SVs mode of release 
were not connected to changes in ION5C evoked [Ca2+]i. One possibility is that actin 
microfilaments have an indirect involvement on the NM-II dependent KR mode 
(represented with HK5C stimulation), potentially through the regulation of calcium level, 
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but this cytoskeleton may directly mediate the Dyn dependent pathway (represented with 
ION5C stimulation).  
We have also found that higher [Ca2+]e using HK20C did not prevent the LAT induced 
perturbation of the RP GLU containing SV release. However, this has to be tested on the 
FM dye release assay to see whether HK20C can switch the RRP mode of release back to 
KR. If the results appears that higher [Ca2+]i could reverse the change in the mode induced 
by actin disassembly, it will prove that we are actually looking at the two distinctive effects 
of LAT application. 
We have used ION5C to work on the Dyn dependent KR pathway and HK5C to work on 
the NM-II dependent KR pathway. However, as we have found that these stimuli may also 
be perturbed by actin disassembly, we sought to check the specificity of our findings for 
the KR mode independent of the stimulus employed. We treated terminals with Go6983 
to change the HK5C to a Dyn dependent KR mode and then disassembled microfilament 
with LAT. However, surprisingly the Go6983 treatment led to recovery of RP containing 
GLU SV release evoked by HK5C. Likewise, the LAT action on HK5C evoked [Ca2+]i 
level has also found to be reversed in the presence of Go6983. Previously, it was proposed 
that LAT action on RP inhibition for HK5C is derived from the reduction in evoked 
[Ca2+]i level and the results with Go6983 suggest that this is correct because this allows 
normal HK5C evoked [Ca2+]i level, and normal release of the RP. These results may 
indicate that active PKCs are important for the effect of actin disassembly on release. To 
check this one will have to conduct similar experiments using the ION5C stimulation. 
However, initial results suggest that the release of RP of GLU containing SVs is still 
blocked using ION5C stimulation following treatment with LAT and Go6983. This 




The properties of the actin cytoskeleton can be further investigated by stabilising 
microfilament with JASP. JASP treatment does not perturb the HK5C or ION5C evoked 
GLU release and FM dye release, although it induces a slight increase in the HK5C evoked 
[Ca2+]i.  
As JASP treatment does not perturb release, we can use it to show that the LAT actions is 
related to actin disassembly as JASP prevents this action of LAT. Indeed, JASP pre-
treatment followed by LAT prevents the effect of LAT so the latter does work by actin 
disassembly. FM dye release in the presence of both drugs were found to produce similar 
result to when LAT was treated alone but this can be shown to be due to the RP now 
releasing by FF and the RRP releasing by KR. OA treatment of the JASP plus LAT treated 
terminals allowed more FM dye release proving that the RRP was originally undergoing 
KR but is now undergoing FF.  
7.2 Future Studies 
Finding from this thesis contributes to the understanding of the properties of distinct pool 
and their release. In particular, it has been discussed herein that the Roscovitine and 
Fluoxetine can allow stimulus to induce SP release. Additionally, effect of different 
protein activities including Dyn, PKA, Ca2+ channels, and actin cytoskeleton, on the mode 
of release were demonstrated. Nevertheless, there are still areas that are required to be 
studied in the future research in order to achieve the full understanding of the field. 
Likewise, some of the experiments proposed in this section may aid current knowledge 
and expand the understanding surrounding SV exocytosis in neurons. 
- Reversibility of Roscovitine and Fluoxetine - Roscovitine and Fluoxetine have 
been established to allow HK5C or ION5C to induce the SP release. The use of 
FM2-10 dye to study the releasing mode of SP exocytosis has not been performed 
in this study. This is due to the fact that in order to load up the SP SVs with dye, 
one has to pre-treat the terminals with either Fluoxetine or Roscovitine so that the 
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SP is released and so it can be labelled with the Fluorescence dye, so that following 
its recycling, one would have labelled SP SVs. Subsequently in Fluoxetine or 
Roscovitine treated terminals, one can then allow HK5C or ION5C to evoke the 
release of FM dye from the exocytosing SP of SVs. However, one problem is that 
these drugs may perturb the SV recycling cycle, such that one may not be able to 
label SP SVs by this method e.g. Cdk5 phosphorylates Dyn following CDE, but 
blocking this may perturb parts of the SV recycling pathway. If drug actions are 
reversibe, then one could allow the SP to be stimulated and labelled with dye and 
then the drug could be removed, if its action is really reversible, this may allow 
for fully functional recycling. Subsequently, fully labelled SP SVs could be 
induced to release by treating with one of these drugs. In the ideal world, one could 
test Roscovitine for pre-stimulation, its removed, and then Fluoxetine for 
stimulation or vice versa. 
- PKA dependency of Roscovitine – In the current study, SP release in Roscovitine 
treated terminals has been discovered to be strongly dependent upon PKC as 1 M 
PMA prevents this, however, other kinases that are known to have important role 
in neurotransmission, such as PKA, were not investigated herein. Thus one could 
investigate whether PKA is a potential regulator of the SP exocytosis. We could 
study this by pharmacologically promoting PKA activity with c-BIMPs, or 
attenuating its activity with KT5720. This is analogous to the PKC studies where 
we supramaximally activated PKCs with 1 M PMA or inhibited PKCs with 
Go6983. 
- More experiments with ION5C – Some of the experiments presented in this thesis 
only employed HK5C and there is a need to test these using ION5C as the stimulus. 
For example, whilst ION5C evoked GLU release is already performed for 
treatment with Go6983 plus LAT, one needs to study ION5C evoked FM dye 
release in the presence of LAT and Go6983. Thus, it is important to investigate 
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the conditions under ION5C stimulation. Additionally, ION5C evoked GLU 
release under Dynasore, Pitstop2TM, JASP, Blebbistatin, and Cys A treatment in 
the presence of Roscovitine need to be checked as was done for HK5C (see chapter 
3). Also, the action for 40 nM Fluoxetine (chapter 4) with 20 min incubation on 
ION5C evoked GLU release also needs to be investigated. 
- Fluoxetine with Serotonergic receptor agonists and antagonists – Fluoxetine has 
been discovered herein to allow HK5C and ION5C to evoke the release of the SP. 
This is intriguing result because Fluoxetine is known as SSRI, but it can also allow 
extra exocytosis of GLU containing SVs from glutamatergic nerve terminals. 
Therefore, it is possible that part of the antidepressant effect of drug may be 
derived from elevating the number of NT vesicles that can be stimulated to release 
and these effects would not be restricted to serotonergic terminals. There is a 
minimal number of serotonergic terminals in the cerebrocortial synaptosomes 
preparation which is over 80% glutamatergic. Thus it can be argued that 
Fluoxetine blocking reuptake of serotonin could not possibly act on all these 
glutamatergic terminals. There would not be enough present to do this and further, 
not all glutamatergic synaptosomes would have serotonin presynaptic receptors to 
produce this substantial increase in GLU release. However, for completion, one 
should add well characterised serotonin receptor agonists and antagonists and see 
what possible effect these could have on evoked GLU release alone. More 
importantly, these could be used in conjunction with Fluoxetine to show that the 
Fluoxetine affect is not due to serotonin levels. 
- Calcium dependency of Fluoxetine action - It is necessary to investigate the 
changes in evoked [Ca2+]i in the condition where Fluoxetine has successfully 
allowed HK5C and ION5C to induce SP release (40 nM for 20 min incubation at 
37oC). This result, in combination with SP release observed at Roscovitine treated 
terminals, will represent the Calcium dependency of the SP regulation. As was 
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done for Roscovitine, it will be important to see whether Fluoxetine action 
depends on one of the three voltage dependent Ca2+ channels that we have tested. 
- Western blotting – Western blotting results presented in Chapter 3 attempted to 
demonstrate that changes in the specific phosphorylation sites in Syn I following 
Roscovitine treatment, are related to the release of the SP. However, this was, by 
necessity, only a preliminary finding and more repeats need to be performed. 
Furthermore, the exact analogous experiment needs to be performed using 
Fluoxetine treated terminals. This may allow us to find some commonalities and 
differences and ascertain those phosphorylations that are truly required for release 
of the SP.  
- FM experiments for HK20C in the presence of LAT – In chapter 6, disassembly 
of actin cytoskeleton with LAT has led to inhibition of HK5C evoked RP release 
and following effect appear to be directly associated with the reduction of [Ca2+]i, 
showcasing an importance of [Ca2+]i in LAT activity on RP release. Hence, it will 
be important to investigate if higher [Ca2+]e with HK20C would overcome the 
LAT effect. The GLU release experiment has revealed that it failed to reverse the 
effect but this also have to be tested under FM dye assay to see if there is any 
difference in the releasing mode.  
- Specificity of calcium channel for LAT induced effect – HK5C evoked GLU 
release in the presence of LAT and Go6983 was found to recover the RP release. 
Furthermore, calcium level was found to be at the equal level with the control 
condition where LAT alone was applied, thus it would be appear that recovery of 
the RP release is linked to recovery of Calcium level. This finding highlights the 
importance of calcium level in LAT action on HK5C evoked release. This could 
be further tested by using various toxins that inhibit specific calcium channel. 
Following experiment will reveal any specificity of calcium channel involved in 
LAT induced effect. 
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- Does OA induced the FF of the RRP SVs following HK5C evoked dye release in 
LAT and Go6983 treated terminals? – The level of FM dye release was discovered 
to be equal to control in LAT and Go6983 treated terminals. However, it is not yet 
certain whether this means RP is releasing in KR and RRP has returned back to 
FF. This could be tested by including the OA in the drug treatment. OA will induce 
FF, thus if any extra release is observed in the following experiment, this will 
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A. 1.1 Review of Previous Research 
Results in this section reflect previous research carried out by the Ashton group. These 
results were created whilst establishing optimal experimental conditions for use with the 
synaptosomes model, and are displayed here to aid understanding of new and original data 
presented and discussed later in this thesis. 
 
A. 1.1.1 Maximal GLU Release 
For a direct comparison between FM 2-10 dye and GLU release assays it was necessary 
that the stimuli employed in this thesis produced a maximal level of GLU release. In order 
to determine this, synaptosomes were treated with the three stimuli (HK, ION and 4AP) – 
see material and methods for further details – in the presence of a range of extracellular 
Ca2+ concentrations ([Ca2+]e) (Fig A1). It can be observed that 5 mM [Ca2+]e produced 
maximal GLU release for all stimuli, and a further increase in [Ca2+]e to 10 mM had no 
effect on HK evoked GLU release (Fig A1 A), and possibly decreased GLU release with 
ION and 4AP (Fig A1 B-C). For all experiments in this study a concentration of 5 mM 






Figure A1: Effect of a Range of [Ca2+]e upon Evoked GLU Release 
Stimulation in the presence of 5 mM [Ca2+]e induces maximal GLU release for HK (A), ION 





Stimulation with 4AP5C produced a lower maximal GLU release (4.5 moles/mg of protein) 
(Fig A1 C) compared to HK5C (10.8 moles/mg of protein) (p<0.05) (Fig A1 A) or ION5C 
(11 moles/mg of protein) (p<0.05) (Figure A1 B) with 5 mM [Ca2+]e. An explanation for 
this can be found when looking at the different changes in [Ca2+]i produced by each stimuli 
(Fig A2). 4AP5C produces a lower, more gradual change in [Ca2+]i (180±20 nM Ca2+) than 
either HK5C or ION5C (370 ±25 nM Ca2+) (p<0.05), which is interpreted as 4AP5C only 
being able to release the RRP of SVs whilst HK5C and ION5C can release both the RRP 
and the RP of SVs. 
Though HK5C and ION5C achieved an equivalent level of [Ca2+]i, in this figure, this is 
mediated by different kinetics (Fig A2). HK5C produced much of the [Ca2+]i increase upon 
the application of stimulation, plateauing rapidly (<10 sec), potentially due to VGCC 
desensitisation (Bähring & Covarrubias, 2011); whilst ION5C produced a more gradual 
increase in [Ca2+]i which plateaus later (~40 sec) (Figure A2). This speed of achieving 
maximum increase in [Ca2+]i applies in every experiment that has been performed in this 
thesis and over 10 years of research. However, it would appear that distinct batches of 
ionomycin may achieve higher maximum [Ca2+]i than HK5C although maximum release 





Figure A2: Effect of Stimuli upon Cytosolic free Calcium [Ca2+]i 
All three stimuli employed in this study produce a change in [Ca2+]i via different kinetics. 
4AP5C evokes a significantly lower [Ca2+]i change than HK5C or ION5C (p<0.05). No 
significant difference was observed between HK5C and ION5C (p>0.05) in this set of 
experiments. Values represented are the mean plus S.E.M. from 3 independent experiments. 
Note in the other experiment reported in the main body of the thesis, ION5C can induce a 




A. 1.2 A Single Round of Exocytosis 
Due to the kinetics of the FM 2-10 dye and GLU release assays, synaptosomes in this study 
are subject to long stimulation periods (between 60-300 sec). Due to this long duration of 
stimulation there is a possibility that SVs could undergo multiple rounds of recycling, 
refilling with and re-release GLU, leading to an erroneous interpretation of GLU release. 
Further, it is possible that a SV releasing via KR could retain its FM 2-10 dye label while 
undergoing several round of KR recycling, or SV could lose its FM 2-10 dye and release 
additional GLU without a link to dye fluorescence. In order to accurately compare GLU 
and FM 2-10 dye release, it is essential to establish that SVs are only undergoing one round 
of release during the stimulation and measurement period. 
 
In order to ensure recycling was not occurring during stimulation and measurement, 
synaptosomes were acutely treated with 1 µM of the selective vacuolar H+ ATPase (V-
ATPase) inhibitor Bafilomycin A1. The V-ATPase pump is a complex found on SVs that 
is responsible for re-acidification of the vesicular lumen after endocytosis, which is vital 
in order for SVs to be re-filled with GLU (Cotter et al, 2015). Such acute bafilomycin A1 
treatment has no effect upon the GLU content of non-exocytosed SVs, and does not 
impede their release upon stimulation (Ikeda and Bekkers, 2008). An acute treatment of 1 
µM Bafilomycin A1 did not significantly affect GLU release compared with untreated 
controls, regardless of stimulation (Fig A3) (p>0.05). If SVs were undergoing multiple 
rounds of recycling, the level of GLU release would be expected to decrease with the 





Figure A3: Effect of 1 µM Bafilomycin A1 upon Evoked GLU release 
Treatment with 1 µM Bafilomycin A1 does not significantly affect GLU release when 
stimulated with HK5C (A), ION5C (B) or 4AP5C (C) compared to untreated controls (p>0.05 




A. 1.3 Maximal Labelling of SVs with FM 2-10 Dye 
Styryl dyes, such as FM 2-10, have been used extensively to label lipid membranes and in 
particular vesicular trafficking and recycling. In all experiments a concentration of 100 
μM FM 2-10 dye was utilised, as many researchers have employed the same concentration 
(Baldwin et al, 2003; Cheung et al, 2010). Clayton and Cousin (2008) however, have 
previously suggested that the labelling of SVs, especially via bulk endocytosis, is 
dependent upon the concentration of FM 2-10 dye, and 1 mM but not 100 μM will fully 
label all SVs (Clayton and Cousin, 2008).  
 
In order to ensure that all SVs are fully labelled with FM 2-10 dye, synaptosomes were 
incubated with 1 mM or 100 μM and evoke to release during a drug treatment (160 µM 
Dynasore) which has been observed to increase exocytosis via FF (Fig A4). In this model 
system there was no significant difference in FM 2-10 dye release seen between 
synaptosomes loaded with 1 mM or 100 μM (p>0.05), and drug treatment had no 
significant impact upon labelling or release of SVs (p>0.05). If 100 μM FM 2-10 dye had 











Figure A4: Difference between SVs Loaded with 1 mM or 100 µM FM 2-10 Dye 
SVs loaded with 1 mM (Blue) or 100 µM (Red) release equivalent levels of FM 2-10 dye 
following stimulation (p>0.05). Drug treatment, 160 µM Dynasore, increases FM 2-10 dye 
release by a corresponding amount, regardless of amount of FM 2-10 dye loaded, following 
stimulation (Green vs Yellow) (p>0.05). Values represented are the mean minus S.E.M from 
4 independent experiments. 
 
A. 1.4 The Mode of Exocytosis is Stimulation Dependent 
Each of the stimuli used in this thesis have been shown to evoke release through distinct 
[Ca2+]i kinetics (Fig A2), and changes in [Ca2+]i have been linked to regulating the mode 
of exocytosis of distinct pools (Alés et al, 1999), therefore each stimuli could evoke release 
of SVs pools via unique modes. As the RRP is suggested to be released within 2 sec of 
stimulation (Rizzoli and Betz, 2005), this time period was studied during FM 2-10 dye 
release for all stimuli (Fig A5 A). 
 
Interestingly HK5C and ION5C did not cause any significantly release of FM 2-10 dye in 
this period (p>0.05), unlike 4AP5C (Fig A5 A) (p<0.05). It could be argued that this 
indicates no SVs are being release during this time period, however when the experiment 
was repeated with a pre-treatment of 0.8 µM OA (Fig A5 B), an inhibitor of protein 
phosphatase 1 and 2A which is known to convert all RRP SVs to FF (Ashton et al, 2011), 
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an increase in FM 2-10 dye release was noted for all stimuli, that was not significantly 
different between stimuli at 2 sec (p>0.05). Comparison of these results are interpreted as 
HK5C and ION5C releasing the RRP via KR under control conditions, while 4AP5C 
releases roughly half the RRP via KR and half by FF. All three stimuli release an 
equivalent amount of FM 2-10 dye with OA during this period (2 sec), suggesting it is the 
RRP being released. 
 
In order to determine the exocytotic mode of the RRP and RP, the fluorescence value of 
FM 2-10 dye release during control conditions was subtracted from the fluorescence value 
achieved during OA treatment (Fig A6). HK5C stimulation caused all RRP SVs to undergo 
KR in the first 2 sec (Fig A6 A), and all RP SVs to release via FF (after 2 sec; Fig A6 B). 
Stimulation with 4AP5C releases all RRP SVs some via KR and some by FF, with 
fluorescence subtraction demonstrating that both modes contribute equally (Fig A6 C). RP 
SVs do not release when synaptosomes are stimulated with 4AP5C, as this stimuli induced 
a lower average [Ca2+]i compared to HK5C and ION5C, and this is unable to drive RP 




Figure A5: Mode of RRP Release during Control and 0.8 µM OA Treatment 
(A) Measurement of control levels of FM 2-10 dye release after stimulation during first 2 sec. 
Only 4AP5C releases a significant amount of dye (p<0.05). (B) Treatment with OA induces 
equivalent release of FM 2-10 dye regardless of stimulation over first 2 sec (p>0.05). Values 





Figure A6: Mode of RRP and RP Release during Control and 0.8 µM OA Treatment 
When FM 2-10 dye fluorescence of control was subtracted from OA conditions, it was found 
that all SVs release via KR during initial 2 sec of HK5C stimulation (A), and remaining SVs 
are released via FF after 2 sec (B). During 4AP5C stimulation (C), all SVs are released by a 
combination of KR and FF for initial 2 sec. Values are average of 3 experiments plus S.E.M, 
taken from (Bhuva, 2015, p. 62) with permission. 
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A. 1.5 Presynaptic Proteins Regulating Exocytosis 
Dyn I could have a role in modulating the mode of exocytosis at the FP. Previous research 
undertaken by Ashton group has demonstrated that inhibition of Dyn I GTPase activity 
with 160 µM Dynasore did not perturb GLU release with any stimuli (Fig A7 A-C) 
(p>0.05), but significantly increased FM 2-10 dye release with ION5C and 4AP5C (Fig 
A7 E-F) (p<0.05). These results were interpreted as ION5C and 4AP5C having a Dyn I 
dependence to release the RRP via KR, while HK5C was able to release the RRP 
independent of Dyn I (Fig A7 D). 
 
 
Figure A7: Effect of 160 µM Dynasore vs Control upon Evoked GLU and FM 2-10 Dye 
Release  
Treatment with 160 µM Dynasore does not perturb GLU release evoked by HK5C (A), 
ION5C (B) or 4AP5C (C) (p>0.05). 160 µM Dynasore had no significant effect of HK5C 
evoked FM dye release (D) (p=0.508), but increased ION5C (E) (p=0.014) and 4AP5C evoked 
FM dye release (F) (p=0.034). Values are mean plus SEM from 4 experiments. Figure taken 




NM-II has also been implicated in regulating the mode of exocytosis at the FP (Chan et al, 
2010; Berberian et al, 2009; Neco et al, 2008). Since no change in FM 2-10 dye release 
was observed when Dyn I was inhibited with Dynasore during HK5C stimulation (Fig A7 
D), it was theorised NM-II could be responsible for regulating the FP during this mode of 
exocytosis. Thus NM-II was blocked with 50 µM Blebbistatin, a selective, high affinity 
small molecule which blocks NM-II by inhibiting ATPase activity (Shu et al, 2005; 
Kovacs et al, 2004). A treatment of 50 µM Blebbistatin did not perturb GLU release with 
any stimuli (p>0.05) (Fig A8), but did significantly increase FM 2-10 dye release with 
HK5C stimulation only (p<0.05) (Fig A9 A). These data may suggest that NM-II is able 
to close the FP during HK5C stimulation, when the [Ca2+]i level at the AZ is high (Fig A2), 
as Ca2+ is required to regulate NM-II phosphorylation and activation (Martinsen et al, 
2014). These data may also suggest that the [Ca2+]i level achieved at the AZ during ION5C 
and 4AP5C stimulation may not be high enough to activate NM-II (Fig A9 B-C), but 





Figure A8: Effect of 50 µM Blebbistatin upon Evoked GLU Release 
Treatment with 50 µM Blebbistatin did not significantly affect GLU release when stimulated 
with HK5C (A), ION5C (B) or 4AP5C (C) (p>0.05). Values represented are the mean plus 





Figure A9: Effect of 50 µM Blebbistatin upon Evoked FM 2-10 Dye Release 
Treatment with 50 µM Blebbistatin significantly increased FM 2-10 dye release when 
stimulated with HK5C (A) (p<0.05), but had no effect when stimulated with ION5C (B) 





The Ca2+-dependent phosphatase calcineurin may also have a role in regulating proteins 
which participate in exocytosis, as calcineurin rapidly dephosphorylates many presynaptic 
proteins upon terminal depolarisation (Robinson et al, 1994). Inhibition of calcineurin with 
1 µM Cyclosporine A (Cys A) did not significantly affect GLU release (Fig A10 A-C) 
(p>0.05), but significantly decreased FM 2-10 dye release when stimulated with HK5C 
and ION5C (Fig A10 D-E, respectively) (p<0.05). This differs with some studies that have 
shown Cys A treatment increases GLU release (Gaydukov et al, 2013), but in the context 
of this model this further indicates maximal GLU release is being observed under these 
conditions already (i.e. with 5 mM [Ca2+]e Fig A1). When the effects of calcineurin 
inhibition with 1 µM Cys A were investigated upon [Ca2+]i levels, a significant increase 
was noted with all three stimuli (Fig A10 G-I) (p<0.05). These data are interpreted as the 
inhibition of calcineurin causing more SVs to release via a KR mode of exocytosis, which 
could be due to the increased [Ca2+]i level attained during Cys A treatment (Fig A10 G-I). 
The lack of effect upon 4AP5C evoked GLU and FM 2-10 dye, even during an increase in 
[Ca2+]i could suggest calcineurin inhibition only affects the RP, since 4AP5C does not 
release the RP (Fig A1 C, and Fig A2), and the RRP is already releasing via KR with both 





Figure A10: Effect of 1 µM Cys A upon Evoked GLU and FM 2-10 Dye Release 
1 µM Cys A did not perturb Glu release evoked by HK5C (A), ION5C (B) or 4AP5C (C) 
(p>0.05 for all). 1 µM Cys A significantly decreased HK5C (D) (p<0.025) and ION5C (E) 
(p<0.023) evoked FM 2-10 dye release, but had no effect upon 4AP5C (F) (p=0.985) evoked 
FM 2-10 dye release. 1 µM Cys A significantly increased [Ca2+]i levels with HK5C (G) 
(p<0.001), ION5C (H) (p<0.044) and 4AP5C (I) (p<0.049) stimulation, compared to controls. 
Values represented are the mean plus S.E.M. from 4 experiments. Figure taken from a 






A.1.1.5.1 Switching of HK5C evoked SV exocytosis from NM-II 
dependent KR to Dyn dependent KR 
Ashton and colleagues have deciphered that HK5C activates PKCs that inactivate Dyn 1 
but that activate NM-II. Thus, one can make HK5C action switch from the NM-II pathway 
to the Dyn dependent pathway by inhibiting PKCs with Go 6983. Neither pre-treatment 
with Go 6983 followed by the addition of Blebbistatin (Fig A11A) or Dynasore (Fig A11B) 
perturbed the HK5C evoked GLU release indicating that these conditions did not perturb 
SV from exocytosing and releasing their NT. 
 
Figure A11. HK5C evoked GLU release in a) non-drug treated control or Go 6983 plus 
Blebbistatin treatment b) non-drug treated control or Go 6983 plus Dynasore treatment.  
The experiment was done N=4 independent times. There is no significant difference between 




However, following pre-treatment with Go 6983, Blebbistatin no longer switched the 
HK5C evoked RRP SVs to a FF mode as there was not an increase in FM dye release 
compared to the control (Fig A12 A). Remarkably, such Go 6983 treatment now allowed 




Figure A12.  HK5C evoked FM2-10 dye release in a) non-drug treated control or Go 6983 
plus Blebbistatin treatment b) non-drug treated control or Go 6983 plus dynasore treatment.  
The experiment was done N=3 independent times. There is no significant difference between 
the control and Go 6983 plus Blebbistatin but there is a significant difference between control 




A.1.1.5.2 Switching of ION5C evoked SV exocytosis from dynamin 
dependent KR to NM-II dependent KR 
Not only can one switch the HK5C stimulus to act on the Dyn dependent KR but one can 
also switched the ION5C stimulus to act through the NM-II dependent pathways. This is 
achieved by using a low concentration of 40 nM PMA (an active phorbol esters) that can 
activate certain PKCs within the synaptosomes. Note that this concentration does not 
switch the RRP SV KR mode to FF alone although a higher concentration (1 M PMA) 
does. However, neither 40 nM PMA plus Blebbistatin (Fig A13 A) treatment nor 40 nM 
plus Dynasore (Fig A 13B) treatment perturbs the ION5C evoked GLU release. This 








Figure A13: ION5C evoked GLU release in a) non-drug treated control or Go 6983 plus 
Blebbistatin treatment b) non-drug treated control or Go 6983 plus Dynasore treatment.  
The experiment was done N=3 independent times. There is no significant difference between 
the control and the drug treated samples.  
 
However, following pre-treatment with 40 nM PMA, Blebbistatin was able to switch the 
ION5C evoked RRP SVs to a FF mode as there was now an increase in FM dye release 
compared to the control (Fig A14 A). Remarkably, such 40 nM PMA treatment now 
prevented Dynasore acting on the ION5C evoked RRP SVs and these remained 






Figure A14: ION5C evoked FM2-10 dye release in a) non-drug treated control or 40 nM PMA 
plus Blebbistatin treatment b) non-drug treated control or 40 nM plus Dynasore treatment.  
The experiment was done N=4 independent times. There is a significant difference between 
the control and Go 6983 plus Blebbistatin but there is no significant difference between 



















Fig A15. Detection of total Syn I (A), phospho-Ser553 in Syn I (B), phospho-Ser-9 in Syn 1 
(C), or phospho-Ser-603 in Syn I (D) using specific antibodies. These bound antibodies were 
detected using a specific secondary antibody conjugated to HRP. This enzyme reacts with 
chemiluminescence substrate and light is produced. Such western blots were exposed for 
different exposure times and the intensity of the detected band determined. These graphs 







Total FM2-10 Dye Content at the beginning of Measurements 
In order for key interpretations drawn in this thesis to be accurate, it is important to 
ascertain if any of the drug treatment employed perturbs the amount of FM 2-10 dye being 
loaded into the nerve terminals. Without this information, comparisons between the FM 
2-10 dye release and GLU assays would lead to incorrect assumptions. The fluorescence 
of the FM 2-10 dye was measured prior to stimulation (time 0) and compared with the 
control utilised in each assay. MITMAB incubated for 5 min had minor significant 
difference but this was unlikely to have affected the result. All the other drugs employed 
herein have had no significant (N.S) impact upon the total FM 2-10 dye uptake (p>0.05). 
Bar charts presented below represents the average nerve terminal fluorescence before 
stimulation began, error bars are plus S.E.M.   
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Appendix 3 (Continued) 
 
 
 
 
 
 
 
 
